

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email info.bmjopen@bmj.com

BMJ Open

Prevalence and patterns of multimorbidity among the elderly in China: a cross-sectional study using national survey data

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-024268
Article Type:	Research
Date Submitted by the Author:	18-May-2018
Complete List of Authors:	zhang, ran; China Pharmaceutical University, School of International Pharmaceutical Business Lu, Yun; China Pharmaceutical University, School of International Pharmaceutical Business Shi, Liuyan; China Pharmaceutical University, School of International Pharmaceutical Business Chang, Feng; China Pharmaceutical University, School of International Pharmaceutical Business
Keywords:	multimorbidity, cross-sectional study, Prevalence, Observed-to-expected ratio, China

SCHOLARONE™
Manuscripts

1
2
3
4 **Prevalence and patterns of multimorbidity among the elderly**
5
6 **in China: a cross-sectional study using national survey data**
7
8
9

<i>Author</i>	<i>E-mail</i>	<i>ORCID ID</i>
<i>First author</i>	Ran Zhang ranzai7@126.com	0000-0002-4142-805X
<i>Co-authors</i>	Yun Lu luyun20159@163.com	0000-0002-7928-7176
<i>Co-authors</i>	Liuyan Shi juliasmithsly@163.com	0000-0001-6965-3235
<i>Corresponding author</i>	Feng Chang cpucf@163.com	0000-0003-2689-4041

10
11
12
13
14
15
16
17
18
19
20
21 **Postal address:** 639 Longmian Road, Jiangning District, Nanjing, Jiangsu
22
23 Province, 211198

24
25
26 **Telephone number:** +86-13805153128 (Feng Chang)

27
28 **Department:** School of International Pharmaceutical Business

29
30
31 **Institution:** China Pharmaceutical University

32
33
34 **City:** Nanjing, Jiangsu Province

35
36
37 **Country:** China

ABSTRACT

Objectives: To examine the prevalence and patterns of multimorbidity among the elderly in China.

Design: The cross-sectional study.

Setting: More than 10,000 households in 28 of the 34 provinces of mainland China.

Participants: 11707 Chinese adults aged over 60.

Primary outcome measures: Prevalence and patterns of multimorbidity of these participants. Relative risks were calculated to estimate the probability of chronic conditions coexisting with other chronic diseases. Observed-to-expected ratios were used to analyze the patterns of multimorbidity.

Results: Multimorbidity was present in 43.6% respondents of the sample, with women having greater prevalence compared to men. 804 different comorbidity combinations were identified, including 76 dyad combinations and 169 triad combinations. The top 10 morbidity dyads and triads accounted for 69.01% and 47.05% of the total dyad and triad combinations respectively. Among the fourteen chronic conditions included in the study, asthma, stroke, heart attack and other six chronic conditions were the main components of multimorbidity due to their high relative risk ratios. The most frequently occurring clusters with higher O/E ratios were stroke and emotional, nervous, or psychiatric problems and memory-related diseases, emotional, nervous, or psychiatric problems and memory-related diseases and asthma, and chronic lung diseases and asthma.

Conclusions: The results of this study highlighted the high prevalence of multimorbidity in the elderly population. Further studies are required to dig into the etiology of multimorbidity and future primary healthcare policies should take multimorbidity into consideration.

Strengths and limitations of this study

Strengths

- This is the first study to estimate the prevalence, patterns of multimorbidity among the elderly in China using data from a nationally representative survey.
- We examined the gender patterns associated with the most common clusters of chronic conditions.

Limitations

- Limitations of this study are the time lag since the data were collected from the 2015 CHARLS.
- The chronic diseases included in the study are predefined and not comprehensive enough.

INTRODUCTION

Multimorbidity, the simultaneous occurrence of two or more chronic conditions in an individual, is increasingly becoming the norm and was reported to increase progressively with age. [1, 2] At present, with China's aging population and increasing prevalence of chronic conditions, multimorbidity among the elderly imposes an enormous societal cost due to increased mortality rates and healthcare utilization. However, to date, researches on chronic conditions in China are focused on a single disease and the coexistence of multiple chronic conditions has not been investigated systematically and thoroughly.

There are significant differences in the etiological analysis between patients with a single chronic condition and those with multimorbidity. [3] The coexistence of chronic conditions in a patient is more than a random event. It is more likely to be due to the causal relationship between diseases and the pathogenic factors they share.[4, 5] Moreover, the interactions between diseases or between disease and organism result in differences in severity of multimorbidity and functional status and prognosis of patients with multimorbidity.[6] Consequently, it is urgent for China to begin research on multimorbidity for the cost-effective treatments it may lead to.[7] The purpose of this study is therefore to determine the prevalence of multimorbidity among the elderly in China and to reveal morbidity combinations, which may benefit the design and implementation of a healthcare system directed to patients with multimorbidity.

METHODS

Data source

Data for this study were collected from the third-wave of China Health and Retirement Longitudinal Survey (CHARLS), which is the most current data available. CHARLS, a nationally representative longitudinal survey of Chinese residents aged 45 and older, was conducted by the Chinese Center for Disease Control and Prevention and Peking University to help China to adjust to rapid ageing of its population through evaluation of social, economic, and health circumstances on the community level using data collected by interviews, physical measurements and blood sample collection.[8] The national baseline survey began in 2011 and involved 17 708 respondents scattered

1
2
3 in 150 county-level units, 450 village-level units, and approximately 10,000
4 households. Thereafter, CHARLS respondents were followed every 2 years with their
5 informed consent and the study was approved by Peking University Biomedical Ethics
6 Committee (IRB00001052-14013-exemption).
7
8

9 For the current study, we used data on gender, age and health status from the section
10 of the general health status and disease history of senior citizens in the 2015 CHARLS,
11 which covered the following 14 common chronic health problems: hypertension,
12 dyslipidemia (high blood lipids or low cholesterol), diabetes or elevated blood glucose
13 (including impaired glucose tolerance and fasting blood glucose), cancer (excluding
14 mild skin cancer), chronic lung disease such as chronic bronchitis or emphysema,
15 pulmonary heart disease (excluding tumor or cancer), liver disease (other than fatty
16 liver, tumor, or cancer), heart disease (such as myocardial infarction, coronary heart
17 disease, angina pectoris, congestive heart failure and other heart diseases), stroke,
18 kidney disease (excluding tumors or cancer), stomach or other digestive diseases
19 (excluding tumor or cancer), emotional and mental problems, memory-related diseases
20 (such as Alzheimer's disease, brain atrophy, Parkinson's disease), arthritis or
21 rheumatism, and asthma. All these data were based on self-reports.
22
23
24
25
26
27
28
29
30
31

32 **Variables**

33 The independent variables in the analysis were: age, sex, number of chronic diseases.
34 Since in China people over 60 were considered as senior citizens, we only included
35 respondents aged over 60 in the sample. In this study, multimorbidity was defined as
36 the coexistence of more than one of the 14 chronic conditions with acute or subacute
37 forms of certain conditions being excluded.
38
39
40
41
42

43 **Statistical analysis**

44 To detect the demographic characteristics of patients with multimorbidity,
45 respondents were divided into two groups: those with multiple chronic conditions
46 (MCC group) and those without multiple chronic conditions (Non-MCC group).
47 Descriptive statistics were calculated and expressed as means (SD) and frequencies
48 (percentage). Adjusted prevalence in the MCC group and the non-MCC group were
49 calculated separately.
50
51
52
53

54 The most common clusters of chronic diseases were identified by estimating the
55 prevalence of morbidity dyads and triads. We also calculated the relative risk of
56
57
58

comorbidity for individual chronic conditions and observed-to-expected ratio (O/E ratio) for chronic condition combinations according to VAN DEN's analysis method.[9] Relative risk of comorbidity is the ratio of the number of people with a certain chronic condition who suffer from multimorbidity to the number of patients with the same disease who do not suffer from multimorbidity.[10, 11] In other words, a higher RR value means a higher probability that the disease coexists with other diseases. But it should be noted that there is no direct relationship between relative risk of comorbidity and the prevalence of diseases. [12, 13] Observed-to-expected ratios were used to estimate the conditional probability of coexistence of two or three chronic conditions. [9]

All analyses in this study was done using STATA SE(StataCorp).

p Values <0.05 were considered statistically significant.

RESULTS

Characteristics of participants

The data were gathered from the third-wave of CHARLS. After exclusion of participants with incomplete data related to these fourteen chronic conditions, 11,707 respondents with available information on related chronic diseases were included in this study. The mean age for the sample was 70.5 (range from 60 to 107) which consisted of 5,705 (48.7%) males and 5,993 (51.2%) females. The demographic characteristics of sample respondents are presented in Table 1.

Table 1 Demographic characteristics of all respondents, the MCC group and non-MCC group (adjusted for the 2015 Chinese population)

	All respondents	MCC group	Non-MCC group	P*
Number of people	11707	5107	6600	
Proportion (%)	100%	43.62%	56.38%	
Mean age				
All respondents (SD)	70.20(7.907)	70.57(7.701)	69.91(8.051)	<0.001
Male (SD)	69.97(7.575)	70.50(7.348)	69.60(7.707)	<0.001
Female (SD)	70.39(8.189)	70.62(7.892)	70.19(8.359)	<0.001
Gender (% females)	51.28%	54.41%	48.83%	<0.001
Mean number of chronic conditions				

All respondents (SD)	1.57(1.560)	3.01(1.259)	0.45(0.498)	<0.001
Male (SD)	1.47(1.534)	2.98(1.265)	0.44(0.496)	<0.001
Female (SD)	1.65(1.581)	3.03(7.982)	0.47(0.499)	<0.001

SD = standard deviation;

p* = statistical significance of the difference between the MCC and the non-MCC sample (t-tests were performed for comparison of means, and chi-square-tests for differences between percentages)

As expected, patients in the MCC group were generally older than those belonged to the non-MCC group. The prevalence of multimorbidity of females was higher compared to men (54.41% vs 45.59%), which could be explained by the longer average life expectancy of women. [14, 15] Figure 1 shows the number and proportion of respondents over 60 according to morbidity numbers. It can be seen that among all the participants aged over 60, 43.6% suffer from multimorbidity. Considering that the prevalence of these fourteen chronic diseases in the elderly population in China has reached 69.10%, multimorbidity would be a major problem faced by the health care system.

Prevalence of chronic conditions

Adjusted prevalence of chronic conditions in the entire sample, the MCC group and the non-MCC group are shown in figure 2. The prevalence of all fourteen chronic conditions in MCC group were all over 10%, significantly higher than that in the entire sample. For instance, the prevalence of arthritis or rheumatism, hypertension, stomach or other digestive disease, heart disease and chronic lung disease in the entire sample were 38.49%, 26.41%, 24.52%, 12.32% and 12.32% respectively, compared to 65.97%, 48.82%, 45.86%, 29.00% and 24.97% in MCC group.

Table 2 shows the relative risks of comorbidity for the 14 chronic diseases. It can be seen from the table that the overall relative risks for asthma, stroke, heart disease and other six conditions were all above ten, which meant these diseases were ten times easier to coexist with other chronic conditions and lead to multimorbidity. In addition, the relative risks for certain diseases were positively associated with gender. For example, men had significantly higher relative risks for asthma yet lower relative risks

for diabetes or high blood sugar compared to women.

Table 2 Relative risks of multimorbidity for different chronic conditions according to gender

Chronic conditions	All respondents	Female	Male
High relative risk of multimorbidity			
Asthma	31.77	23.13	32.86
Stroke	22.60	17.94	19.82
Heart disease	18.88	15.65	14.61
Diabetes or high blood sugar	17.47	17.41	10.72
Dyslipidemia	17.05	14.42	13.54
Memory-related disease	16.61	14.07	12.58
Kidney disease	14.04	15.30	9.08
Liver disease	13.46	14.00	9.25
Chronic lung diseases	11.97	10.37	9.47
Low relative risk of multimorbidity			
Emotional, nervous, or psychiatric problems	9.00	7.14	7.62
Stomach or other digestive disease	6.96	6.00	5.30
Hypertension	6.52	5.25	5.53
Cancer or malignant tumor	5.92	5.24	3.73
Arthritis or rheumatism	4.65	3.81	3.79

Common multimorbidity combinations

804 possible comorbidity combinations were identified in the MCC group after statistical analysis, including 76 dyad combinations and 169 triad combinations. The leading 10 most frequently occurring morbidity dyads and triads were presented respectively in [table 3](#) and [table 4](#).

Table 3 Adjusted prevalence of the 10 most common morbidity dyads

Ranking	Morbidity dyads	Prevalence			Mean Age	Proportion
		All respondents	male	female		
1	Arthritis or rheumatism and Stomach or other digestive disease	4.73%	38.63%	61.37%	69.20	23.33%
2	Arthritis or rheumatism and	2.85%	39.64%	60.36%	71.25	14.06%

	Hypertension					
3	Arthritis or rheumatism and Chronic lung diseases	1.13%	55.30%	44.70%	71.55	5.56%
4	Hypertension and heart problems	1.03%	50.00%	50.00%	71.80	5.05%
5	Hypertension and Stomach or other digestive disease	0.89%	48.08%	51.92%	69.07	4.38%
6	Hypertension and Dyslipidemia	0.86%	48.51%	51.49%	68.58	4.25%
7	Arthritis or rheumatism and heart problems	0.76%	35.96%	64.04%	70.72	3.75%
8	Arthritis or rheumatism and Kidney disease	0.64%	58.67%	41.33%	68.24	3.16%
9	Hypertension and Diabetes or high blood sugar	0.58%	44.12%	55.88%	70.97	2.86%
10	Chronic lung diseases and Asthma	0.53%	62.90%	37.10%	71.15	2.61%

Table 4 Adjusted prevalence of the 10 most common morbidity triads

Rank ing	Morbidity triads	Prevalence			Mean Age	Proport ion
		All respondents	male	female		
1	Arthritis or rheumatism, Stomach or other digestive disease and Hypertension	1.19%	45.08%	54.92%	70.96	10.14%
2	Arthritis or rheumatism, Stomach or other digestive disease and Chronic lung diseases	0.82%	34.53%	65.47%	70.82	7.00%
3	Arthritis or rheumatism, Heart disease and Hypertension	0.63%	60.42%	39.58%	69.93	5.40%
4	Arthritis or rheumatism, Heart disease and Stomach or other digestive disease	0.59%	29.73%	70.27%	71.51	5.03%
5	Hypertension, Dyslipidemia and Arthritis or rheumatism	0.44%	21.74%	78.26%	70.13	3.79%

6	Hypertension, Dyslipidemia and Heart problems	0.42%	36.54%	63.46%	71.17	3.57%
7	Arthritis or rheumatism, Kidney disease and Stomach or other digestive disease	0.42%	42.86%	57.14%	70.14	3.57%
8	Arthritis or rheumatism, Asthma and Chronic lung diseases	0.40%	48.98%	51.02%	69.18	3.43%
9	Hypertension, Dyslipidemia and Diabetes or high blood sugar	0.35%	59.57%	40.43%	71.51	2.99%
10	Arthritis or rheumatism, Stomach or other digestive disease and Liver disease	0.53%	51.22%	48.78%	70.29	2.61%

Theoretically, there were 91 possible dyad combinations and 364 triad combinations of 14 different chronic conditions. However, only 79.12% (72 types) of the possible dyad combinations and 46.43% (169 types) of the triad combinations emerged in the sample. The 10 most frequently occurring morbidity dyads accounted for 69.01% of the 72 dyad combinations, and the proportion of the 10 most common triad combinations in the 169 triad combinations was 47.05%. Arthritis or rheumatism, which appeared five times in the top ten dyad combinations and eight times in the top ten triad combinations of chronic conditions, became the main component of the leading morbidity dyads and triads.

There were significant gender differences in the odds of these multimorbidity combinations. The number of women with triad combinations of chronic diseases were generally higher than that of men with the same morbidity triads. For example, women had significantly higher prevalence of arthritis and hypertension and hyperlipidemia than men (78.26% vs 21.74%). Among morbidity dyads, the prevalence of heart disease and arthritis or rheumatism in women was nearly two times higher than that in men while the cluster of arthritis or rheumatism and kidney disease occurred more

frequently in men than in women. No age difference in the probability of these multimorbidity combinations was detected.

O/E ratio was also used to analyze the multimorbidity pattern. [16] The higher the value, the higher the probability of coexistence of chronic conditions. [17] Table 5 shows O/E ratios for the 10 most prevalent morbidity dyads and triads. In the midst of those triad combinations of chronic conditions, the two clusters with significantly higher O/E ratios were emotional, nervous, or psychiatric problems and stroke and memory-related disease (O/E ratio=10287.72), emotional, nervous, or psychiatric problems and memory-related disorders and asthma (O/E ratio=8498.56). These four conditions also dominated the three leading dyads with the highest O/E ratios: 97.73 for the combination of emotional and mental disorders and memory-related diseases, 23.66 for the combination of stroke and memory related disease and 19.55 for the combination of memory-related disease and asthma.

Table 5 O/E ratios for the 10 most prevalent morbidity dyads and triads

Number of chronic conditions	Ranking	Chronic conditions	O/E ratio
2	1	Chronic lung diseases and Asthma	162.15
	2	Emotional, nervous, or psychiatric problems and Memory-related disease	97.73
	3	Dyslipidemia and Diabetes or high blood sugar	38.39
	4	Heart disease and Memory-related disease	25.69
	5	Stroke and Memory-related disease	23.66
	6	Hypertension and Stroke	22.85
	7	Hypertension and Diabetes or high blood sugar	20.64
	8	Cancer or malignant tumor and Stroke	19.55
	9	Memory-related disease and Asthma	19.55
	10	Stroke and Asthma	19.55
3	1	Stroke, Emotional, nervous, or psychiatric problems and Memory-related disease	10287.72

2	Emotional, nervous, or psychiatric problems, Memory-related disease and Asthma	8498.56
3	Emotional, nervous, or psychiatric problems, Chronic lung diseases and Asthma	2274.26
4	Heart disease, Stroke and Memory-related disease	2253.50
5	Chronic lung diseases, Heart disease and Asthma	1992.69
6	Dyslipidemia, Heart disease and Memory-related disease	1443.25
7	Hypertension, Dyslipidemia and Diabetes or high blood sugar	1398.31
8	Hypertension, Stroke and Memory-related disease	1387.35
9	Chronic lung diseases, Memory-related disease and Asthma	1376.53
10	Chronic lung diseases, Arthritis or rheumatism and Asthma	1265.95

DISCUSSION

This is the first study to estimate the prevalence, patterns of multimorbidity among the elderly in China based on the nationally representative data from CHARLS, which covered 11,707 Chinese senior citizens aged over 60. The results of the study indicated that the prevalence of the 14 chronic diseases in the elderly reached 69.10% in China, and 43.6% of the elderly population suffered from multimorbidity. The average age of the entire sample was 0.66 years higher than that of the non-MCC group and in the MCC group, the mean age of women was 0.59 years higher than that of men, which was comparable to the results of previous studies. [18-22]

The prevalence of multimorbidity estimated in this study was much lower than that from previous studies in developed countries. A study of 543 patients over 65 in Ghent, Belgium showed that the multimorbidity rate was as high as 82.6%, [23].

1
2
3 Another study in Australia showed that 83.2% of the respondents suffered from
4 multimorbidity, [24] However, it is difficult to compare the prevalence generated from
5 different studies due to differences in the definition of multimorbidity, demographic
6 characteristics and study methodologies. [25-29]
7
8
9

10 In line with previous studies, increased age was found to be significantly associated
11 with higher prevalence of multimorbidity and there was also gender differences in the
12 rates of certain clusters of chronic conditions, which is understandable in view of the
13 distinction between female and male in terms of physiological features and lifestyles.
14 [30, 31]
15
16
17
18

19 In agreement with previous reports, arthritis or rheumatism, hypertension, stomach
20 or other digestive disease were the most common diseases in the MCC group. [10]
21 The prevalence of these three conditions was all above 20% in the entire sample and
22 above 45% in the MCC group. The most prevalent chronic combinations in the
23 sample could also be found in other studies. [23]
24
25
26
27
28

29 Although, arthritis or rheumatism, a component of all the leading three morbidity
30 dyads and triads, was also the most commonly occurring disease in multimorbidity, the
31 relative risk of this disease was only 4.65, the lowest in the 14 chronic diseases.
32 Moreover, arthritis or rheumatism is less common in morbidity clusters with large O/E
33 ratios. Therefore, the frequent occurrence of arthritis or rheumatism in multimorbidity
34 might be simply due to the high prevalence of the disease.
35
36
37
38
39

40 The relative risks for asthma, stroke, heart disease, and other six conditions were all
41 above ten, which meant that patients with these diseases were ten times easier to be
42 tormented by multimorbidity. These diseases also occurred at a high frequency in
43 multimorbidity with high O/E ratios, such as the clusters of pulmonary disease and
44 asthma, emotional and mental illness and memory-related disease, dyslipidemia and
45 diabetes, and stroke and emotional or mental illness and memory-related disease.
46 Patients with these diseases were vulnerable to comorbidity compared to those without
47 these diseases and thus should be the focus of future study.
48
49
50
51
52
53

54 This study featured the nationally representative sample of Chinese elderly
55
56
57

1
2
3 population, which was crucial to get an overall picture regarding multimorbidity among
4 the elderly in China. However, there were also limitations. First, this study used data
5 from the third wave of CHARLS, a survey which was conducted in 2015, the time lag
6 therefore was inevitable. Second, the chronic diseases included in the study were not
7 comprehensive enough, since only 15 chronic conditions were included in the survey.
8 Third, the outcome was based on self-report, which may have introduced some
9 misclassification bias. Later researches on the prevalence and patterns of
10 multimorbidity need to be carried out in depth with a more extensive survey of chronic
11 disease.
12
13
14
15
16
17
18
19
20

21 **CONCLUSIONS**

22
23 Multimorbidity still remains an underexplored area of research in China. [32].
24 Despite the increasing prevalence of multimorbidity, there is no specific proposals for
25 its diagnosis and treatment. [33] This study contributes to the understanding of the
26 prevalence and patterns of comorbidity among the elderly in China. Considering
27 China's aging population and the high prevalence of comorbidity in senior citizens, the
28 elderly should be prioritized in the fields of disease prevention and health promotion.
29
30
31
32
33
34
35
36
37

38 **Acknowledgements** The authors would like to thank the Chinese Center for Disease
39 Control and Prevention and Peking University for China Health and Retirement
40 Longitudinal Survey.
41
42

43 **Contributors** RZ analyzed and interpreted data, drafted the manuscript, approved the
44 final manuscript as submitted. YL revised the manuscript for important intellectual
45 content. LS analyzed and interpreted data and revised the manuscript for important
46 intellectual content. FC helped on the study design and revised the manuscript on the
47 study design and revised the manuscript.
48
49
50
51

52 **Funding** This work was funded by the National Natural Science Foundation of China
53 (7167030838).
54
55
56
57

1
2
3 **Competing interests** None declared.

4
5 **Patient consent** Obtained.

6
7 **Ethics approval** The original CHARLS was approved by the ethics review committee
8 of Peking University, and all participants gave written informed consent at the time of
9 participation
10

11
12 **Data sharing statement** No additional data are available
13
14

15 16 REFERENCES

- 17
18 1. Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and
19 implications for health care, research, and medical education: a cross-sectional
20 study. *Lancet* 2012; 380:37–43.doi: 10.1016/S0140-6736(12)60240-2
21
22 2. World Health Organization. Global status report on noncommunicable diseases,
23 2014.http://apps.who.int/nmh/publications/ncd-status-report-2014/en/index.html
24 (accessed 27 Oct 2017)
25
26 3. Moffat K, Mercer SW. Challenges of managing people with multimorbidity in
27 today's healthcare systems. *BMC Fam Prac* 2015;16:129.doi:
28 10.1186/s12875-015-0344-4
29
30 4. Schäfer Ingmar, von Leitner Eike-Christin, Schön Gerhard et al. Multimorbidity
31 patterns in the elderly: a new approach of disease clustering identifies complex
32 interrelations between chronic conditions. *PLoS One* 2010;12:e15941.doi:
33 10.1371/journal.pone.0015941
34
35 5. Atun R. Transitioning health systems for multimorbidity. *Lancet* 2015;386:721–
36 2.doi: 10.1016/S0140-6736(14)62254-6
37
38 6. Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of
39 multiple chronic conditions in the elderly. *Arch Intern Med* 2002;20: 2269-2276.doi:
40 10.1001/archinte.162.20.2269
41
42 7. Yang L, Wu M, Cui B, et al. Economic burden of cardiovascular diseases in China.
43 *Expert Rev Pharmacoecon Outcomes Res* 2008;8:349–56.doi:
44 10.1586/14737167.8.4.349
45
46
47
48
49
50
51
52
53
54
55
56

- 1
2
3 8. Zhao Y, Hu Y, Smith JP, et al. Cohort profile: the China Health and Retirement
4 Longitudinal Study (CHARLS). *Int J Epidemiol* 2014;1:61-69.doi:
5 10.1093/ije/dys203
6
7
- 8
9 9. Van den Bussche H, Koller D, Kolonko T, et al. Which chronic diseases and disease
10 combinations are specific to multimorbidity in the elderly? Results of a claims data
11 based cross-sectional study in Germany. *BMC Public Health* 2011;11:101-110.doi:
12 10.1186/1471-2458-11-101
13
14
- 15
16 10. Viera AJ. Odds ratios and risk ratios: what's the difference and why does it matter?
17 *South Med J* 2008; 7: 30-34.doi:10.1097/SMJ.0b013e31817a7ee4
18
- 19
20 11. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in
21 cohort studies of common outcomes. *JAMA*1998;19:1690-1691.doi:
22 10.1001/jama.280.19.1690
23
24
- 25
26 12. McNutt LA, Wu C, Xue X, et al. Estimating the Relative Risk in Cohort Studies
27 and Clinical Trials of Common Outcomes. *Am J Epidemiol* 2003;10:940-943.doi:
28 10.1002/cncr.30192
29
30
- 31
32 13. Marengoni A, Rizzuto D, Wang HX, et al. Patterns of chronic multimorbidity in the
33 elderly population. *J Am Geriatr Soc*2009;57:225-
34 30.doi:10.1111/j.1532-5415.2008.02109.x
35
- 36
37 14. Zhao, Shuyan. An Exploration of the Underlying Causes for Formation that a Gap
38 between Chinese Woman's and Man's Life Expectancy is Narrower than World
39 Average. *Ssrn Electronic Journal* 2014; 2: 212-221.doi:10.2139/ssrn.2410569
40
- 41
42 15. Crimmins EM, Kim JK, Solé-Auró A. Gender differences in health: results from
43 SHARE, ELSA and HRS. *Eur J Public Health* 2011;21:81-91.doi:
44 10.1093/eurpub/ckq022
45
46
- 47
48 16. Best WR, Cowper DC. The Ratio of Observed-to-Expected Mortality as a Quality
49 of Care Indicator in Non-Surgical VA Patients. *Med Care* 1994;4:390-400.doi:
50 10.1097/00005650-199404000-00007
51
- 52
53 17. Kastenholz KE, Weis M, Hagelstein C, et al. Correlation of Observed-to-Expected
54 MRI Fetal Lung Volume and Ultrasound Lung-to-Head Ratio at Different
55
56

- 1
2
3 Gestational Times in Fetuses With Congenital Diaphragmatic Hernia. *AJR Am J*
4 *Roentgenol*2016;4:856-866.doi:10.2214/AJR.15.15018
5
6
7 18. Melis R, Marengoni A, Angleman S, et al. Incidence and predictors of
8 multimorbidity in the elderly: a population-based longitudinal study. *PLoS One*
9 2014; 9: e103120.doi:10.1371/journal.pone.0103120
10
11
12 19. Laan W, Bleijenberg N, Drubbel I, et al. Factors associated with increasing
13 functional decline in multimorbid independently living older people. *Maturitas*
14 2013; 75: 276–81.doi:10.1016/j.maturitas.2013.04.005
15
16
17 20. Eckerblad J, Theander K, Ekdahl A, et al. To adjust and endure: a qualitative study
18 of symptom burden in older people with multimorbidity. *Appl Nurs Res*
19 2015;28:322–7.doi:10.1016/j.apnr.2015.03.008
20
21
22 21. Wister A, Kendig H, Mitchell B, et al. Multimorbidity, health and aging in Canada
23 and Australia: a tale of two countries. *BMC Geriatr*2016;1:163-176.doi:
24 10.1186/s12877-016-0341-z
25
26
27 22. Afshar S, Roderick PJ, Kowal P, et al. Multimorbidity and the inequalities of global
28 ageing: a cross-sectional study of 28 countries using the World Health Surveys.
29 *BMC Public Health*2015;15:776-786.doi:10.1186/s12889-015-2008-7
30
31
32 23. Boeckxstaens P, Peersman W, Goubin G, et al. A practice-based analysis of
33 combinations of diseases in patients aged 65 or older in primary care. *BMC Family*
34 *Practice* 2014;1:1-6.doi:
35
36
37 24. Britt HC , Harrison CM , Miller GC , et al . Prevalence and patterns of
38 multimorbidity in Australia. *Med J Aust* 2008;2: 72-77
39
40
41 25. Glynn LG , Valderas JM , Healy P , et al . The prevalence of multimorbidity in
42 primary care and its effect on health care utilization and cost. *Fam Pract*
43 2011;28:516–23.doi:10.1093/fampra/cm1013
44
45
46 26. Marengoni A , Angleman S , Melis R , et al . Aging with multimorbidity: a
47 systematic review of the literature. *Ageing Res Rev* 2011;10:430–
48 9.doi:10.1016/j.arr.2011.03.003
49
50
51 27. Barnett K , Mercer SW , Norbury M , et al . Epidemiology of multimorbidity and
52 implications for health care, research, and medical education: a cross-sectional
53 study. *Lancet* 2012;380:37–43.doi:10.1016/S0140-6736(12)60240-2
54
55
56
57
58
59
60

- 1
2
3 28. Fortin M , Stewart M , Poitras ME , et al . A systematic review of prevalence studies
4 on multimorbidity: toward a more uniform methodology. *Ann Fam Med*
5 2012;10:142–51.doi:10.1370/afm.1337
6
7
8 29. Fortin M , Hudon C , Haggerty J , et al . Prevalence estimates of multimorbidity: a
9 comparative study of two sources. *BMC Health Serv Res*
10 2010;10:111.doi:10.1186/1472-6963-10-1
11
12 30. Schäfer I, von Leitner E C, Schön G, et al. Multimorbidity Patterns in the Elderly: A
13 New Approach of Disease Clustering Identifies Complex Interrelations between
14 Chronic Conditions[J]. *Plos One*, 2010, 5(12):e15941.doi:
15 10.1371/journal.pone.0015941
16
17 31. Scherer M, Hansen H, Gensichen J, et al. Association between multimorbidity
18 patterns and chronic pain in elderly primary care patients: a cross-sectional
19 observational study. *BMC Family Practice*. 2016;17:68.
20
21 doi:10.1186/s12875-016-0468-1.
22
23
24 32. Bao W, Hu D, Shi X, et al. Comorbidity increased the risk of falls in Chinese older
25 adults: A cross-sectional study. *Int J Clin Exp Med*,2017;7:10753-10763.
26
27
28 33. Gao N, Yuan Z, Tang X, et al. Prevalence of CHD-related metabolic comorbidity of
29 diabetes mellitus in Northern Chinese adults: the REACTION study. *J Diabetes*
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1. Frequency and percentage of people aged over 60 suffering from different diseases based on CHARLS data

211x107mm (96 x 96 DPI)




Figure 2. Prevalence rates of the chronic condition in elderly people over 60 years old based on CHARLS data.jpg

161x91mm (150 x 150 DPI)

STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology*
Checklist for cohort, case-control, and cross-sectional studies (combined)

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any pre-specified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	4
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	Not applicable
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	4
Bias	9	Describe any efforts to address potential sources of bias	Not applicable
Study size	10	Explain how the study size was arrived at	4
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	5
		(b) Describe any methods used to examine subgroups and interactions	5
		(c) Explain how missing data were addressed	Not applicable
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	5

		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	Not applicable
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	4
		(b) Give reasons for non-participation at each stage	Not applicable
		(c) Consider use of a flow diagram	Not applicable
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	6
		(b) Indicate number of participants with missing data for each variable of interest	5
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	Not applicable
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	Not applicable
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	Not applicable
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	5
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	6
		(b) Report category boundaries when continuous variables were categorized	8
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	10
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	6-12
Discussion			
Key results	18	Summarise key results with reference to study objectives	12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	14
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	14
Generalisability	21	Discuss the generalisability (external validity) of the study results	14
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	14

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.

BMJ Open

Prevalence and patterns of multimorbidity among the elderly in China: a cross-sectional study using national survey data

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-024268.R1
Article Type:	Research
Date Submitted by the Author:	23-Oct-2018
Complete List of Authors:	zhang, ran; China Pharmaceutical University, School of International Pharmaceutical Business Lu, Yun; China Pharmaceutical University, School of International Pharmaceutical Business Shi, Liuyan; China Pharmaceutical University, School of International Pharmaceutical Business Zhang, SongLin; China Pharmaceutical University, School of International Pharmaceutical Business Chang, Feng; China Pharmaceutical University, School of International Pharmaceutical Business
Primary Subject Heading:	Health informatics
Secondary Subject Heading:	Public health, Qualitative research
Keywords:	multimorbidity, cross-sectional study, Prevalence, Observed-to-expected ratio, China

SCHOLARONE™
Manuscripts

1
2
3
4 **Prevalence and patterns of multimorbidity among the elderly in**
5
6 **China: a cross-sectional study using national survey data**
7
8
9

10
11 **Corresponding author:** Feng Chang

12
13 **Postal address:** 639 Longmian Road, Jiangning District, Nanjing, Jiangsu
14
15 Province, 211198

16
17 **E-mail:** cpucf@163.com

18
19 **telephone number:** +86-13805153128
20
21

22
23 **First author:** Ran Zhang

24
25 **E-mail:** ranzai7@126.com

26
27 **Department:** China Pharmaceutical University

28
29 **Institution:** School of International Pharmaceutical Business

30
31 **City:** Nanjing, Jiangsu Province

32
33 **Country:** China
34
35

36
37 **Co-authors:** Yun Lu **E-mail:** luyun20159@163.com

38
39 **Co-authors:** Liuyan Shi **E-mail:** juliasmithsly@163.com

40
41 **Co-authors:** Songlin Zhang **E-mail:** 1069822493@qq.com

42
43 **Department:** China Pharmaceutical University

44
45 **Institution:** School of International Pharmaceutical Business

46
47 **City:** Nanjing, Jiangsu Province

48
49 **Country:** China
50
51

52
53 **Keywords**

54
55
56 Multimorbidity; cross-sectional study; Prevalence; Observed-to-expected ratio; China
57
58

1
2
3
4 **Word count 3853**
5
6
7

8 **ABSTRACT**
9

10 **Objectives:** Examination of the prevalence and patterns of multimorbidity among the
11 elderly in China.
12

13 **Design:** Cross-sectional study.
14

15 **Setting:** More than 10,000 households in 28 of the 34 provinces of mainland China.
16

17 **Participants:** 11,707 Chinese adults aged 60 and over.
18

19 **Primary outcome measures:** Prevalence and patterns of multimorbidity among the
20 participants. Relative risks were calculated to estimate the probability of up to 14 chronic
21 conditions coexisting with each other. Observed-to-expected (O/E) ratios were used to
22 analyze the patterns of multimorbidity.
23
24
25
26
27

28 **Results:** Multimorbidity was present in 43.6% of respondents from the sample population,
29 with women having the greater prevalence compared to men. There were 804 different
30 comorbidity combinations identified, including 76 dyad combinations and 169 triad
31 combinations. The top 10 morbidity dyads and triads accounted for 69.01% and 47.05% of
32 the total dyad and triad combinations observed, respectively. Among the 14 chronic
33 conditions included in the study, asthma, stroke, heart attack and six other chronic
34 conditions were the main components of multimorbidity due to their high relative risk
35 ratios. The most frequently occurring clusters with higher O/E ratios were stroke along
36 with emotional, nervous, or psychiatric problems; memory-related diseases together
37 emotional, nervous, or psychiatric problems; and memory-related diseases and asthma
38 accompanied by chronic lung diseases and asthma.
39
40
41
42
43
44
45
46
47
48
49

50 **Conclusions:** The results of this study highlight the high prevalence of multimorbidity in
51 the elderly population in China. Further studies are required to understand the etiology of
52 multimorbidity, and future primary healthcare policies should be made while taking
53
54
55
56

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

multimorbidity into consideration.

For peer review only

Strengths and limitations of this study

Strengths

- This is the first study to estimate the prevalence and patterns of multimorbidity among the elderly population in China.
- Data for this study were collected from a nationally representative longitudinal survey of 17,708 Chinese residents.

Limitations

- Only 14 predefined chronic diseases were included in the study, and these may not be comprehensive of the conditions of the population.
- The data analyzed from the CHARLS were originally collected by population self-reporting, not clinician evaluation, and could partially reflect some associated biases or confounds.
- The exclusion of incomplete data may cause a selection bias.

INTRODUCTION

Multimorbidity, or the simultaneous occurrence of two or more chronic conditions in an individual, is becoming increasingly common, and this has been reported to increase progressively with age. [1, 2] At present, with China's aging population having an increasing prevalence of chronic conditions, multimorbidity among the elderly poses an enormous societal cost due to increased mortality rates and healthcare utilization. [3] However, to date, research on chronic conditions in China has focused on single disease states, and the coexistence of multiple chronic conditions has not been investigated systematically and thoroughly.

There is a significant difference in the etiological analysis between patients with single chronic conditions and those with multimorbidity. [4] The coexistence of chronic conditions in a patient is more than a random event, it is more typically due to the causal relationship between some diseases and shared pathogenic factors. [5, 6] Moreover, the interactions between diseases or between a disease and host result in differences in the severity of multimorbidity and functional status and prognosis of patients with multimorbidity. [7] Consequently, it is imperative to begin research on multimorbidity in China for the cost-effective treatments that the results may help to suggest. [8] The purpose of this study was therefore to determine the prevalence of multimorbidity among the elderly in China and to reveal morbidity combinations, which may benefit the design and implementation of a modified healthcare system with consideration for patients with multimorbidity.

METHODS

Data source

Data for this study were collected from the third response of the China Health and Retirement Longitudinal Survey (CHARLS), which is the most current data available. The CHARLS is a nationally representative longitudinal survey of Chinese residents aged 45

1
2
3 and older that was conducted by the Chinese Center for Disease Control and Prevention,
4 along with Peking University, to help China to adjust to the rapid aging of its population
5 through the evaluation of social, economic, and health circumstances on the community
6 level using data collected by interviews, physical measurements and blood sample
7 collection. [9] The national baseline survey began in 2011 and involved 17,708 respondents
8 from 150 county-level units, 450 village-level units, and approximately 10,000 households.
9 Afterwards, CHARLS respondents were followed every second year, with their informed
10 consent, and the study was approved by the Peking University Biomedical Ethics
11 Committee (IRB00001052-14013-exemption).
12
13
14
15
16
17
18
19

20 **Variables**

21
22 The core CHARLS questionnaires included sections requesting information on
23 demographic factors, family structure and changes, health status and functioning,
24 healthcare and insurance, work, retirement and pension, income and consumption, and
25 assets (individual and household). Information was collected by interview by trained staff.
26 For the current study, the eligible and included participants were determined by being aged
27 60 and over, and data on gender, age and health status was used from the general health
28 status and disease history section of senior citizens in the 2015 CHARLS data. This
29 information included the following 14 common chronic health problems: hypertension,
30 dyslipidemia (high blood lipids or low cholesterol), diabetes or elevated blood glucose
31 (including impaired glucose tolerance and fasting blood glucose), cancer (excluding mild
32 skin cancers), chronic lung disease such as chronic bronchitis or emphysema, pulmonary
33 heart disease (excluding tumors or cancer), liver disease (other than fatty liver, tumors, or
34 cancer), heart disease (such as myocardial infarction, coronary heart disease, angina
35 pectoris, congestive heart failure and other heart diseases), stroke, kidney disease
36 (excluding tumors or cancer), stomach or other digestive diseases (excluding tumors or
37 cancer), emotional and mental problems, memory-related diseases (such as Alzheimer's
38 disease, brain atrophy, Parkinson's disease), arthritis or rheumatism, and asthma. All these
39 data were based on self-reports. Accordingly, multimorbidity was defined as the
40 coexistence of more than one of the 14 chronic conditions, with acute or subacute forms of
41 certain conditions being excluded in this study due to the CHARLS data collection protocol.
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56

Statistical analysis

To detect the demographic characteristics of patients with multimorbidity, respondents were divided into two groups: those with multiple chronic conditions (MCC group) and those without multiple chronic conditions (Non-MCC group). Descriptive statistics were calculated and expressed as means (SD) and frequencies (percentage). We applied the T² and χ^2 tests to test the differences in age, gender and the mean number of chronic conditions across different subgroups. Respective prevalence in the MCC group and the non-MCC group were calculated separately.

To determine the most common combination of chronic diseases, the prevalence of morbidity and multimorbidity dyads and triads were estimated, respectively. Next, the expected number of patients with a chronic disease were calculated, and the observed-to-expected (O/E) ratios were determined by dividing the number of patients in those groups by the expected number of patients. Observed-to-expected ratios were used to estimate the conditional probability of coexistence of two or three chronic conditions. [10] As an important indicator for assessing the correlation between diseases, the O/E ratio has been used in many areas of comorbidity. [10, 11] The relative risk of comorbidity for individual chronic conditions was also calculated. Relative risk of comorbidity (RR) is the ratio of the number of people with a certain chronic condition who suffer from multimorbidity to the number of patients with the same disease who do not suffer from multimorbidity. [11, 12] In other words, a higher RR value means a higher probability that the disease coexists with other diseases. However, it should be noted that there is no direct relationship between the relative risk of comorbidity and the overall prevalence of the diseases. [13, 14]

All analyses in this study were completed using Stata software V.14.0 for Windows (Stata Corp). P Values <0.05 were considered to be statistically significant.

Patient and public involvement

Patients and the public were not involved in the development of the research question or outcome measures of the study, nor were they involved in study design and execution. There are no plans to disseminate the research results to study participants.

RESULTS

Characteristics of participants

The data were gathered from the third response set of CHARLS. After exclusion of participants with incomplete data (1,002) and aged under 60 (9,259), there were 11,707 respondents with available information on related chronic diseases that were included in this study. The selection process of study sample is shown in Figure 1. The demographic characteristics of sample respondents and statistical significance test results are presented in Table 1.

Overall, the mean age for the sample population was 70.5 (ranging from 60 to 107). The sample population consisted of 5,705 (48.7%) males and 6002 (51.2%) females, and 43.6% of them suffered from multimorbidity. The median of chronic conditions in the MCC group was 3.01, compared to 0.45 in the Non-MCC group. Samples in the MCC group were 0.66 year older than those belonged to the non-MCC group. Gender differences with regard to the age of samples between the MCC group and the non-MCC group (70.57 for MCC group and 69.91 for non-MCC group) were small but statistically significant ($p < 0.001$). The prevalence of multimorbidity in the female population was higher than that for the males (54.41% vs 45.59%), which is in accordance with trends reported in other available literature. [15, 16] Figure 2 shows the number and proportion of respondents over 60 according to morbidity numbers. It can be seen that among all the participants aged over 60, 43.6% suffer from multimorbidity. Considering that only 30.9% of the respondents did not have the 14 chronic diseases, and 43.7% of them had two or more chronic diseases, multimorbidity would be a major problem faced by the health care system.

Table 1. Demographic characteristics of all respondents, the MCC group and non-MCC group

	All respondent	MCC group	Non-MCC group	P*
Number of people	11707	5107	6600	
Proportion (%)	100%	43.62%	56.38%	
Mean age				

All respondents (SD)	70.20(7.907)	70.57(7.701)	69.91(8.051)	<0.001
Male (SD)	69.97(7.575)	70.50(7.348)	69.60(7.707)	<0.001
Female (SD)	70.39(8.189)	70.62(7.892)	70.19(8.359)	<0.001
Gender (% females)	51.28%	54.41%	48.83%	<0.001
Mean number of chronic conditions				
All respondents (SD)	1.57(1.560)	3.01(1.259)	0.45(0.498)	<0.001
Male (SD)	1.47(1.534)	2.98(1.265)	0.44(0.496)	<0.001
Female (SD)	1.65(1.581)	3.03(7.982)	0.47(0.499)	<0.001

SD = standard deviation;
p* = statistical significance of the difference between the MCC and the non-MCC sample (t-tests were performed for comparison of means, and chi-square-tests for differences between percentages)

Prevalence of chronic conditions

The prevalence of chronic conditions in the entire sample, the MCC group and the non-MCC group are shown in [Figure 3](#). The prevalence of all fourteen chronic conditions in the MCC group was significantly higher than that in the entire sample. For instance, the prevalence of arthritis or rheumatism, hypertension, stomach or other digestive disease, heart disease and chronic lung disease were 65.97%, 48.82%, 45.86%, 29.00% and 24.97% in the MCC group, compared to 38.49%, 26.41%, 24.52%, 12.32% and 12.32% in the entire sample, respectively.

[Table 2](#) shows the relative risks of comorbidity determined for the 14 chronic diseases reported in this study. It can be seen that the overall relative risks for asthma, stroke, heart disease and six other conditions were all above 10, which meant these diseases were >10 times easier to coexist with other chronic conditions and result in multimorbidity. In addition, the relative risks for certain diseases were positively associated with gender. For example, men had significantly higher relative risks for asthma, but lower relative risks for diabetes or high blood sugar, compared to women.

Table 2 Relative risks of multimorbidity for different chronic conditions according to gender

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

Chronic conditions	All respondents	95% Confidence Interval		Female	95% Confidence Interval		Male	95% Confidence Interval	
		Lower Bound	Upper Bound		Lower Bound	Upper Bound		Lower Bound	Upper Bound
		High relative risk of multimorbidity							
Asthma	26.18	17.82	38.46	20.67	11.85	36.06	32.68	19.18	55.67
Stroke	18.62	12.11	28.64	21.57	10.61	43.86	17.43	10.13	29.99
Heart disease	15.56	12.99	18.63	16.48	12.80	21.21	14.26	11.02	18.46
Diabetes or high blood sugar	14.40	11.18	18.55	15.68	10.86	22.63	13.11	9.24	18.62
Dyslipidemia	14.05	11.54	17.12	15.13	11.37	20.14	12.97	9.86	17.05
Memory-related disease	13.69	8.85	21.16	34.17	12.63	92.44	9.28	5.66	15.21
Kidney disease	11.57	9.24	14.49	15.01	10.17	22.43	10.24	7.78	13.48
Liver disease	11.10	8.37	14.71	16.07	9.70	26.63	9.15	6.49	12.89
Chronic lung diseases	9.87	8.43	11.55	10.71	8.26	13.88	9.74	8.00	11.86
Low relative risk of multimorbidity									
Emotional, nervous, or psychiatric problems	7.42	4.94	11.15	6.24	3.78	10.30	9.36	4.65	18.85
Stomach or other digestive disease	5.73	5.25	6.25	6.20	5.48	7.02	5.23	4.62	5.91
Hypertension	5.38	4.96	5.84	4.90	4.40	5.47	5.92	5.24	6.69
Cancer or malignant tumor	4.88	3.20	7.45	5.33	3.06	9.29	3.99	2.07	7.72
Arthritis or rheumatism	3.83	3.61	4.05	3.70	3.43	3.99	3.91	3.59	4.26

Common multimorbidity combinations

There were 804 possible comorbidity combinations that were identified in the MCC group after statistical analysis, including 72 dyads and 169 triads. The 10 most frequently occurring morbidity dyads and triads are presented respectively in [Table 3](#) and [Table 4](#).

Table 3 Prevalence of the 10 most common morbidity dyads

Rank	Morbidity dyads	Prevalence			Mean Age
		All respondents	female	male	

1	Arthritis or rheumatism and Stomach or other digestive disease	4.73%	3.56%	5.96%	69.20
2	Arthritis or rheumatism and Hypertension	2.85%	2.20%	3.53%	71.25
3	Arthritis or rheumatism and Chronic lung diseases	1.13%	1.22%	1.04%	71.55
4	Hypertension and heart problems	1.03%	1.00%	1.06%	71.80
5	Hypertension and Stomach or other digestive disease	0.89%	0.83%	0.95%	69.07
6	Hypertension and Dyslipidemia	0.86%	0.81%	0.91%	68.58
7	Arthritis or rheumatism and heart problems	0.76%	0.53%	1.00%	70.72
8	Arthritis or rheumatism and Kidney disease	0.64%	0.73%	0.54%	68.24
9	Hypertension and Diabetes or high blood sugar	0.58%	0.50%	0.67%	70.97
10	Chronic lung diseases and Asthma	0.53%	0.65%	0.40%	71.15

Table 4 Prevalence of the 10 most common morbidity triads

Rank	Morbidity triads	Prevalence			Mean Age
		All respondents	female	male	
1	Arthritis or rheumatism, Stomach or other digestive disease and Hypertension	1.19%	0.80%	1.60%	70.96
2	Arthritis or rheumatism, Stomach or other digestive disease and Chronic lung diseases	0.82%	0.97%	0.67%	70.82
3	Arthritis or rheumatism, Heart disease and Hypertension	0.63%	0.37%	0.91%	69.93
4	Arthritis or rheumatism, Heart disease and Stomach or other digestive disease	0.59%	0.25%	0.95%	71.51

5	Hypertension, Dyslipidemia and Arthritis or rheumatism	0.44%	0.31%	0.57%	70.13
6	Hypertension, Dyslipidemia and Heart problems	0.42%	0.35%	0.49%	71.17
7	Arthritis or rheumatism, Kidney disease and Stomach or other digestive disease	0.42%	0.40%	0.44%	70.14
8	Arthritis or rheumatism, Asthma and Chronic lung diseases	0.40%	0.46%	0.33%	69.18
9	Hypertension, Dyslipidemia and Diabetes or high blood sugar	0.35%	0.35%	0.35%	71.51
10	Arthritis or rheumatism, Stomach or other digestive disease and Liver disease	0.53%	0.57%	0.49%	70.29

Theoretically, there are 91 dyad combinations and 364 triad combinations possible given the 14 different chronic conditions considered in this study. However, only 72 types (79.12%) of dyads and 169 types (46.43%) of triads emerged in the sample. The 10 most frequently occurring morbidity dyads accounted for 69.01% of the 72 dyad combinations, and the proportion of the 10 most common triad combinations in the 169 triad combinations was 47.05%. Arthritis or rheumatism, which appeared in five of the top 10 dyad combinations and eight of the top 10 triad combinations of chronic conditions, was the main component of the leading morbidity dyads and triads.

There were significant gender differences observed in the occurrences of these multimorbidity combinations. The numbers of women with triad combinations of chronic diseases were generally higher than for men with the same morbidity triads. For example, women had significantly higher prevalence of arthritis and hypertension and hyperlipidemia than men (78.26% vs 21.74%). Among morbidity dyads, the prevalence of heart disease and arthritis or rheumatism in women was nearly two times higher than that in men, while the cluster of arthritis or rheumatism and kidney disease occurred more frequently in men than in women. No age difference was detected in the probability of

these particular multimorbidity combinations occurring.

The O/E ratio was also used to analyze the multimorbidity pattern. [17] The higher the O/E value, the higher the probability of coexistence of chronic conditions. [18] Table 5 shows O/E ratios determined for the 10 most prevalent morbidity dyads and triads. The prevalence of each conditions and the dyad and triad prevalence are presented in Annex 1. In the midst of those triad combinations of chronic conditions, the two clusters with significantly higher O/E ratios were emotional, nervous, or psychiatric problems and stroke and memory-related disease (O/E ratio = 10287.72), emotional, nervous, or psychiatric problems and memory-related disorders and asthma (O/E ratio = 8498.56). These four conditions also dominated the three leading dyads with the highest O/E ratios: 97.73 for the combination of emotional and mental disorders and memory- related diseases, 23.66 for the combination of stroke and memory related disease and 19.55 for the combination of memory-related disease and asthma.

Table 5 O/E ratios for the 10 most prevalent morbidity dyads and triads

Number of chronic conditions	Rank	Chronic conditions	O/E ratio
2	1	Chronic lung diseases and Asthma	162.15
	2	Emotional, nervous, or psychiatric problems and Memory-related disease	97.73
	3	Dyslipidemia and Diabetes or high blood sugar	38.39
	4	Heart disease and Memory-related disease	25.69
	5	Stroke and Memory-related disease	23.66
	6	Hypertension and Stroke	22.85
	7	Hypertension and Diabetes or high blood sugar	20.64
	8	Cancer or malignant tumor and Stroke	19.55
	9	Memory-related disease and Asthma	19.55

	10	Stroke and Asthma	19.55
3	1	Stroke, Emotional, nervous, or psychiatric problems and Memory-related disease	10287.72
	2	Emotional, nervous, or psychiatric problems, Memory-related disease and Asthma	8498.56
	3	Emotional, nervous, or psychiatric problems, Chronic lung diseases and Asthma	2274.26
	4	Heart disease, Stroke and Memory-related disease	2253.50
	5	Chronic lung diseases, Heart disease and Asthma	1992.69
	6	Dyslipidemia, Heart disease and Memory-related disease	1443.25
	7	Hypertension, Dyslipidemia and Diabetes or high blood sugar	1398.31
	8	Hypertension, Stroke and Memory-related disease	1387.35
	9	Chronic lung diseases, Memory-related disease and Asthma	1376.53
	10	Chronic lung diseases, Arthritis or rheumatism and Asthma	1265.95

DISCUSSION

This is the first study to estimate the prevalence and patterns of multimorbidity among the elderly in China based on the nationally representative data from CHARLS, which covered 11,707 Chinese senior citizens of age 60 and over. The results of the study indicated that the prevalence of the 14 chronic diseases evaluated in the elderly reached 69.10% in China, and that 43.6% of the elderly population suffered from multimorbidity. The average age of the MCC group was 0.66 years higher than that of the non-MCC group and in the MCC group, the mean age of women was 0.66 years higher than that of men, which was comparable to the results of previous studies. [19-23]

1
2
3
4 The prevalence of multimorbidity estimated in this study was much lower than that from
5 previous studies in other developed countries. For example, a study of 543 patients over
6 age 65 in Ghent, Belgium showed that the multimorbidity rate was as high as 82.6%, [24].
7
8 Another study in Australia showed that 83.2% of the respondents suffered from
9 multimorbidity. [25] However, it is difficult to compare the prevalence generated from
10 different studies due to differences in the selected definitions of multimorbidity,
11 demographic characteristics of the samples, and different study methodologies. [26-30]
12
13

14
15
16 In agreement with previous reports, arthritis or rheumatism, hypertension, stomach or
17 other digestive disease were the most common diseases in the MCC group. [11] The
18 prevalence of these three conditions was each above 20% in the entire sample, and above
19 45% in the MCC group. The most prevalent chronic combinations in the sample could also
20 be found in other studies. [24] The results of this study showed that the prevalence of
21 arthritis or rheumatism was high and easy to coexist with other conditions. In addition to
22 the chronic conditions mentioned above, previous studies demonstrated that women with
23 rheumatoid arthritis might have a predisposition to gallstones which could manifest in
24 middle or older age compared with women in the general population. This phenomenon
25 could be related to chronic inflammation and HDL metabolism. [31]
26
27
28
29
30
31
32
33
34
35
36
37

38 Although arthritis or rheumatism, a component of all the leading three morbidity dyads
39 and triads, was also the most commonly occurring disease in multimorbidity, the relative
40 risk of this disease was only 4.65, the lowest in the 14 chronic diseases. Moreover, arthritis
41 or rheumatism is less common in morbidity clusters with large O/E ratios. Therefore, the
42 frequent occurrence of arthritis or rheumatism in multimorbidity might be simply due to
43 the high prevalence of the disease.
44
45
46
47
48
49

50 The relative risks for asthma, stroke, heart disease, and six other conditions were all
51 above 10, which means that patients with these diseases were 10 times more likely to be
52 afflicted by multimorbidity. These diseases also occurred at a high frequency in
53
54
55
56

1
2
3
4 multimorbidity with high O/E ratios, such as the clusters of pulmonary disease and asthma,
5
6 emotional and mental illness and memory-related disease, dyslipidemia and diabetes, and
7
8 stroke and emotional or mental illness and memory-related disease. Patients with these
9
10 diseases were more likely to express comorbidity compared to those without these diseases,
11
12 and thus should be the focus of future research studies.

13
14 This study featured a nationally representative sample of the Chinese elderly population,
15
16 which was crucial to get an overall understanding of multimorbidity among the elderly in
17
18 China. However, there were also limitations with the data sample and study. For example,
19
20 this study used data from the third wave report of CHARLS, a survey which was conducted
21
22 in 2015, and there is accordingly a time lag to now that exists. Additionally, the chronic
23
24 diseases included in the study were not comprehensive, since only 14 chronic conditions
25
26 were included in the survey. Finally, the data obtained from the survey was based on self-
27
28 reporting, which may have introduced some misclassification bias or other confounds.
29
30 Later research on the prevalence and patterns of multimorbidity should be carried out in-
31
32 depth with a more extensive survey of chronic disease.
33
34
35

36 CONCLUSIONS

37
38 Multimorbidity remains an underexplored area of research in China. [32]. Despite the
39
40 increasing prevalence of multimorbidity, there are no specific proposals for its diagnosis
41
42 and treatment. [33] This study contributes to the understanding of the prevalence and
43
44 patterns of comorbidity among the elderly in China. Considering China's aging population
45
46 and the high prevalence of comorbidity in senior citizens, the elderly should be prioritized
47
48 in the fields of disease prevention and health promotion.
49
50
51
52
53

54 **Acknowledgements** The authors would like to thank the Chinese Center for Disease
55
56

1
2
3
4 Control and Prevention and Peking University for access to China Health and Retirement
5
6 Longitudinal Survey data.

7
8 **Contributors** Ran Zhang analyzed and interpreted data, drafted the manuscript, approved
9
10 the final manuscript as submitted. Yun Lu revised the manuscript for important intellectual
11
12 content. Liuyan Shi analyzed and interpreted data and revised the manuscript for important
13
14 intellectual content. Songlin Zhang handled and solved the data problems, analyzed and
15
16 revised the data. Feng Chang helped on the study design and revised the manuscript.

17
18 **Funding** This work was funded by the National Natural Science Foundation of China
19
20 (7167030838).

21
22 **Competing interests** None declared.

23
24 **Patient consent** Obtained.

25
26 **Ethics approval** The original CHARLS was approved by the ethics review committee of
27
28 Peking University, and all participants gave written informed consent at the time of
29
30 participation

31
32 **Data sharing statement** No additional data are available

33 34 35 36 REFERENCES

- 37
38 1. Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and
39
40 implications for health care, research, and medical education: a cross-sectional study.
41
42 *Lancet* 2012; 380:37–43.doi:10.1016/S0140-6736(12)60240-2
43
44 2. World Health Organization. Global status report on noncommunicable diseases,
45
46 2014.http://apps.who.int/nmh/publications/ncd-status-report-2014/en/index.html
47
48 (accessed 27 Oct 2017)
49
50 3. Lee J T, Hamid F, Pati S, et al. Impact of Noncommunicable Disease Multimorbidity
51
52 on Healthcare Utilisation and Out-Of-Pocket Expenditures in Middle-Income
53
54 Countries: Cross Sectional Analysis. *PLoS One* 2015;10:103-110. doi:
55
56

- 1
2
3
4 10.1371/journal.pone.0127199
5
6 4. Moffat K, Mercer SW. Challenges of managing people with multimorbidity in today's
7 healthcare systems. *BMC Fam Pract* 2015;16:129.doi: 10.1186/s12875-015-0344-4
8
9
10 5. Schäfer Ingmar, von Leitner Eike-Christin, Schön Gerhard et al. Multimorbidity
11 patterns in the elderly: a new approach of disease clustering identifies complex
12 interrelations between chronic conditions. *PLoS One* 2010;12:e15941.doi:
13 10.1371/journal.pone.0015941
14
15
16 6. Atun R. Transitioning health systems for multimorbidity. *Lancet* 2015;386:721–2.doi:
17 10.1016/S0140-6736(14)62254-6
18
19
20 7. Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of
21 multiple chronic conditions in the elderly. *Arch Intern Med* 2002;20: 2269-2276.doi:
22 10.1001/archinte.162.20.2269
23
24
25 8. Yang L, Wu M, Cui B, et al. Economic burden of cardiovascular diseases in China.
26 *Expert Rev Pharmacoecon Outcomes Res* 2008;8:349–56.doi:
27 10.1586/14737167.8.4.349
28
29
30 9. Zhao Y, Hu Y, Smith JP, et al. Cohort profile: the China Health and Retirement
31 Longitudinal Study (CHARLS). *Int J Epidemiol* 2014;1:61-69.doi: 10.1093/ije/dys203
32
33
34 10. Van den Bussche H, Koller D, Kolonko T, et al. Which chronic diseases and disease
35 combinations are specific to multimorbidity in the elderly? Results of a claims data
36 based cross-sectional study in Germany. *BMC Public Health* 2011;11:101-110.doi:
37 10.1186/1471-2458-11-101
38
39
40 11. Viera AJ. Odds ratios and risk ratios: what's the difference and why does it matter?
41 *South Med J* 2008; 7: 30-34.doi:10.1097/SMJ.0b013e31817a7ee4
42
43
44 12. Vettore MV, Meira GF, Rebelo MA et al. Multimorbidity patterns of oral clinical
45 conditions, social position, and oral health-related quality of life in a population-based
46 survey of 12-yr-old children. *Eur J Oral Sci.* 2016 ; 6:580-590. doi:
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 10.1111/eos.12304. Epub 2016 Oct 8.
5
6 13. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in
7 cohort studies of common outcomes. *JAMA* 1998;19:1690-1691.doi:
8 10.1001/jama.280.19.1690
9
10
11
12 14. McNutt LA, Wu C, Xue X, et al. Estimating the Relative Risk in Cohort Studies and
13 Clinical Trials of Common Outcomes. *Am J Epidemiol* 2003;10:940-943.doi:
14 10.1002/cncr.30192
15
16
17
18 15. Zhao, Shuyan. An Exploration of the Underlying Causes for Formation that a Gap
19 between Chinese Woman's and Man's Life Expectancy is Narrower than World
20 Average. *Ssrn Electronic Journal* 2014; 2: 212-221.doi:10.2139/ssrn.2410569
21
22
23
24 16. Crimmins EM, Kim JK, Solé-Auró A. Gender differences in health: results from
25 SHARE, ELSA and HRS. *Eur J Public Health* 2011;21:81-91.doi:
26 10.1093/eurpub/ckq022
27
28
29
30 17. Marengoni A, Rizzuto D, Wang HX, et al. Patterns of chronic multimorbidity in the
31 elderly population. *J Am Geriatr Soc* 2009;57:225-30.doi:10.1111/j.1532-
32 5415.2008.02109.x
33
34
35
36 18. Best WR, Cowper DC. The Ratio of Observed-to-Expected Mortality as a Quality of
37 Care Indicator in Non-Surgical VA Patients. *Med Care* 1994;4:390-400.doi:
38 10.1097/00005650-199404000-00007
39
40
41
42 19. Kastenholz KE, Weis M, Hagelstein C, et al. Correlation of Observed-to-Expected MRI
43 Fetal Lung Volume and Ultrasound Lung-to-Head Ratio at Different Gestational Times
44 in Fetuses With Congenital Diaphragmatic Hernia. *AJR Am J Roentgenol* 2016;4:856-
45 866.doi:10.2214/AJR.15.15018
46
47
48
49
50 20. Melis R, Marengoni A, Angleman S, et al. Incidence and predictors of multimorbidity
51 in the elderly: a population-based longitudinal study. *PLoS One* 2014; 9:
52 e103120.doi:10.1371/journal.pone.0103120
53
54
55
56
57
58
59
60

- 1
2
3
4 21. Laan W, Bleijenberg N, Drubbel I, et al. Factors associated with increasing functional
5 decline in multimorbid independently living older people. *Maturitas* 2013; 75: 276–
6 81.doi:10.1016/j.maturitas.2013.04.005
7
8
9
10 22. Eckerblad J, Theander K, Ekdahl A, et al. To adjust and endure: a qualitative study of
11 symptom burden in older people with multimorbidity. *Appl Nurs Res* 2015;28:322–
12 7.doi:10.1016/j.apnr.2015.03.008
13
14
15
16 23. Wister A, Kendig H, Mitchell B, et al. Multimorbidity, health and aging in Canada and
17 Australia: a tale of two countries. *BMC Geriatr*2016;1:163-176.doi: 10.1186/s12877-
18 016-0341-z
19
20
21
22 24. Afshar S, Roderick PJ, Kowal P, et al. Multimorbidity and the inequalities of global
23 ageing: a cross-sectional study of 28 countries using the World Health Surveys. *BMC*
24 *Public Health*2015;15:776-786.doi:10.1186/s12889-015-2008-7
25
26
27
28 25. Boeckxstaens P, Peersman W, Goubin G, et al. A practice-based analysis of
29 combinations of diseases in patients aged 65 or older in primary care. *BMC Family*
30 *Practice* 2014;1:1-6.doi: 10.1186/1471-2296-15-159.
31
32
33 26. Britt HC , Harrison CM , Miller GC , et al . Prevalence and patterns of
34 multimorbidity in Australia. *Med J Aust* 2008;2: 72-77
35
36
37 27. Glynn LG , Valderas JM , Healy P , et al . The prevalence of multimorbidity in primary
38 care and its effect on health care utilization and cost. *Fam Pract* 2011;28:516–
39 23.doi:10.1093/fampra/cmz013
40
41
42 28. Marengoni A , Angleman S , Melis R , et al . Aging with multimorbidity: a systematic
43 review of the literature. *Ageing Res Rev* 2011;10:430–9.doi:10.1016/j.arr.2011.03.003
44
45
46 29. Barnett K , Mercer SW , Norbury M , et al . Epidemiology of multimorbidity and
47 implications for health care, research, and medical education: a cross-sectional study.
48 *Lancet* 2012;380:37–43.doi:10.1016/S0140-6736(12)60240-2
49
50
51 30. Fortin M , Stewart M , Poitras ME , et al . A systematic review of prevalence studies
52 on multimorbidity: toward a more uniform methodology. *Ann Fam Med* 2012;10:142–
53 51.doi:10.1370/afm.1337.
54
55
56 31. García-Gómez M C, De L E, Ordoñez-Palau S, et al. High Prevalence of Gallstone

1
2
3
4 Disease in Rheumatoid Arthritis: A New Comorbidity Related to Dyslipidemia? [J].
5 *Reumatol Clin*, 2017;14:294-300. doi: 10.1016/j.reuma.2018.03.012.
6


7
8 32. Bao W, Hu D, Shi X, et al. Comorbidity increased the risk of falls in Chinese older
9 adults: A cross-sectional study. *Int J Clin Exp Med*,2017;7:10753-10763.
10

11
12 33. Gao N, Yuan Z, Tang X, et al. Prevalence of CHD-related metabolic comorbidity of
13 diabetes mellitus in Northern Chinese adults: the REACTION study. *J Diabetes*
14 *Complications*2016;2:199-205.doi:10.1016/j.jdiacomp.2015.11.018
15
16
17
18
19
20
21

22 **Figure 1 Flowchart for selecting the study sample from the original sample population.**
23 **CHARLS, China Health and Retirement Longitudinal Survey**
24
25
26
27

28 **Figure 2 Frequency and percentage of people aged over 60 suffering from different**
29 **diseases based on CHARLS data**
30
31
32
33

34 **Figure 3 Prevalence Rates of 14 common chronic diseases in Chinese people over 60**
35 **years old based on CHARLS data.**
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60






Figure 1 Flowchart for selecting the study sample from the original sample population. CHARLS, China Health and Retirement Longitudinal Survey

171x93mm (300 x 300 DPI)




Figure 2 Frequency and percentage of people aged over 60 suffering from different diseases based on CHARLS data

222x119mm (300 x 300 DPI)




Figure 3 Prevalence Rates of chronic condition in elderly people over 60 years old based on CHARLS data

151x140mm (300 x 300 DPI)

Annex 1 O/E ratio of all binary and triads comorbidities pattern present in participants

Rank	binary comorbidities pattern	O/E ratio
1	Chronic lung diseases and Asthma	161.00
2	Emotional, nervous, or psychiatric problems and Memory-related disease	98.57
3	Dyslipidemia and Diabetes or high blood sugar	38.69
4	Heart disease and Memory-related disease	25.96
5	Stroke and Memory-related disease	24.19
6	Hypertension and Stroke	23.10
7	Hypertension and Diabetes or high blood sugar	20.77
8	Cancer or malignant tumor and Stroke	19.71
9	Memory-related disease and Asthma	19.71
10	Stroke and Asthma	19.71
11	Hypertension and Heart disease	19.07
12	Hypertension and Dyslipidemia	18.98
13	Dyslipidemia and Heart disease	17.39
14	Diabetes or high blood sugar and Heart disease	14.87
15	Diabetes or high blood sugar and Liver disease	14.40
16	Cancer or malignant tumor and Liver disease	13.65
17	Diabetes or high blood sugar and Kidney disease	13.38
18	Hypertension and Memory-related disease	13.33
19	Dyslipidemia and Cancer or malignant tumor	12.51
20	Stomach or other digestive disease and Arthritis or rheumatism	10.80
21	Liver disease and Heart disease	10.49
22	Dyslipidemia and Stroke	10.23
23	Dyslipidemia and Stomach or other digestive disease	9.81
24	Dyslipidemia and Kidney disease	9.61
25	Chronic lung diseases and Memory-related disease	9.56
26	Chronic lung diseases and Stroke	9.56
27	Kidney disease and Arthritis or rheumatism	9.42
28	Heart disease and Kidney disease	9.29
29	Chronic lung diseases and Heart disease	9.12
30	Stomach or other digestive disease and Asthma	9.03
31	Liver disease and Kidney disease	8.99
32	Kidney disease and Stomach or other digestive disease	8.92
33	Memory-related disease and Arthritis or rheumatism	8.89
34	Stroke and Arthritis or rheumatism	8.89
35	Arthritis or rheumatism and Asthma	8.77
36	Liver disease and Memory-related disease	8.38
37	Diabetes or high blood sugar and Memory-related disease	8.32
38	Diabetes or high blood sugar and Stroke	8.32
39	Chronic lung diseases and Arthritis or rheumatism	8.14
40	Heart disease and Stomach or other digestive disease	8.11

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

41	Heart disease and Arthritis or rheumatism	7.45
42	Stomach or other digestive disease and Emotional, nervous, or psychiatric problems	7.39
43	Liver disease and Stomach or other digestive disease	7.33
44	Diabetes or high blood sugar and Cancer or malignant tumor	6.78
45	Diabetes or high blood sugar and Asthma	6.78
46	Diabetes or high blood sugar and Arthritis or rheumatism	6.44
47	Liver disease and Arthritis or rheumatism	6.16
48	Chronic lung diseases and Kidney disease	5.98
49	Chronic lung diseases and Stomach or other digestive disease	5.97
50	Hypertension and Arthritis or rheumatism	5.74
51	Chronic lung diseases and Liver disease	5.52
52	Kidney disease and Emotional, nervous, or psychiatric problems	5.29
53	Kidney disease and Asthma	5.29
54	Chronic lung diseases and Emotional, nervous, or psychiatric problems	5.19
55	Dyslipidemia and Memory-related disease	5.12
56	Hypertension and Emotional, nervous, or psychiatric problems	5.07
57	Hypertension and Chronic lung diseases	5.03
58	Hypertension and Kidney disease	5.01
59	Cancer or malignant tumor and Arthritis or rheumatism	4.96
60	Cancer or malignant tumor and Stomach or other digestive disease	4.93
61	Dyslipidemia and Arthritis or rheumatism	4.75
62	Hypertension and Liver disease	4.61
63	Diabetes or high blood sugar and Chronic lung diseases	4.38
64	Heart disease and Stroke	4.33
65	Dyslipidemia and Asthma	4.17
66	Hypertension and Stomach or other digestive disease	3.85
67	Cancer or malignant tumor and Heart disease	3.53
68	Heart disease and Asthma	3.53
69	Emotional, nervous, or psychiatric problems and Arthritis or rheumatism	3.43
70	Diabetes or high blood sugar and Stomach or other digestive disease	3.12
71	Hypertension and Cancer or malignant tumor	2.17
72	Hypertension and Asthma	2.17
73	Stomach or other digestive disease and Memory-related disease	2.02
74	Stroke and Stomach or other digestive disease	2.02
75	Dyslipidemia and Liver disease	1.77
76	Dyslipidemia and Chronic lung diseases	1.35

Rank	triads comorbidities pattern	O/E ratio
1	Stroke, Emotional, nervous, or psychiatric problems and Memory-related disease	10491.60
2	Emotional, nervous, or psychiatric problems, Memory-related disease, Asthma,	8548.88
3	Heart disease, Stroke and Memory-related disease	2302.62
4	Chronic lung diseases, Emotional, nervous, or psychiatric problems and Asthma	2252.13
5	Chronic lung diseases, Heart disease, Asthma,	1977.13
6	Dyslipidemia, Heart disease and Memory-related disease	1461.04
7	Hypertension, Stroke and Memory-related disease	1418.54
8	Hypertension, Dyslipidemia and Diabetes or high blood sugar	1409.29
9	Chronic lung diseases, Memory-related disease and Asthma	1381.96
10	Chronic lung diseases, Arthritis or rheumatism and Asthma	1256.63
11	Dyslipidemia, Diabetes or high blood sugar and Kidney disease	1255.51
12	Cancer or malignant tumor, Chronic lung diseases and Asthma	1126.07
13	Chronic lung diseases, Kidney disease and Asthma	1112.24
14	Liver disease, Kidney disease and Asthma	974.52
15	Dyslipidemia, Diabetes or high blood sugar and Liver disease	972.21
16	Chronic lung diseases, Liver disease and Asthma	956.96
17	Dyslipidemia, Diabetes or high blood sugar and Stroke	935.99
18	Chronic lung diseases, Stomach or other digestive disease and Asthma	921.21
19	Hypertension, Dyslipidemia and Heart disease	876.36
20	Diabetes or high blood sugar, Liver disease and Kidney disease	822.11
21	Hypertension, Diabetes or high blood sugar and Stroke	812.58
22	Hypertension, Chronic lung diseases and Asthma	812.01
23	Hypertension, Dyslipidemia and Stroke	800.07
24	Dyslipidemia, Heart disease and Asthma	793.67
25	Diabetes or high blood sugar, Heart disease and Stroke	791.41
26	Hypertension, Emotional, nervous, or psychiatric problems and Memory-related disease	770.58
27	Dyslipidemia, Diabetes or high blood sugar and Cancer or malignant tumor	762.67
28	Dyslipidemia, Diabetes or high blood sugar and Emotional, nervous, or psychiatric problems	762.67
29	Dyslipidemia, Diabetes or high blood sugar and Heart disease	669.54
30	Liver disease, Heart disease and Emotional, nervous, or psychiatric problems	649.62
31	Heart disease, Kidney disease and Memory-related disease	617.74
32	Heart disease, Stroke and Kidney disease	617.74
33	Dyslipidemia, Chronic lung diseases and Asthma	584.58
34	Diabetes or high blood sugar, Liver disease and Heart disease	548.02

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

35	Hypertension, Diabetes or high blood sugar and Heart disease	523.14
36	Hypertension, Heart disease and Stroke	507.36
37	Diabetes or high blood sugar, Chronic lung diseases and Asthma	474.98
38	Liver disease, Stomach or other digestive disease and Asthma	454.02
39	Stomach or other digestive disease, Emotional, nervous, or psychiatric problems and Memory-related disease	437.10
40	Hypertension, Memory-related disease, Asthma,	385.29
41	Diabetes or high blood sugar, Stomach or other digestive disease and Asthma	300.46
42	Hypertension, Dyslipidemia and Memory-related disease	300.03
43	Liver disease, Kidney disease and Arthritis or rheumatism	277.66
44	Hypertension, Heart disease and Memory-related disease	253.68
45	Dyslipidemia, Liver disease and Kidney disease	252.95
46	Hypertension, Chronic lung diseases and Stroke	249.13
47	Stroke, Memory-related disease and Arthritis or rheumatism	249.11
48	Dyslipidemia, Chronic lung diseases and Liver disease	248.40
49	Cancer or malignant tumor, Chronic lung diseases and Heart disease	247.14
50	Chronic lung diseases, Heart disease and Emotional, nervous, or psychiatric problems	247.14
51	Hypertension, Dyslipidemia and Asthma	244.47
52	Cancer or malignant tumor, Heart disease and Stomach or other digestive disease	234.50
53	Chronic lung diseases, Memory-related disease and Arthritis or rheumatism	229.69
54	Chronic lung diseases, Stroke and Stomach or other digestive disease	211.98
55	Hypertension, Stroke and Arthritis or rheumatism	210.41
56	Chronic lung diseases, Liver disease and Heart disease	210.03
57	Hypertension, Cancer or malignant tumor and Heart disease	206.71
58	Hypertension, Heart disease and Emotional, nervous, or psychiatric problems	206.71
59	Memory-related disease, Arthritis or rheumatism and Asthma	202.98
60	Emotional, nervous, or psychiatric problems, Memory-related disease and Arthritis or rheumatism	202.98
61	Stroke, Emotional, nervous, or psychiatric problems and Arthritis or rheumatism	202.98
62	Stroke, Kidney disease and Arthritis or rheumatism	200.49
63	Dyslipidemia, Diabetes or high blood sugar and Stomach or other digestive disease	194.98
64	Liver disease, Stomach or other digestive disease and Memory-related disease	185.73
65	Dyslipidemia, Stomach or other digestive disease and Asthma	184.90
66	Diabetes or high blood sugar, Stomach or other digestive disease and Memory-related disease	184.37
67	Diabetes or high blood sugar, Heart disease and Arthritis or rheumatism	183.74

1		
2		
3		
4	68	Chronic lung diseases, Stroke and Arthritis or rheumatism 164.06
5	69	Kidney disease, Arthritis or rheumatism and Asthma 163.36
6		
7	70	Dyslipidemia, Diabetes or high blood sugar and Arthritis or rheumatism 162.98
8	71	Hypertension, Diabetes or high blood sugar and Memory-related disease 162.52
9	72	Hypertension, Dyslipidemia and Kidney disease 160.98
10		
11	73	Hypertension, Heart disease and Kidney disease 158.80
12	74	Chronic lung diseases, Liver disease and Kidney disease 157.53
13	75	Dyslipidemia, Liver disease and Stomach or other digestive disease 157.13
14	76	Heart disease, Kidney disease and Stomach or other digestive disease 154.42
15		
16	77	Cancer or malignant tumor, Liver disease and Stomach or other digestive disease 151.34
17		
18		
19	78	Liver disease, Stomach or other digestive disease and Emotional, nervous, or psychiatric problems 151.34
20		
21	79	Heart disease, Arthritis or rheumatism and Asthma 145.20
22	80	Stroke, Kidney disease and Stomach or other digestive disease 143.91
23		
24	81	Liver disease, Emotional, nervous, or psychiatric problems and Arthritis or rheumatism 140.56
25		
26	82	Diabetes or high blood sugar, Arthritis or rheumatism and Asthma 139.53
27	83	Hypertension, Dyslipidemia and Liver disease 138.50
28		
29	84	Hypertension, Heart disease and Asthma 137.80
30		
31	85	Kidney disease, Stomach or other digestive disease and Arthritis or rheumatism 136.43
32		
33	86	Chronic lung diseases, Emotional, nervous, or psychiatric problems and Arthritis or rheumatism 133.68
34		
35	87	Hypertension, Liver disease and Asthma 133.40
36	88	Hypertension, Diabetes or high blood sugar and Cancer or malignant tumor 132.42
37		
38	89	Chronic lung diseases, Stomach or other digestive disease and Arthritis or rheumatism 131.24
39		
40	90	Hypertension, Diabetes or high blood sugar and Kidney disease 130.80
41		
42	91	Heart disease, Stomach or other digestive disease and Arthritis or rheumatism 128.06
43		
44	92	Dyslipidemia, Heart disease and Stomach or other digestive disease 121.74
45	93	Hypertension, Heart disease and Arthritis or rheumatism 121.06
46		
47	94	Stomach or other digestive disease, Arthritis or rheumatism and Asthma 118.39
48	95	Chronic lung diseases, Heart disease and Arthritis or rheumatism 117.36
49	96	Hypertension, Liver disease and Heart disease 117.11
50		
51	97	Diabetes or high blood sugar, Kidney disease and Arthritis or rheumatism 114.85
52		
53	98	Chronic lung diseases, Heart disease and Stomach or other digestive disease 113.73
54		
55	99	Hypertension, Diabetes or high blood sugar and Liver disease 112.54
56	100	Diabetes or high blood sugar, Chronic lung diseases and Heart disease 104.24
57		
58	101	Liver disease, Stomach or other digestive disease and Arthritis or rheumatism 104.21
59		
60	102	Stroke, Stomach or other digestive disease and Arthritis or rheumatism 103.78

1		
2		
3		
4	103	Hypertension, Kidney disease and Emotional, nervous, or psychiatric problems
5		
6	104	Chronic lung diseases, Liver disease and Arthritis or rheumatism
7	105	Hypertension, Dyslipidemia and Arthritis or rheumatism
8	106	Liver disease, Kidney disease and Stomach or other digestive disease
9		
10	107	Dyslipidemia, Cancer or malignant tumor and Stomach or other digestive disease
11		
12	108	Dyslipidemia, Stomach or other digestive disease and Emotional, nervous, or psychiatric problems
13		
14	109	Hypertension, Dyslipidemia and Chronic lung diseases
15	110	Hypertension, Chronic lung diseases and Heart disease
16	111	Heart disease, Stroke and Arthritis or rheumatism
17	112	Hypertension, Heart disease and Stomach or other digestive disease
18	113	Chronic lung diseases, Heart disease and Kidney disease
19	114	Chronic lung diseases, Kidney disease and Arthritis or rheumatism
20	115	Diabetes or high blood sugar, Chronic lung diseases and Arthritis or rheumatism
21		
22	116	Chronic lung diseases, Kidney disease and Stomach or other digestive disease
23		
24	117	Hypertension, Diabetes or high blood sugar and Arthritis or rheumatism
25	118	Hypertension, Dyslipidemia and Stomach or other digestive disease
26	119	Chronic lung diseases, Liver disease and Stomach or other digestive disease
27		
28	120	Hypertension, Memory-related disease and Arthritis or rheumatism
29	121	Stomach or other digestive disease, Memory-related disease and Arthritis or rheumatism
30	122	Heart disease, Kidney disease and Arthritis or rheumatism
31	123	Liver disease, Arthritis or rheumatism and Asthma
32	124	Diabetes or high blood sugar, Cancer or malignant tumor and Arthritis or rheumatism
33	125	Kidney disease, Memory-related disease and Arthritis or rheumatism
34	126	Dyslipidemia, Heart disease and Arthritis or rheumatism
35	127	Diabetes or high blood sugar, Heart disease and Stomach or other digestive disease
36		
37	128	Dyslipidemia, Chronic lung diseases and Heart disease
38	129	Hypertension, Kidney disease and Arthritis or rheumatism
39	130	Dyslipidemia, Stomach or other digestive disease and Arthritis or rheumatism
40		
41	131	Hypertension, Chronic lung diseases and Memory-related disease
42	132	Dyslipidemia, Kidney disease and Stomach or other digestive disease
43	133	Hypertension, Stroke and Stomach or other digestive disease
44	134	Cancer or malignant tumor, Chronic lung diseases and Stomach or other digestive disease
45		
46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		

1		
2		
3		
4	135	Cancer or malignant tumor, Chronic lung diseases and Arthritis or rheumatism
5		
6	136	Hypertension, Stomach or other digestive disease and Arthritis or rheumatism
7		
8	137	Dyslipidemia, Memory-related disease and Arthritis or rheumatism
9	138	Dyslipidemia, Stroke and Arthritis or rheumatism
10	139	Hypertension, Cancer or malignant tumor and Chronic lung diseases
11	140	Hypertension, Chronic lung diseases and Kidney disease
12	141	Liver disease, Heart disease and Arthritis or rheumatism
13	142	Hypertension, Cancer or malignant tumor and Arthritis or rheumatism
14	143	Hypertension, Liver disease and Kidney disease
15	144	Hypertension, Chronic lung diseases and Liver disease
16	145	Dyslipidemia, Cancer or malignant tumor and Arthritis or rheumatism
17	146	Dyslipidemia, Arthritis or rheumatism and Asthma
18	147	Hypertension, Diabetes or high blood sugar and Chronic lung diseases
19	148	Dyslipidemia, Kidney disease and Arthritis or rheumatism
20	149	Stomach or other digestive disease, Emotional, nervous, or psychiatric problems and Arthritis or rheumatism
21	150	Hypertension, Liver disease and Arthritis or rheumatism
22	151	Hypertension, Stomach or other digestive disease and Memory-related disease
23	152	Diabetes or high blood sugar, Stomach or other digestive disease and Arthritis or rheumatism
24	153	Hypertension, Arthritis or rheumatism and Asthma
25	154	Dyslipidemia, Liver disease and Arthritis or rheumatism
26	155	Heart disease, Emotional, nervous, or psychiatric problems and Arthritis or rheumatism
27	156	Hypertension, Chronic lung diseases and Arthritis or rheumatism
28	157	Dyslipidemia, Chronic lung diseases and Arthritis or rheumatism
29	158	Hypertension, Diabetes or high blood sugar and Stomach or other digestive disease
30	159	Cancer or malignant tumor, Stomach or other digestive disease and Arthritis or rheumatism
31	160	Liver disease, Heart disease and Stomach or other digestive disease
32	161	Dyslipidemia, Chronic lung diseases and Stomach or other digestive disease
33	162	Diabetes or high blood sugar, Liver disease and Arthritis or rheumatism
34	163	Hypertension, Kidney disease and Stomach or other digestive disease
35	164	Diabetes or high blood sugar, Chronic lung diseases and Stomach or other digestive disease
36	165	Hypertension, Emotional, nervous, or psychiatric problems and Arthritis or rheumatism
37	166	Hypertension, Liver disease and Stomach or other digestive disease
38		
39		
40		
41		
42		
43		
44		
45		
46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		

167	Hypertension, Cancer or malignant tumor and Stomach or other digestive disease	16.05
168	Hypertension, Stomach or other digestive disease and Emotional, nervous, or psychiatric problems	16.05
169	Hypertension, Chronic lung diseases and Stomach or other digestive disease	15.57

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

BMJ Open

Prevalence and patterns of multimorbidity among the elderly in China: a cross-sectional study using national survey data

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-024268.R2
Article Type:	Research
Date Submitted by the Author:	28-Feb-2019
Complete List of Authors:	zhang, ran; China Pharmaceutical University, School of International Pharmaceutical Business Lu, Yun; China Pharmaceutical University, School of International Pharmaceutical Business Shi, Liuyan; China Pharmaceutical University, School of International Pharmaceutical Business Zhang, SongLin; China Pharmaceutical University, School of International Pharmaceutical Business Chang, Feng; China Pharmaceutical University, School of International Pharmaceutical Business
Primary Subject Heading:	Health informatics
Secondary Subject Heading:	Public health, Qualitative research
Keywords:	multimorbidity, cross-sectional study, Prevalence, Observed-to-expected ratio, China

SCHOLARONE™
Manuscripts

1
2
3
4 **Prevalence and patterns of multimorbidity among the elderly**
5
6 **in China: a cross-sectional study using national survey data**
7
8

9 **Author**

10
11 **NAME: Ran Zhang**

12
13 **Postal address: 639 Longmian Road, Nanjing, Jiangsu Province, CHINA**

14
15 **E-mail: ranzai7@126.com**

16
17 **Institutions: China Pharmaceutical University**

18
19 **City & Country: Jiangsu Province, CHINA**

20
21 **Telephone: +86-18115161231**

22
23 **Corresponding Author**

24
25 **NAME: Feng Chang**

26
27 **Postal address: 639 Longmian Road, Nanjing, Jiangsu Province, CHINA**

28
29 **E-mail: cpucf@163.com**

30
31 **Institutions: China Pharmaceutical University**

32
33 **City & Country: Jiangsu Province, CHINA**

34
35 **Telephone: +86-13805153128**

36
37 **Co-Authors**

38
39 **NAME: Yun Lu, Liuyan Shi, Songlin Zhang**

40
41 **Institutions: China Pharmaceutical University**

42
43 **City & Country: Jiangsu Province, CHINA**

44
45 **Keywords:**

46
47 **multimorbidity, Cross-sectional study, Prevalence, Observed-to-expected ratio,**

48
49 **China**

50
51 **Word count: 4911**
52
53
54
55
56
57
58
59
60

ABSTRACT

Objectives: Examination of the prevalence and patterns of multimorbidity among the elderly in China.

Design: Cross-sectional study.

Setting: More than 10,000 households in 28 of the 34 provinces of mainland China.

Participants: 11,707 Chinese adults aged 60 and over.

Primary outcome measures: Prevalence and patterns of multimorbidity among the participants. Relative risks were calculated to estimate the probability of up to 14 chronic conditions coexisting with each other. Observed-to-expected (O/E) ratios were used to analyze the patterns of multimorbidity.

Results: Multimorbidity was present in 43.6% of respondents from the sample population, with women having the greater prevalence compared to men. There were 804 different comorbidity combinations identified, including 76 dyad combinations and 169 triad combinations. The top 10 morbidity dyads and triads accounted for 69.01% and 47.05% of the total dyad and triad combinations observed, respectively. Among the 14 chronic conditions included in the study, asthma, stroke, heart attack and six other chronic conditions were the main components of multimorbidity due to their high relative risk ratios. The most frequently occurring clusters with higher O/E ratios were stroke along with emotional, nervous, or psychiatric problems; memory-related diseases together emotional, nervous, or psychiatric problems; and memory-related diseases and asthma accompanied by chronic lung diseases and asthma.

Conclusions: The results of this study highlight the high prevalence of multimorbidity in the elderly population in China. Further studies are required to understand the etiology of multimorbidity, and future primary healthcare policies should be made while taking multimorbidity into consideration.

Strengths and limitations of this study

Strengths

- This is the first study to estimate the prevalence and patterns of multimorbidity among the elderly population in China.
- Data for this study were collected from a nationally representative longitudinal survey of 17,708 Chinese residents.

Limitations

- Only 14 predefined chronic diseases were included in the study, and these may not be comprehensive of the conditions of the population.
- The data analyzed from the CHARLS were originally collected by population self-reporting, not clinician evaluation, and could partially reflect some associated biases or confounds.
- The exclusion of incomplete data may cause a selection bias.

INTRODUCTION

Multimorbidity, or the simultaneous occurrence of two or more chronic conditions in an individual, is becoming increasingly common, and this has been reported to increase progressively with age. [1, 2] At present, with China's aging population having an increasing prevalence of chronic conditions, multimorbidity among the elderly poses an enormous societal cost due to increased mortality rates and healthcare utilization. [3] However, to date, research on chronic conditions in China has focused on single disease states, and the coexistence of multiple chronic conditions has not been investigated systematically and thoroughly.

There is a significant difference in the etiological analysis between patients with single chronic conditions and those with multimorbidity. [4] The coexistence of chronic conditions in a patient is more than a random event, it is more typically due to the causal relationship between some diseases and shared pathogenic factors. [5, 6] Moreover, the interactions between diseases or between a disease and host result in differences in the severity of multimorbidity and functional status and prognosis of patients with multimorbidity. [7] Consequently, it is imperative to begin research on multimorbidity in China for the cost-effective treatments that the results may help to suggest. [8] The purpose of this study was therefore to determine the prevalence of multimorbidity among the elderly in China and to reveal morbidity combinations, which may benefit the design and implementation of a modified healthcare system with consideration for patients with multimorbidity.

METHODS

Data source

Data for this study were collected from the third response of the China Health and Retirement Longitudinal Survey (CHARLS), which is the most current data available. The CHARLS is a nationally representative longitudinal survey of Chinese residents aged 45 and older that was conducted by the Chinese Center for Disease Control and Prevention, along with Peking University, to help China to adjust to the rapid aging of its population through the evaluation of social, economic, and health circumstances on

1
2
3 the community level using data collected by interviews, physical measurements and
4 blood sample collection. [9] The national baseline survey began in 2011 and involved
5 17,708 respondents from 150 county-level units, 450 village-level units, and
6 approximately 10,000 households. Afterwards, CHARLS respondents were followed
7 every second year, with their informed consent, and the study was approved by the
8 Peking University Biomedical Ethics Committee (IRB00001052-14013-exemption).
9
10
11
12
13

14 15 **Variables**

16
17 The core CHARLS questionnaires included sections requesting information on
18 demographic factors, family structure and changes, health status and functioning,
19 healthcare and insurance, work, retirement and pension, income and consumption, and
20 assets (individual and household). Information was collected by interview by trained
21 staff. For the current study, the eligible and included participants were determined by
22 being aged 60 and over, and data on gender, age and health status was used from the
23 general health status and disease history section of senior citizens in the 2015 CHARLS
24 data. This information included the following 14 common chronic health problems:
25 hypertension, dyslipidemia (high blood lipids or low cholesterol), diabetes or elevated
26 blood glucose (including impaired glucose tolerance and fasting blood glucose), cancer
27 (excluding mild skin cancers), chronic lung disease such as chronic bronchitis or
28 emphysema, pulmonary heart disease (excluding tumors or cancer), liver disease (other
29 than fatty liver, tumors, or cancer), heart disease (such as myocardial infarction,
30 coronary heart disease, angina pectoris, congestive heart failure and other heart
31 diseases), stroke, kidney disease (excluding tumors or cancer), stomach or other
32 digestive diseases (excluding tumors or cancer), emotional and mental problems,
33 memory-related diseases (such as Alzheimer's disease, brain atrophy, Parkinson's
34 disease), arthritis or rheumatism, and asthma. All these data were based on self-reports.
35 Accordingly, multimorbidity was defined as the coexistence of more than one of the 14
36 chronic conditions, with acute or subacute forms of certain conditions being excluded
37 in this study due to the CHARLS data collection protocol.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

55 **Statistical analysis**

56 To detect the demographic characteristics of patients with multimorbidity,
57 respondents were divided into two groups: those with multiple chronic conditions
58 (MCC group) and those without multiple chronic conditions (Non-MCC group).
59
60

1
2
3 Descriptive statistics were calculated and expressed as means (SD) and frequencies
4 (percentage). We applied the T^2 and χ^2 tests to test the differences in age, gender and
5 the mean number of chronic conditions across different subgroups. Respective
6 prevalence in the MCC group and the non-MCC group were calculated separately.
7
8 Given the exclusion of participants with incomplete data or aged under 60, a sensitivity
9 analysis was conducted to compare the characteristics of the complete cases and the
10 incomplete cases, which is presented in [Annex 1](#).
11
12
13
14

15 To determine the most common combination of chronic diseases, the prevalence of
16 morbidity and multimorbidity dyads and triads were estimated, respectively. Next, the
17 expected number of patients with a chronic disease were calculated, and the observed-
18 to-expected (O/E) ratios were determined by dividing the number of patients in those
19 groups by the expected number of patients. Observed-to-expected ratios were used to
20 estimate the conditional probability of coexistence of two or three chronic conditions.
21 [10] As an important indicator for assessing the correlation between diseases, the O/E
22 ratio has been used in many areas of comorbidity. [10, 11] The relative risk of
23 comorbidity for individual chronic conditions was also calculated. Relative risk of
24 comorbidity (RR) is the ratio of the number of people with a certain chronic condition
25 who suffer from multimorbidity to the number of patients with the same disease who
26 do not suffer from multimorbidity. [11, 12] In other words, a higher RR value means a
27 higher probability that the disease coexists with other diseases. However, it should be
28 noted that there is no direct relationship between the relative risk of comorbidity and
29 the overall prevalence of the diseases. [13, 14]
30
31
32
33
34
35
36
37
38
39
40

41 All analyses in this study were completed using Stata software V.14.0 for Windows
42 (Stata Corp). P Values <0.05 were considered to be statistically significant.
43
44
45

46 **Patient and public involvement**

47 Patients and the public were not involved in the development of the research
48 question or outcome measures of the study, nor were they involved in study design and
49 execution. There are no plans to disseminate the research results to study participants.
50
51
52
53

54 **RESULTS**

55 **Characteristics of participants**

56 The data were gathered from the third response set of CHARLS. After exclusion
57
58
59
60

of participants with incomplete data (1,002) or aged under 60 (9,259), there were 11,707 respondents with available information on related chronic diseases that were included in this study. The selection process of study sample is shown in Figure 1. The demographic characteristics of sample respondents and statistical significance test results are presented in Table 1.

Overall, the mean age for the sample population was 70.5 (ranging from 60 to 107). The sample population consisted of 5,705 (48.7%) males and 6002 (51.2%) females, and 43.6% of them suffered from multimorbidity. The median of chronic conditions in the MCC group was 3.01, compared to 0.45 in the Non-MCC group. Samples in the MCC group were 0.66 year older than those belonged to the non-MCC group. Gender differences with regard to the age of samples between the MCC group and the non-MCC group (70.57 for MCC group and 69.51 for non-MCC group) were small but statistically significant ($p < 0.001$). The prevalence of multimorbidity in the female population was higher than that for the males (54.41% vs 45.59%). Figure 2 shows the number and proportion of respondents over 60 according to morbidity numbers. It can be seen that among all the participants aged over 60, only 30.9% of them did not have the 14 chronic diseases and 43.6% suffer from multimorbidity.

Table 1. Demographic characteristics of all respondents, the MCC group and non-MCC group

	All respondent	MCC group	Non-MCC group	P*
Number of people	11707	5107	6600	
Proportion (%)	100%	43.62%	56.38%	
Mean age				
All respondents (SD)	70.20(7.907)	70.57(7.701)	69.91(8.051)	<0.001
Male (SD)	69.97(7.575)	70.50(7.348)	69.60(7.707)	<0.001
Female (SD)	70.39(8.189)	70.62(7.892)	70.19(8.359)	<0.001
Gender (% females)	51.28%	54.41%	48.83%	<0.001
Mean number of chronic conditions				
All respondents (SD)	1.57(1.560)	3.01(1.259)	0.45(0.498)	<0.001
Male (SD)	1.47(1.534)	2.98(1.265)	0.44(0.496)	<0.001
Female (SD)	1.65(1.581)	3.03(7.982)	0.47(0.499)	<0.001

SD = standard deviation;

p* = statistical significance of the difference between the MCC and the non-MCC sample (t-tests were performed for comparison of means, and chi-square-tests for differences between percentages)

Prevalence of chronic conditions

The prevalence of chronic conditions in the entire sample, the MCC group and the non-MCC group are shown in Figure 3. The prevalence of all fourteen chronic conditions in the MCC group was significantly higher than that in the entire sample. For instance, the prevalence of arthritis or rheumatism, hypertension, stomach or other digestive disease, heart disease and chronic lung disease were 65.97%, 48.82%, 45.86%, 29.00% and 24.97% in the MCC group, compared to 38.49%, 26.41%, 24.52%, 12.32% and 12.32% in the entire sample, respectively.

Table 2 shows the relative risks of comorbidity determined for the 14 chronic diseases reported in this study. It can be seen that the overall relative risks for asthma, stroke, heart disease and six other conditions were all above 10, which meant these diseases were >10 times easier to coexist with other chronic conditions and result in multimorbidity. In addition, the relative risks for certain diseases were positively associated with gender. For example, men had significantly higher relative risks for asthma, but lower relative risks for diabetes or high blood sugar, compared to women.

Table 2 Relative risks of multimorbidity for different chronic conditions according to gender

Chronic conditions	All respondents	95% Confidence Interval		Female	95% Confidence Interval		Male	95% Confidence Interval		
		Lower Bound	Upper Bound		Lower Bound	Upper Bound		Lower Bound	Upper Bound	
High relative risk of multimorbidity										
Asthma	26.18	17.82	38.46	20.67	11.85	36.06	32.68	19.18	55.67	
Stroke	18.62	12.11	28.64	21.57	10.61	43.86	17.43	10.13	29.99	
Heart disease	15.56	12.99	18.63	16.48	12.80	21.21	14.26	11.02	18.46	
Diabetes or high blood sugar	14.40	11.18	18.55	15.68	10.86	22.63	13.11	9.24	18.62	

1										
2										
3										
4	Dyslipidemia	14.05	11.54	17.12	15.13	11.37	20.14	12.97	9.86	17.05
5	Memory-related disease	13.69	8.85	21.16	34.17	12.63	92.44	9.28	5.66	15.21
6										
7	Kidney disease	11.57	9.24	14.49	15.01	10.17	22.43	10.24	7.78	13.48
8										
9	Liver disease	11.10	8.37	14.71	16.07	9.70	26.63	9.15	6.49	12.89
10	Chronic lung diseases	9.87	8.43	11.55	10.71	8.26	13.88	9.74	8.00	11.86
11	<hr/>									
12	Low relative risk of multimorbidity									
13										
14	Emotional, nervous, or									
15	psychiatric problems	7.42	4.94	11.15	6.24	3.78	10.30	9.36	4.65	18.85
16										
17	Stomach or other digesti									
18	ve disease	5.73	5.25	6.25	6.20	5.48	7.02	5.23	4.62	5.91
19										
20	Hypertension	5.38	4.96	5.84	4.90	4.40	5.47	5.92	5.24	6.69
21										
22	Cancer or malignant									
23	tumor	4.88	3.20	7.45	5.33	3.06	9.29	3.99	2.07	7.72
24										
25	Arthritis or rheumatism	3.83	3.61	4.05	3.70	3.43	3.99	3.91	3.59	4.26
26	<hr/>									

Common multimorbidity combinations

There were 804 possible comorbidity combinations that were identified in the MCC group after statistical analysis, including 72 dyads and 169 triads. The 10 most frequently occurring morbidity dyads and triads are presented respectively in [Table 3](#) and [Table 4](#).

Table 3 Prevalence of the 10 most common morbidity dyads

Rank	Morbidity dyads	Prevalence			Mean Age
		All respondents	female	male	
1	Arthritis or rheumatism and Stomach or other digestive disease	4.73%	3.56%	5.96%	69.20
2	Arthritis or rheumatism and Hypertension	2.85%	2.20%	3.53%	71.25
3	Arthritis or rheumatism and Chronic lung diseases	1.13%	1.22%	1.04%	71.55
4	Hypertension and heart problems	1.03%	1.00%	1.06%	71.80
5	Hypertension and Stomach or other digestive disease	0.89%	0.83%	0.95%	69.07
6	Hypertension	0.86%	0.81%	0.91%	68.58

	and Dyslipidemia				
	Arthritis				
7	or rheumatism	0.76%	0.53%	1.00%	70.72
	and heart problems				
	Arthritis				
8	or rheumatism	0.64%	0.73%	0.54%	68.24
	and Kidney disease				
	Hypertension				
9	and Diabetes or high blood sugar	0.58%	0.50%	0.67%	70.97
	Chronic lung diseases and Asthma				
10		0.53%	0.65%	0.40%	71.15

Table 4 Prevalence of the 10 most common morbidity triads

Rank	Morbidity triads	Prevalence			Mean Age
		All respondents	female	male	
1	Arthritis or rheumatism, Stomach or other digestive disease and Hypertension	1.19%	0.80%	1.60%	70.96
2	Arthritis or rheumatism, Stomach or other digestive disease and Chronic lung diseases	0.82%	0.97%	0.67%	70.82
3	Arthritis or rheumatism, Heart disease and Hypertension	0.63%	0.37%	0.91%	69.93
4	Arthritis or rheumatism, Heart disease and Stomach or other digestive disease	0.59%	0.25%	0.95%	71.51
5	Hypertension, Dyslipidemia and Arthritis or rheumatism	0.44%	0.31%	0.57%	70.13
6	Hypertension, Dyslipidemia and Heart problems	0.42%	0.35%	0.49%	71.17
7	Arthritis or rheumatism, Kidney disease and Stomach or other digestive disease	0.42%	0.40%	0.44%	70.14
8	Arthritis or rheumatism, Asthma and Chronic lung diseases	0.40%	0.46%	0.33%	69.18
9	Hypertension, Dyslipidemia and Diabetes or high blood sugar	0.35%	0.35%	0.35%	71.51
10	Arthritis or rheumatism, Stomach or other digestive disease	0.53%	0.57%	0.49%	70.29

and Liver disease

Theoretically, there are 91 dyad combinations and 364 triad combinations possible given the 14 different chronic conditions considered in this study. However, only 72 types (79.12%) of dyads and 169 types (46.43%) of triads emerged in the sample. The 10 most frequently occurring morbidity dyads accounted for 69.01% of the 72 dyad combinations, and the proportion of the 10 most common triad combinations in the 169 triad combinations was 47.05%. Arthritis or rheumatism, which appeared in five of the top 10 dyad combinations and eight of the top 10 triad combinations of chronic conditions, was the main component of the leading morbidity dyads and triads.

There were significant gender differences observed in the occurrences of these multimorbidity combinations. The numbers of women with triad combinations of chronic diseases were generally higher than for men with the same morbidity triads. For example, women had significantly higher prevalence of arthritis and hypertension and hyperlipidemia than men (78.26% vs 21.74%). Among morbidity dyads, the prevalence of heart disease and arthritis or rheumatism in women was nearly two times higher than that in men, while the cluster of arthritis or rheumatism and kidney disease occurred more frequently in men than in women. No age difference was detected in the probability of these particular multimorbidity combinations occurring.

The O/E ratio was also used to analyze the multimorbidity pattern. [15] The higher the O/E value, the higher the probability of coexistence of chronic conditions. [16] Table 5 shows O/E ratios determined for the 10 most prevalent morbidity dyads and triads. The prevalence of each conditions and the dyad and triad prevalence are presented in Annex 2. In the midst of those triad combinations of chronic conditions, the two clusters with significantly higher O/E ratios were emotional, nervous, or psychiatric problems and stroke and memory-related disease (O/E ratio = 10287.72), emotional, nervous, or psychiatric problems and memory-related disorders and asthma (O/E ratio = 8498.56). These four conditions also dominated the three leading dyads

with the highest O/E ratios: 97.73 for the combination of emotional and mental disorders and memory- related diseases, 23.66 for the combination of stroke and memory related disease and 19.55 for the combination of memory-related disease and asthma.

Table 5 O/E ratios for the 10 most prevalent morbidity dyads and triads

Number of chronic conditions	Rank	Chronic conditions	O/E ratio
2	1	Chronic lung diseases and Asthma	162.15
	2	Emotional, nervous, or psychiatric problems and Memory-related disease	97.73
	3	Dyslipidemia and Diabetes or high blood sugar	38.39
	4	Heart disease and Memory-related disease	25.69
	5	Stroke and Memory-related disease	23.66
	6	Hypertension and Stroke	22.85
	7	Hypertension and Diabetes or high blood sugar	20.64
	8	Cancer or malignant tumor and Stroke	19.55
	9	Memory-related disease and Asthma	19.55
	10	Stroke and Asthma	19.55
3	1	Stroke, Emotional, nervous, or psychiatric problems and Memory-related disease	10287.72
	2	Emotional, nervous, or psychiatric problems, Memory-related disease and Asthma	8498.56
	3	Emotional, nervous, or psychiatric problems, Chronic lung diseases and Asthma	2274.26
	4	Heart disease, Stroke and Memory-related disease	2253.50
	5	Chronic lung diseases, Heart disease and Asthma	1992.69
	6	Dyslipidemia, Heart disease and Memory-related disease	1443.25
	7	Hypertension, Dyslipidemia and Diabetes or high blood sugar	1398.31

8	Hypertension, Stroke and Memory-related disease	1387.35
9	Chronic lung diseases, Memory-related disease and Asthma	1376.53
10	Chronic lung diseases, Arthritis or rheumatism and Asthma	1265.95

DISCUSSION

This is the first study to estimate the prevalence and patterns of multimorbidity among the elderly in China based on the nationally representative data from CHARLS, which covered 11,707 Chinese senior citizens of age 60 and over. The results of the study indicated that 69.1% of the elderly population in China had at least one of the 14 diseases and 43.6% of them suffered from multimorbidity. The average age of the MCC group was 0.66 years higher than that of the non-MCC group and in the MCC group, the mean age of women was 0.12 years higher than that of men, which was comparable to the results of previous studies. [17-21]

The prevalence of multimorbidity estimated in this study was much lower than that from previous studies in other developed countries. For example, a study of 543 patients over age 65 in Ghent, Belgium showed that the multimorbidity rate was as high as 82.6%, [22]. Another study in Australia showed that 83.2% of the respondents suffered from multimorbidity. [23] However, it is difficult to compare the prevalence generated from different studies due to differences in the selected definitions of multimorbidity, demographic characteristics of the samples, and different study methodologies. [24-28]

In agreement with previous reports, arthritis or rheumatism, hypertension, stomach or other digestive disease were the most common diseases in the MCC group. [11] The prevalence of these three conditions was each above 20% in the entire sample, and above 45% in the MCC group. The most prevalent chronic combinations in the sample could also be found in other studies. [22] The results of this study showed that the prevalence of arthritis or rheumatism was high and easy to coexist with other conditions.

1
2
3
4 In addition to the chronic conditions mentioned above, previous studies demonstrated
5 that women with rheumatoid arthritis might have a predisposition to gallstones which
6 could manifest in middle or older age compared with women in the general population.
7
8 This phenomenon could be related to chronic inflammation and HDL metabolism. [29]
9
10

11 Although arthritis or rheumatism, a component of all the leading three morbidity
12 dyads and triads, was also the most commonly occurring disease in multimorbidity, the
13 relative risk of this disease was only 4.65, the lowest in the 14 chronic diseases.
14
15 Moreover, arthritis or rheumatism is less common in morbidity clusters with large O/E
16 ratios. Therefore, the frequent occurrence of arthritis or rheumatism in multimorbidity
17 might be simply due to the high prevalence of the disease. Doctor-diagnosed arthritis
18 is a common and disabling chronic condition in the world. During 2013 to 2015, an
19 average of more than one in five (54.4 million) adults in the United States were
20 diagnosed with arthritis [30]. The unadjusted prevalences of arthritis among adults with
21 obesity, heart disease, or diabetes were 30.6%, 49.3%, and 47.1%, respectively. In
22 adults with obesity, heart disease, or diabetes, the age-adjusted prevalences of arthritis
23 were respectively 1.5, 1.7 and 1.9 times higher than those without these diseases.
24
25 Improving the health of adults with arthritis and related comorbid conditions calls for
26 wider dissemination and implementation of evidence-based interventions, such as self-
27 management education and physical activity promotion [31].
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 The relative risks for asthma, stroke, heart disease, and six other conditions were all
43 above 10, which means that patients with these diseases were 10 times more likely to
44 be afflicted by multimorbidity. These diseases also occurred at a high frequency in
45 multimorbidity with high O/E ratios, such as the clusters of pulmonary disease and
46 asthma, emotional and mental illness and memory-related disease, dyslipidemia and
47 diabetes, and stroke and emotional or mental illness and memory-related disease.
48
49 Patients with these diseases were more likely to express comorbidity compared to those
50 without these diseases, and thus should be the focus of future research studies.
51
52
53
54
55
56
57

58 This study featured a nationally representative sample of the Chinese elderly
59
60

1
2
3
4 population, which was crucial to get an overall understanding of multimorbidity among
5 the elderly in China. However, there were also limitations with the data sample and
6 study. For example, this study used data from the third wave report of CHARLS, a
7 survey which was conducted in 2015, and there is accordingly a time lag to now that
8 exists. Additionally, the chronic diseases included in the study were not comprehensive,
9 since only 14 chronic conditions were included in the survey. Finally, the data obtained
10 from the survey was based on self-reporting, which may have introduced some
11 misclassification bias or other confounds. Later research on the prevalence and patterns
12 of multimorbidity should be carried out in-depth with a more extensive survey of
13 chronic disease.
14
15
16
17
18
19
20
21
22
23
24
25

26 CONCLUSIONS

27
28 Multimorbidity remains an underexplored area of research in China. [32]. Despite
29 the increasing prevalence of multimorbidity, there are no specific proposals for its
30 diagnosis and treatment. [33] This study contributes to the understanding of the
31 prevalence and patterns of comorbidity among the elderly in China. Considering
32 China's aging population and the high prevalence of comorbidity in senior citizens, the
33 elderly should be prioritized in the fields of disease prevention and health promotion.
34
35
36
37
38
39
40
41
42
43
44

45 **Acknowledgements** The authors would like to thank the Chinese Center for Disease
46 Control and Prevention and Peking University for access to China Health and
47 Retirement Longitudinal Survey data.
48
49

50 **Contributors** RZ analyzed and interpreted data, drafted the manuscript, approved the
51 final manuscript as submitted. YL revised the manuscript for important intellectual
52 content. YLS analyzed and interpreted data and revised the manuscript for important
53 intellectual content. FC helped on the study design and revised the manuscript.
54
55
56
57

58 **Funding** This work was funded by the National Natural Science Foundation of China
59
60

(7167030838).

Competing interests None declared.

Patient consent Obtained.

Ethics approval The original CHARLS was approved by the ethics review committee of Peking University, and all participants gave written informed consent at the time of participation

Data sharing statement No additional data are available

REFERENCES

1. Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. *Lancet* 2012; 380:37–43. doi:10.1016/S0140-6736(12)60240-2
2. World Health Organization. Global status report on noncommunicable diseases, 2014. <http://apps.who.int/nmh/publications/ncd-status-report-2014/en/index.html> (accessed 27 Oct 2017)
3. Lee J T, Hamid F, Pati S, et al. Impact of Noncommunicable Disease Multimorbidity on Healthcare Utilisation and Out-Of-Pocket Expenditures in Middle-Income Countries: Cross Sectional Analysis. *PLoS One* 2015;10:103-110. doi: 10.1371/journal.pone.0127199
4. Moffat K, Mercer SW. Challenges of managing people with multimorbidity in today's healthcare systems. *BMC Fam Prac* 2015;16:129. doi: 10.1186/s12875-015-0344-4
5. Schäfer Ingmar, von Leitner Eike-Christin, Schön Gerhard et al. Multimorbidity patterns in the elderly: a new approach of disease clustering identifies complex interrelations between chronic conditions. *PLoS One* 2010;12:e15941. doi: 10.1371/journal.pone.0015941
6. Atun R. Transitioning health systems for multimorbidity. *Lancet* 2015;386:721–2. doi: 10.1016/S0140-6736(14)62254-6

- 1
2
3
4 7. Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of
5 multiple chronic conditions in the elderly. *Arch Intern Med* 2002;20: 2269-2276.doi:
6 10.1001/archinte.162.20.2269
7
8
- 9
10 8. Yang L, Wu M, Cui B, et al. Economic burden of cardiovascular diseases in China.
11 *Expert Rev Pharmacoecon Outcomes Res*2008;8:349–56.doi:
12 10.1586/14737167.8.4.349
13
14
- 15
16 9. Zhao Y, Hu Y, Smith JP, et al. Cohort profile: the China Health and Retirement
17 Longitudinal Study (CHARLS). *Int J Epidemiol* 2014;1:61-69.doi:
18 10.1093/ije/dys203
19
20
- 21
22 10. Van den Bussche H, Koller D, Kolonko T, et al. Which chronic diseases and disease
23 combinations are specific to multimorbidity in the elderly? Results of a claims data
24 based cross-sectional study in Germany. *BMC Public Health* 2011;11:101-110.doi:
25 10.1186/1471-2458-11-101
26
27
- 28
29 11. Viera AJ. Odds ratios and risk ratios: what's the difference and why does it matter?
30 *South Med J* 2008; 7: 30-34.doi:10.1097/SMJ.0b013e31817a7ee4
31
32
- 33
34 12. Vettore MV, Meira GF, Rebelo MA et al. Multimorbidity patterns of oral clinical
35 conditions, social position, and oral health-related quality of life in a population-
36 based survey of 12-yr-old children. *Eur J Oral Sci.*2016 ; 6:580-590. doi:
37 10.1111/eos.12304. Epub 2016 Oct 8.
38
39
- 40
41 13. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in
42 cohort studies of common outcomes. *JAMA*1998;19:1690-1691.doi:
43 10.1001/jama.280.19.1690
44
45
- 46
47 14. McNutt LA, Wu C, Xue X, et al. Estimating the Relative Risk in Cohort Studies
48 and Clinical Trials of Common Outcomes. *Am J Epidemiol* 2003;10:940–943.doi:
49 10.1002/cncr.30192
50
51
- 52
53 15. Marengoni A, Rizzuto D, Wang HX, et al. Patterns of chronic multimorbidity in the
54 elderly population. *J Am Geriatr Soc*2009;57:225–30.doi:10.1111/j.1532-
55 5415.2008.02109.x
56
57
58
59
60

- 1
2
3
4 16. Best WR, Cowper DC. The Ratio of Observed-to-Expected Mortality as a Quality
5 of Care Indicator in Non-Surgical VA Patients. *Med Care* 1994;4:390-400.doi:
6 10.1097/00005650-199404000-00007
7
8
- 9
10 17. Kastenholz KE, Weis M, Hagelstein C, et al. Correlation of Observed-to-Expected
11 MRI Fetal Lung Volume and Ultrasound Lung-to-Head Ratio at Different
12 Gestational Times in Fetuses With Congenital Diaphragmatic Hernia. *AJR Am J*
13 *Roentgenol*2016;4:856-866.doi:10.2214/AJR.15.15018
14
15
- 16
17 18. Melis R, Marengoni A, Angleman S, et al. Incidence and predictors of
18 multimorbidity in the elderly: a population-based longitudinal study. *PLoS One*
19 2014; 9: e103120.doi:10.1371/journal.pone.0103120
20
21
- 22
23 19. Laan W, Bleijenberg N, Drubbel I, et al. Factors associated with increasing
24 functional decline in multimorbid independently living older people. *Maturitas*
25 2013; 75: 276–81.doi:10.1016/j.maturitas.2013.04.005
26
27
- 28
29 20. Eckerblad J, Theander K, Ekdahl A, et al. To adjust and endure: a qualitative study
30 of symptom burden in older people with multimorbidity. *Appl Nurs Res*
31 2015;28:322–7.doi:10.1016/j.apnr.2015.03.008
32
33
- 34
35 21. Wister A, Kendig H, Mitchell B, et al. Multimorbidity, health and aging in Canada
36 and Australia: a tale of two countries. *BMC Geriatr*2016;1:163-176.doi:
37 10.1186/s12877-016-0341-z
38
39
- 40
41 22. Afshar S, Roderick PJ, Kowal P, et al. Multimorbidity and the inequalities of global
42 ageing: a cross-sectional study of 28 countries using the World Health Surveys.
43 *BMC Public Health*2015;15:776-786.doi:10.1186/s12889-015-2008-7
44
45
- 46
47 23. Boeckxstaens P, Peersman W, Goubin G, et al. A practice-based analysis of
48 combinations of diseases in patients aged 65 or older in primary care. *BMC Family*
49 *Practice* 2014;1:1-6.doi: 10.1186/1471-2296-15-159.
50
51
- 52
53 24. Britt HC , Harrison CM , Miller GC , et al . Prevalence and patterns of
54 multimorbidity in Australia. *Med J Aust* 2008;2: 72-77
55
56
- 57
58 25. Glynn LG , Valderas JM , Healy P , et al . The prevalence of multimorbidity in
59 primary care and its effect on health care utilization and cost. *Fam Pract*
60 2011;28:516–23.doi:10.1093/fampra/cmr013

- 1
2
3 26. Marengoni A , Angleman S , Melis R , et al . Aging with multimorbidity: a
4 systematic review of the literature. *Ageing Res Rev* 2011;10:430–
5 9. doi:10.1016/j.arr.2011.03.003
6
7
8 27. Barnett K , Mercer SW , Norbury M , et al . Epidemiology of multimorbidity and
9 implications for health care, research, and medical education: a cross-sectional
10 study. *Lancet* 2012;380:37–43. doi:10.1016/S0140-6736(12)60240-2
11
12 28. Fortin M , Stewart M , Poitras ME , et al . A systematic review of prevalence studies
13 on multimorbidity: toward a more uniform methodology. *Ann Fam Med*
14 2012;10:142–51. doi:10.1370/afm.1337.
15
16 29. García-Gómez M C, De L E, Ordoñez-Palau S, et al. High Prevalence of Gallstone
17 Disease in Rheumatoid Arthritis: A New Comorbidity Related to Dyslipidemia? [J].
18 *Reumatol Clin*, 2017;14:294-300. doi: 10.1016/j.reuma.2018.03.012.
19
20 30. Barbour KE, Helmick CG, Boring M, et al. Vital Signs: Prevalence of Doctor-
21 Diagnosed Arthritis and Arthritis-Attributable Activity Limitation — United States,
22 2013–2015. *MMWR Morb Mortal Wkly Rep*, 2017;66:246–253. doi:
23 http://dx.doi.org/10.15585/mmwr.mm6609e1.
24
25 31. Ward BW, Schiller JS. Prevalence of multiple chronic conditions among US adults:
26 estimates from the National Health Interview Survey, 2010. *Prev Chronic Dis*
27 2013;10:120203. doi: 10.5888/pcd10.120203
28
29 32. Bao W, Hu D, Shi X, et al. Comorbidity increased the risk of falls in Chinese older
30 adults: A cross-sectional study. *Int J Clin Exp Med*, 2017;7:10753-10763.
31
32 33. Gao N, Yuan Z, Tang X, et al. Prevalence of CHD-related metabolic comorbidity
33 of diabetes mellitus in Northern Chinese adults: the REACTION study. *J Diabetes*
34 *Complications* 2016;2:199-205. doi:10.1016/j.jdiacomp.2015.11.018
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure legends

Figure 1 Flowchart for selecting the study sample from the original sample population. CHARLS, China Health and Retirement Longitudinal Survey

Figure 2 Frequency and percentage of people aged over 60 suffering from different diseases based on CHARLS data

Figure 3 Prevalence Rates of chronic condition in elderly people over 60 years old based on CHARLS data




Figure 1 Flowchart for selecting the study sample from the original sample population. CHARLS, China Health and Retirement Longitudinal Survey

171x93mm (300 x 300 DPI)




Figure 2 Frequency and percentage of people aged over 60 suffering from different diseases based on CHARLS data

222x119mm (300 x 300 DPI)




Figure 3 Prevalence Rates of chronic condition in elderly people over 60 years old based on CHARLS data

151x140mm (300 x 300 DPI)

Annex 1 Sensitivity analysis, Comparison of the characteristics of complete samples and incomplete samples

	Complete samples	Incomplete samples	P*
Number of people	11707	876	
Proportion (%)	93.04%	6.96%	
Mean age All respondents (SD)	70.20(7.907)	69.60 (7.824)	<0.001
Male (SD)	69.97(7.575)	69.58 (7.721)	<0.001
Female (SD)	70.39(8.189)	69.62 (7.973)	<0.001
Gender (% females)	51.28%	49.27%	0.193

Annex 2 O/E ratio of all binary and triads comorbidities pattern present in participants

Rank	binary comorbidities pattern	O/E ratio
1	Chronic lung diseases and Asthma	161.00
2	Emotional, nervous, or psychiatric problems and Memory-related disease	98.57
3	Dyslipidemia and Diabetes or high blood sugar	38.69
4	Heart disease and Memory-related disease	25.96
5	Stroke and Memory-related disease	24.19
6	Hypertension and Stroke	23.10
7	Hypertension and Diabetes or high blood sugar	20.77
8	Cancer or malignant tumor and Stroke	19.71
9	Memory-related disease and Asthma	19.71
10	Stroke and Asthma	19.71
11	Hypertension and Heart disease	19.07
12	Hypertension and Dyslipidemia	18.98
13	Dyslipidemia and Heart disease	17.39
14	Diabetes or high blood sugar and Heart disease	14.87
15	Diabetes or high blood sugar and Liver disease	14.40
16	Cancer or malignant tumor and Liver disease	13.65
17	Diabetes or high blood sugar and Kidney disease	13.38
18	Hypertension and Memory-related disease	13.33
19	Dyslipidemia and Cancer or malignant tumor	12.51
20	Stomach or other digestive disease and Arthritis or rheumatism	10.80
21	Liver disease and Heart disease	10.49
22	Dyslipidemia and Stroke	10.23
23	Dyslipidemia and Stomach or other digestive disease	9.81
24	Dyslipidemia and Kidney disease	9.61
25	Chronic lung diseases and Memory-related disease	9.56
26	Chronic lung diseases and Stroke	9.56
27	Kidney disease and Arthritis or rheumatism	9.42
28	Heart disease and Kidney disease	9.29
29	Chronic lung diseases and Heart disease	9.12
30	Stomach or other digestive disease and Asthma	9.03
31	Liver disease and Kidney disease	8.99
32	Kidney disease and Stomach or other digestive disease	8.92
33	Memory-related disease and Arthritis or rheumatism	8.89
34	Stroke and Arthritis or rheumatism	8.89
35	Arthritis or rheumatism and Asthma	8.77
36	Liver disease and Memory-related disease	8.38
37	Diabetes or high blood sugar and Memory-related disease	8.32
38	Diabetes or high blood sugar and Stroke	8.32
39	Chronic lung diseases and Arthritis or rheumatism	8.14
40	Heart disease and Stomach or other digestive disease	8.11

1			
2			
3	41	Heart disease and Arthritis or rheumatism	7.45
4			
5	42	Stomach or other digestive disease and Emotional, nervous, or	7.39
6		psychiatric problems	
7	43	Liver disease and Stomach or other digestive disease	7.33
8	44	Diabetes or high blood sugar and Cancer or malignant tumor	6.78
9	45	Diabetes or high blood sugar and Asthma	6.78
10	46	Diabetes or high blood sugar and Arthritis or rheumatism	6.44
11	47	Liver disease and Arthritis or rheumatism	6.16
12	48	Chronic lung diseases and Kidney disease	5.98
13	49	Chronic lung diseases and Stomach or other digestive disease	5.97
14	50	Hypertension and Arthritis or rheumatism	5.74
15	51	Chronic lung diseases and Liver disease	5.52
16	52	Kidney disease and Emotional, nervous, or psychiatric problems	5.29
17	53	Kidney disease and Asthma	5.29
18	54	Chronic lung diseases and Emotional, nervous, or psychiatric problems	5.19
19	55	Dyslipidemia and Memory-related disease	5.12
20	56	Hypertension and Emotional, nervous, or psychiatric problems	5.07
21	57	Hypertension and Chronic lung diseases	5.03
22	58	Hypertension and Kidney disease	5.01
23	59	Cancer or malignant tumor and Arthritis or rheumatism	4.96
24	60	Cancer or malignant tumor and Stomach or other digestive disease	4.93
25	61	Dyslipidemia and Arthritis or rheumatism	4.75
26	62	Hypertension and Liver disease	4.61
27	63	Diabetes or high blood sugar and Chronic lung diseases	4.38
28	64	Heart disease and Stroke	4.33
29	65	Dyslipidemia and Asthma	4.17
30	66	Hypertension and Stomach or other digestive disease	3.85
31	67	Cancer or malignant tumor and Heart disease	3.53
32	68	Heart disease and Asthma	3.53
33	69	Emotional, nervous, or psychiatric problems and Arthritis or rheumatism	3.43
34	70	Diabetes or high blood sugar and Stomach or other digestive disease	3.12
35	71	Hypertension and Cancer or malignant tumor	2.17
36	72	Hypertension and Asthma	2.17
37	73	Stomach or other digestive disease and Memory-related disease	2.02
38	74	Stroke and Stomach or other digestive disease	2.02
39	75	Dyslipidemia and Liver disease	1.77
40	76	Dyslipidemia and Chronic lung diseases	1.35
41			
42			
43			
44			
45			
46			
47			
48			
49			
50			
51			
52			
53			
54			
55			
56			
57			
58			
59			
60			

Rank	triads comorbidities pattern	O/E ratio
1	Stroke, Emotional, nervous, or psychiatric problems and Memory-related disease	10491.60
2	Emotional, nervous, or psychiatric problems, Memory-related disease, Asthma,	8548.88
3	Heart disease, Stroke and Memory-related disease	2302.62
4	Chronic lung diseases, Emotional, nervous, or psychiatric problems and Asthma	2252.13
5	Chronic lung diseases, Heart disease, Asthma,	1977.13
6	Dyslipidemia, Heart disease and Memory-related disease	1461.04
7	Hypertension, Stroke and Memory-related disease	1418.54
8	Hypertension, Dyslipidemia and Diabetes or high blood sugar	1409.29
9	Chronic lung diseases, Memory-related disease and Asthma	1381.96
10	Chronic lung diseases, Arthritis or rheumatism and Asthma	1256.63
11	Dyslipidemia, Diabetes or high blood sugar and Kidney disease	1255.51
12	Cancer or malignant tumor, Chronic lung diseases and Asthma	1126.07
13	Chronic lung diseases, Kidney disease and Asthma	1112.24
14	Liver disease, Kidney disease and Asthma	974.52
15	Dyslipidemia, Diabetes or high blood sugar and Liver disease	972.21
16	Chronic lung diseases, Liver disease and Asthma	956.96
17	Dyslipidemia, Diabetes or high blood sugar and Stroke	935.99
18	Chronic lung diseases, Stomach or other digestive disease and Asthma	921.21
19	Hypertension, Dyslipidemia and Heart disease	876.36
20	Diabetes or high blood sugar, Liver disease and Kidney disease	822.11
21	Hypertension, Diabetes or high blood sugar and Stroke	812.58
22	Hypertension, Chronic lung diseases and Asthma	812.01
23	Hypertension, Dyslipidemia and Stroke	800.07
24	Dyslipidemia, Heart disease and Asthma	793.67
25	Diabetes or high blood sugar, Heart disease and Stroke	791.41
26	Hypertension, Emotional, nervous, or psychiatric problems and Memory-related disease	770.58
27	Dyslipidemia, Diabetes or high blood sugar and Cancer or malignant tumor	762.67
28	Dyslipidemia, Diabetes or high blood sugar and Emotional, nervous, or psychiatric problems	762.67
29	Dyslipidemia, Diabetes or high blood sugar and Heart disease	669.54
30	Liver disease, Heart disease and Emotional, nervous, or psychiatric problems	649.62
31	Heart disease, Kidney disease and Memory-related disease	617.74
32	Heart disease, Stroke and Kidney disease	617.74
33	Dyslipidemia, Chronic lung diseases and Asthma	584.58
34	Diabetes or high blood sugar, Liver disease and Heart disease	548.02

35	Hypertension, Diabetes or high blood sugar and Heart disease	523.14
36	Hypertension, Heart disease and Stroke	507.36
37	Diabetes or high blood sugar, Chronic lung diseases and Asthma	474.98
38	Liver disease, Stomach or other digestive disease and Asthma	454.02
39	Stomach or other digestive disease, Emotional, nervous, or psychiatric problems and Memory-related disease	437.10
40	Hypertension, Memory-related disease, Asthma,	385.29
41	Diabetes or high blood sugar, Stomach or other digestive disease and Asthma	300.46
42	Hypertension, Dyslipidemia and Memory-related disease	300.03
43	Liver disease, Kidney disease and Arthritis or rheumatism	277.66
44	Hypertension, Heart disease and Memory-related disease	253.68
45	Dyslipidemia, Liver disease and Kidney disease	252.95
46	Hypertension, Chronic lung diseases and Stroke	249.13
47	Stroke, Memory-related disease and Arthritis or rheumatism	249.11
48	Dyslipidemia, Chronic lung diseases and Liver disease	248.40
49	Cancer or malignant tumor, Chronic lung diseases and Heart disease	247.14
50	Chronic lung diseases, Heart disease and Emotional, nervous, or psychiatric problems	247.14
51	Hypertension, Dyslipidemia and Asthma	244.47
52	Cancer or malignant tumor, Heart disease and Stomach or other digestive disease	234.50
53	Chronic lung diseases, Memory-related disease and Arthritis or rheumatism	229.69
54	Chronic lung diseases, Stroke and Stomach or other digestive disease	211.98
55	Hypertension, Stroke and Arthritis or rheumatism	210.41
56	Chronic lung diseases, Liver disease and Heart disease	210.03
57	Hypertension, Cancer or malignant tumor and Heart disease	206.71
58	Hypertension, Heart disease and Emotional, nervous, or psychiatric problems	206.71
59	Memory-related disease, Arthritis or rheumatism and Asthma	202.98
60	Emotional, nervous, or psychiatric problems, Memory-related disease and Arthritis or rheumatism	202.98
61	Stroke, Emotional, nervous, or psychiatric problems and Arthritis or rheumatism	202.98
62	Stroke, Kidney disease and Arthritis or rheumatism	200.49
63	Dyslipidemia, Diabetes or high blood sugar and Stomach or other digestive disease	194.98
64	Liver disease, Stomach or other digestive disease and Memory-related disease	185.73
65	Dyslipidemia, Stomach or other digestive disease and Asthma	184.90
66	Diabetes or high blood sugar, Stomach or other digestive disease and Memory-related disease	184.37
67	Diabetes or high blood sugar, Heart disease and Arthritis or rheumatism	183.74

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

68	Chronic lung diseases, Stroke and Arthritis or rheumatism	164.06
69	Kidney disease, Arthritis or rheumatism and Asthma	163.36
70	Dyslipidemia, Diabetes or high blood sugar and Arthritis or rheumatism	162.98
71	Hypertension, Diabetes or high blood sugar and Memory-related disease	162.52
72	Hypertension, Dyslipidemia and Kidney disease	160.98
73	Hypertension, Heart disease and Kidney disease	158.80
74	Chronic lung diseases, Liver disease and Kidney disease	157.53
75	Dyslipidemia, Liver disease and Stomach or other digestive disease	157.13
76	Heart disease, Kidney disease and Stomach or other digestive disease	154.42
77	Cancer or malignant tumor, Liver disease and Stomach or other digestive disease	151.34
78	Liver disease, Stomach or other digestive disease and Emotional, nervous, or psychiatric problems	151.34
79	Heart disease, Arthritis or rheumatism and Asthma	145.20
80	Stroke, Kidney disease and Stomach or other digestive disease	143.91
81	Liver disease, Emotional, nervous, or psychiatric problems and Arthritis or rheumatism	140.56
82	Diabetes or high blood sugar, Arthritis or rheumatism and Asthma	139.53
83	Hypertension, Dyslipidemia and Liver disease	138.50
84	Hypertension, Heart disease and Asthma	137.80
85	Kidney disease, Stomach or other digestive disease and Arthritis or rheumatism	136.43
86	Chronic lung diseases, Emotional, nervous, or psychiatric problems and Arthritis or rheumatism	133.68
87	Hypertension, Liver disease and Asthma	133.40
88	Hypertension, Diabetes or high blood sugar and Cancer or malignant tumor	132.42
89	Chronic lung diseases, Stomach or other digestive disease and Arthritis or rheumatism	131.24
90	Hypertension, Diabetes or high blood sugar and Kidney disease	130.80
91	Heart disease, Stomach or other digestive disease and Arthritis or rheumatism	128.06
92	Dyslipidemia, Heart disease and Stomach or other digestive disease	121.74
93	Hypertension, Heart disease and Arthritis or rheumatism	121.06
94	Stomach or other digestive disease, Arthritis or rheumatism and Asthma	118.39
95	Chronic lung diseases, Heart disease and Arthritis or rheumatism	117.36
96	Hypertension, Liver disease and Heart disease	117.11
97	Diabetes or high blood sugar, Kidney disease and Arthritis or rheumatism	114.85
98	Chronic lung diseases, Heart disease and Stomach or other digestive disease	113.73
99	Hypertension, Diabetes or high blood sugar and Liver disease	112.54
100	Diabetes or high blood sugar, Chronic lung diseases and Heart disease	104.24
101	Liver disease, Stomach or other digestive disease and Arthritis or rheumatism	104.21
102	Stroke, Stomach or other digestive disease and Arthritis or rheumatism	103.78

1		
2		
3		
4	103	Hypertension, Kidney disease and Emotional, nervous, or psychiatric problems
5		
6	104	Chronic lung diseases, Liver disease and Arthritis or rheumatism
7	105	Hypertension, Dyslipidemia and Arthritis or rheumatism
8	106	Liver disease, Kidney disease and Stomach or other digestive disease
9		
10	107	Dyslipidemia, Cancer or malignant tumor and Stomach or other digestive disease
11		
12	108	Dyslipidemia, Stomach or other digestive disease and Emotional, nervous, or psychiatric problems
13		
14	109	Hypertension, Dyslipidemia and Chronic lung diseases
15	110	Hypertension, Chronic lung diseases and Heart disease
16	111	Heart disease, Stroke and Arthritis or rheumatism
17	112	Hypertension, Heart disease and Stomach or other digestive disease
18	113	Chronic lung diseases, Heart disease and Kidney disease
19	114	Chronic lung diseases, Kidney disease and Arthritis or rheumatism
20	115	Diabetes or high blood sugar, Chronic lung diseases and Arthritis or rheumatism
21		
22	116	Chronic lung diseases, Kidney disease and Stomach or other digestive disease
23		
24	117	Hypertension, Diabetes or high blood sugar and Arthritis or rheumatism
25	118	Hypertension, Dyslipidemia and Stomach or other digestive disease
26	119	Chronic lung diseases, Liver disease and Stomach or other digestive disease
27		
28	120	Hypertension, Memory-related disease and Arthritis or rheumatism
29	121	Stomach or other digestive disease, Memory-related disease and Arthritis or rheumatism
30	122	Heart disease, Kidney disease and Arthritis or rheumatism
31	123	Liver disease, Arthritis or rheumatism and Asthma
32	124	Diabetes or high blood sugar, Cancer or malignant tumor and Arthritis or rheumatism
33	125	Kidney disease, Memory-related disease and Arthritis or rheumatism
34	126	Dyslipidemia, Heart disease and Arthritis or rheumatism
35	127	Diabetes or high blood sugar, Heart disease and Stomach or other digestive disease
36		
37	128	Dyslipidemia, Chronic lung diseases and Heart disease
38	129	Hypertension, Kidney disease and Arthritis or rheumatism
39	130	Dyslipidemia, Stomach or other digestive disease and Arthritis or rheumatism
40		
41	131	Hypertension, Chronic lung diseases and Memory-related disease
42	132	Dyslipidemia, Kidney disease and Stomach or other digestive disease
43	133	Hypertension, Stroke and Stomach or other digestive disease
44	134	Cancer or malignant tumor, Chronic lung diseases and Stomach or other digestive disease
45		
46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		

1		
2		
3		
4	135	Cancer or malignant tumor, Chronic lung diseases and Arthritis or rheumatism 53.47
5		
6	136	Hypertension, Stomach or other digestive disease and Arthritis or rheumatism 52.98
7		
8	137	Dyslipidemia, Memory-related disease and Arthritis or rheumatism 52.69
9	138	Dyslipidemia, Stroke and Arthritis or rheumatism 52.69
10	139	Hypertension, Cancer or malignant tumor and Chronic lung diseases 50.75
11	140	Hypertension, Chronic lung diseases and Kidney disease 50.13
12	141	Liver disease, Heart disease and Arthritis or rheumatism 46.27
13	142	Hypertension, Cancer or malignant tumor and Arthritis or rheumatism 44.73
14	143	Hypertension, Liver disease and Kidney disease 43.92
15	144	Hypertension, Chronic lung diseases and Liver disease 43.13
16	145	Dyslipidemia, Cancer or malignant tumor and Arthritis or rheumatism 42.93
17	146	Dyslipidemia, Arthritis or rheumatism and Asthma 42.93
18	147	Hypertension, Diabetes or high blood sugar and Chronic lung diseases 42.81
19	148	Dyslipidemia, Kidney disease and Arthritis or rheumatism 42.40
20	149	Stomach or other digestive disease, Emotional, nervous, or psychiatric problems and Arthritis or rheumatism 42.28
21	150	Hypertension, Liver disease and Arthritis or rheumatism 41.18
22	151	Hypertension, Stomach or other digestive disease and Memory-related disease 39.40
23	152	Diabetes or high blood sugar, Stomach or other digestive disease and Arthritis or rheumatism 39.24
24	153	Hypertension, Arthritis or rheumatism and Asthma 37.27
25	154	Dyslipidemia, Liver disease and Arthritis or rheumatism 36.48
26	155	Heart disease, Emotional, nervous, or psychiatric problems and Arthritis or rheumatism 36.30
27	156	Hypertension, Chronic lung diseases and Arthritis or rheumatism 34.95
28	157	Dyslipidemia, Chronic lung diseases and Arthritis or rheumatism 34.70
29	158	Hypertension, Diabetes or high blood sugar and Stomach or other digestive disease 33.85
30	159	Cancer or malignant tumor, Stomach or other digestive disease and Arthritis or rheumatism 33.83
31	160	Liver disease, Heart disease and Stomach or other digestive disease 33.21
32	161	Dyslipidemia, Chronic lung diseases and Stomach or other digestive disease 29.89
33	162	Diabetes or high blood sugar, Liver disease and Arthritis or rheumatism 29.64
34	163	Hypertension, Kidney disease and Stomach or other digestive disease 26.42
35	164	Diabetes or high blood sugar, Chronic lung diseases and Stomach or other digestive disease 24.29
36	165	Hypertension, Emotional, nervous, or psychiatric problems and Arthritis or rheumatism 22.36
37	166	Hypertension, Liver disease and Stomach or other digestive disease 20.46
38		
39		
40		
41		
42		
43		
44		
45		
46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		

1		
2		
3		
4	167	Hypertension, Cancer or malignant tumor and Stomach or other digestive disease
5		
6	168	Hypertension, Stomach or other digestive disease and Emotional, nervous, or psychiatric problems
7		
8		
9	169	Hypertension, Chronic lung diseases and Stomach or other digestive disease
10		
11		
12		
13		
14		
15		
16		
17		
18		
19		
20		
21		
22		
23		
24		
25		
26		
27		
28		
29		
30		
31		
32		
33		
34		
35		
36		
37		
38		
39		
40		
41		
42		
43		
44		
45		
46		
47		
48		
49		
50		
51		
52		
53		
54		
55		
56		
57		
58		
59		
60		

For peer review only

BMJ Open

Prevalence and patterns of multimorbidity among the elderly in China: a cross-sectional study using national survey data

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-024268.R3
Article Type:	Research
Date Submitted by the Author:	27-Apr-2019
Complete List of Authors:	zhang, ran; China Pharmaceutical University, School of International Pharmaceutical Business Lu, Yun; China Pharmaceutical University, School of International Pharmaceutical Business Shi, Liuyan; China Pharmaceutical University, School of International Pharmaceutical Business Zhang, SongLin; China Pharmaceutical University, School of International Pharmaceutical Business Chang, Feng; China Pharmaceutical University, School of International Pharmaceutical Business
Primary Subject Heading:	Health informatics
Secondary Subject Heading:	Public health, Qualitative research
Keywords:	multimorbidity, cross-sectional study, Prevalence, Observed-to-expected ratio, China

SCHOLARONE™
Manuscripts

1
2
3
4 **Prevalence and patterns of multimorbidity among the elderly**
5
6 **in China: a cross-sectional study using national survey data**
7
8

9 **Author**

10 **NAME: Ran Zhang**

11 **Postal address: 639 Longmian Road, Nanjing, Jiangsu Province, CHINA**

12 **E-mail: ranzai7@126.com**

13 **Institutions: China Pharmaceutical University**

14 **City & Country: Jiangsu Province, CHINA**

15 **Telephone: +86-18115161231**

16 **Co-Authors**

17 **NAME: Yun Lu, Liuyan Shi, Songlin Zhang**

18 **Institutions: China Pharmaceutical University**

19 **City & Country: Jiangsu Province, CHINA**

20 **Corresponding Author**

21 **NAME: Feng Chang**

22 **Postal address: 639 Longmian Road, Nanjing, Jiangsu Province, CHINA**

23 **E-mail: cpucf@163.com**

24 **Institutions: China Pharmaceutical University**

25 **City & Country: Jiangsu Province, CHINA**

26 **Telephone: +86-13805153128**

27 **Keywords:**

28 **multimorbidity, Cross-sectional study, Prevalence, Observed-to-expected ratio,**

29 **China**

30 **Word count: 4911**

ABSTRACT

Objectives: Examination of the prevalence and patterns of multimorbidity among the elderly in China.

Design: Cross-sectional study.

Setting: More than 10,000 households in 28 of the 34 provinces of mainland China.

Participants: 11,707 Chinese adults aged 60 and over.

Primary outcome measures: Prevalence and patterns of multimorbidity among the participants. Relative risks were calculated to estimate the probability of up to 14 chronic conditions coexisting with each other. Observed-to-expected (O/E) ratios were used to analyze the patterns of multimorbidity.

Results: Multimorbidity was present in 43.6% of respondents from the sample population, with women having the greater prevalence compared to men. There were 804 different comorbidity combinations identified, including 76 dyad combinations and 169 triad combinations. The top 10 morbidity dyads and triads accounted for 69.01% and 47.05% of the total dyad and triad combinations observed, respectively. Among the 14 chronic conditions included in the study, asthma, stroke, heart attack and six other chronic conditions were the main components of multimorbidity due to their high relative risk ratios. The most frequently occurring clusters with higher O/E ratios were stroke along with emotional, nervous, or psychiatric problems; memory-related diseases together emotional, nervous, or psychiatric problems; and memory-related diseases and asthma accompanied by chronic lung diseases and asthma.

Conclusions: The results of this study highlight the high prevalence of multimorbidity in the elderly population in China. Further studies are required to understand the etiology of multimorbidity, and future primary healthcare policies should be made while taking multimorbidity into consideration.

Strengths and limitations of this study

Strengths

- This is the first study to estimate the prevalence and patterns of multimorbidity among the elderly population in China.
- Data for this study were collected from a nationally representative longitudinal survey of 17,708 Chinese residents.

Limitations

- Only 14 predefined chronic diseases were included in the study, and these may not be comprehensive of the conditions of the population.
- The data analyzed from the CHARLS were originally collected by population self-reporting, not clinician evaluation, and could partially reflect some associated biases or confounds.
- This study only included older patients aged 60 years and above with complete data, and there was no selection bias between the inclusion cases and exclusion cases, but further research would be needed in other populations.

INTRODUCTION

Multimorbidity, or the simultaneous occurrence of two or more chronic conditions in an individual, is becoming increasingly common, and this has been reported to increase progressively with age. [1, 2] At present, with China's aging population having an increasing prevalence of chronic conditions, multimorbidity among the elderly poses an enormous societal cost due to increased mortality rates and healthcare utilization. [3] However, to date, research on chronic conditions in China has focused on single disease states, and the coexistence of multiple chronic conditions has not been investigated systematically and thoroughly.

There is a significant difference in the etiological analysis between patients with single chronic conditions and those with multimorbidity. [4] The coexistence of chronic conditions in a patient is more than a random event, it is more typically due to the causal relationship between some diseases and shared pathogenic factors. [5, 6] Moreover, the interactions between diseases or between a disease and host result in differences in the severity of multimorbidity and functional status and prognosis of patients with multimorbidity. [7] Consequently, it is imperative to begin research on multimorbidity in China for the cost-effective treatments that the results may help to suggest. [8] The purpose of this study was therefore to determine the prevalence of multimorbidity among the elderly in China and to reveal morbidity combinations, which may benefit the design and implementation of a modified healthcare system with consideration for patients with multimorbidity.

METHODS

Data source

Data for this study were collected from the third response of the China Health and Retirement Longitudinal Survey (CHARLS), which is the most current data available. The CHARLS is a nationally representative longitudinal survey of Chinese residents aged 45 and older that was conducted by the Chinese Center for Disease Control and Prevention, along with Peking University, to help China to adjust to the rapid aging of its population through the evaluation of social, economic, and health circumstances on

1
2
3 the community level using data collected by interviews, physical measurements and
4 blood sample collection. [9] The national baseline survey began in 2011 and involved
5 17,708 respondents from 150 county-level units, 450 village-level units, and
6 approximately 10,000 households. Afterwards, CHARLS respondents were followed
7 every second year, with their informed consent, and the study was approved by the
8 Peking University Biomedical Ethics Committee (IRB00001052-14013-exemption).
9
10
11
12
13

14 15 **Variables**

16
17 The core CHARLS questionnaires included sections requesting information on
18 demographic factors, family structure and changes, health status and functioning,
19 healthcare and insurance, work, retirement and pension, income and consumption, and
20 assets (individual and household). Information was collected by interview by trained
21 staff. For the current study, the eligible and included participants were determined by
22 being aged 60 and over, and data on gender, age and health status was used from the
23 general health status and disease history section of senior citizens in the 2015 CHARLS
24 data. This information included the following 14 common chronic health problems:
25 hypertension, dyslipidemia (high blood lipids or low cholesterol), diabetes or elevated
26 blood glucose (including impaired glucose tolerance and fasting blood glucose), cancer
27 (excluding mild skin cancers), chronic lung disease such as chronic bronchitis or
28 emphysema, pulmonary heart disease (excluding tumors or cancer), liver disease (other
29 than fatty liver, tumors, or cancer), heart disease (such as myocardial infarction,
30 coronary heart disease, angina pectoris, congestive heart failure and other heart
31 diseases), stroke, kidney disease (excluding tumors or cancer), stomach or other
32 digestive diseases (excluding tumors or cancer), emotional and mental problems,
33 memory-related diseases (such as Alzheimer's disease, brain atrophy, Parkinson's
34 disease), arthritis or rheumatism, and asthma. All these data were based on self-reports.
35 Accordingly, multimorbidity was defined as the coexistence of more than one of the 14
36 chronic conditions, with acute or subacute forms of certain conditions being excluded
37 in this study due to the CHARLS data collection protocol.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

55 **Statistical analysis**

56 To detect the demographic characteristics of patients with multimorbidity,
57 respondents were divided into two groups: those with multiple chronic conditions
58 (MCC group) and those without multiple chronic conditions (Non-MCC group).
59
60

1
2
3 Descriptive statistics were calculated and expressed as means (SD) and frequencies
4 (percentage). We applied the T² and χ^2 tests to test the differences in age, gender and
5 the mean number of chronic conditions across different subgroups. Respective
6 prevalence in the MCC group and the non-MCC group were calculated separately.
7
8 Given the exclusion of participants with incomplete data, a sensitivity analysis was
9 conducted to compare the characteristics of the complete cases aged 60 years and above
10 and the counterpart in the incomplete cases, which is presented in [Annex 1](#).
11
12
13
14

15 To determine the most common combination of chronic diseases, the prevalence of
16 morbidity and multimorbidity dyads and triads were estimated, respectively. Next, the
17 expected number of patients with a chronic disease were calculated, and the observed-
18 to-expected (O/E) ratios were determined by dividing the number of patients in those
19 groups by the expected number of patients. Observed-to-expected ratios were used to
20 estimate the conditional probability of coexistence of two or three chronic conditions.
21 [10] As an important indicator for assessing the correlation between diseases, the O/E
22 ratio has been used in many areas of comorbidity. [10, 11] The relative risk of
23 comorbidity for individual chronic conditions was also calculated. Relative risk of
24 comorbidity (RR) is the ratio of the number of people with a certain chronic condition
25 who suffer from multimorbidity to the number of patients with the same disease who
26 do not suffer from multimorbidity. [11, 12] In other words, a higher RR value means a
27 higher probability that the disease coexists with other diseases. However, it should be
28 noted that there is no direct relationship between the relative risk of comorbidity and
29 the overall prevalence of the diseases. [13, 14]
30
31
32
33
34
35
36
37
38
39
40

41 All analyses in this study were completed using Stata software V.14.0 for Windows
42 (Stata Corp). P Values <0.05 were considered to be statistically significant.
43
44
45

46 **Patient and public involvement**

47 Patients and the public were not involved in the development of the research
48 question or outcome measures of the study, nor were they involved in study design and
49 execution. There are no plans to disseminate the research results to study participants.
50
51
52
53

54 **RESULTS**

55 **Characteristics of participants**

56 The data were gathered from the third response set of CHARLS. After exclusion
57
58
59
60

of participants with incomplete data (1,002) or aged under 60 (9,259), there were 11,707 respondents with available information on related chronic diseases that were included in this study. The selection process of study sample is shown in Figure 1. The demographic characteristics of sample respondents and statistical significance test results are presented in Table 1.

Overall, the mean age for the sample population was 70.5 (ranging from 60 to 107). The sample population consisted of 5,705 (48.7%) males and 6002 (51.2%) females, and 43.6% of them suffered from multimorbidity. The median of chronic conditions in the MCC group was 3.01, compared to 0.45 in the Non-MCC group. Samples in the MCC group were 0.66 year older than those belonged to the non-MCC group. Gender differences with regard to the age of samples between the MCC group and the non-MCC group (70.57 for MCC group and 69.51 for non-MCC group) were small but statistically significant ($p < 0.001$). The prevalence of multimorbidity in the female population was higher than that for the males (54.41% vs 45.59%). Figure 2 shows the number and proportion of respondents over 60 according to morbidity numbers. It can be seen that among all the participants aged over 60, only 30.9% of them did not have the 14 chronic diseases and 43.6% suffer from multimorbidity.

Table 1. Demographic characteristics of all respondents, the MCC group and non-MCC group

	All respondent	MCC group	Non-MCC group	P*
Number of people	11707	5107	6600	
Proportion (%)	100%	43.62%	56.38%	
Mean age				
All respondents (SD)	70.20(7.907)	70.57(7.701)	69.91(8.051)	<0.001
Male (SD)	69.97(7.575)	70.50(7.348)	69.60(7.707)	<0.001
Female (SD)	70.39(8.189)	70.62(7.892)	70.19(8.359)	<0.001
Gender (% females)	51.28%	54.41%	48.83%	<0.001
Mean number of chronic conditions				
All respondents (SD)	1.57(1.560)	3.01(1.259)	0.45(0.498)	<0.001
Male (SD)	1.47(1.534)	2.98(1.265)	0.44(0.496)	<0.001
Female (SD)	1.65(1.581)	3.03(7.982)	0.47(0.499)	<0.001

SD = standard deviation;

p* = statistical significance of the difference between the MCC and the non-MCC sample (t-tests were performed for comparison of means, and chi-square-tests for differences between percentages)

Prevalence of chronic conditions

The prevalence of chronic conditions in the entire sample, the MCC group and the non-MCC group are shown in Figure 3. The prevalence of all fourteen chronic conditions in the MCC group was significantly higher than that in the entire sample. For instance, the prevalence of arthritis or rheumatism, hypertension, stomach or other digestive disease, heart disease and chronic lung disease were 65.97%, 48.82%, 45.86%, 29.00% and 24.97% in the MCC group, compared to 38.49%, 26.41%, 24.52%, 12.32% and 12.32% in the entire sample, respectively.

Table 2 shows the relative risks of comorbidity determined for the 14 chronic diseases reported in this study. It can be seen that the overall relative risks for asthma, stroke, heart disease and six other conditions were all above 10, which meant these diseases were >10 times easier to coexist with other chronic conditions and result in multimorbidity. In addition, the relative risks for certain diseases were positively associated with gender. For example, men had significantly higher relative risks for asthma, but lower relative risks for diabetes or high blood sugar, compared to women.

Table 2 Relative risks of multimorbidity for different chronic conditions according to gender

Chronic conditions	All respondents	95% Confidence Interval		Female	95% Confidence Interval		Male	95% Confidence Interval		
		Lower Bound	Upper Bound		Lower Bound	Upper Bound		Lower Bound	Upper Bound	
High relative risk of multimorbidity										
Asthma	26.18	17.82	38.46	20.67	11.85	36.06	32.68	19.18	55.67	
Stroke	18.62	12.11	28.64	21.57	10.61	43.86	17.43	10.13	29.99	
Heart disease	15.56	12.99	18.63	16.48	12.80	21.21	14.26	11.02	18.46	
Diabetes or high blood sugar	14.40	11.18	18.55	15.68	10.86	22.63	13.11	9.24	18.62	

1										
2										
3										
4	Dyslipidemia	14.05	11.54	17.12	15.13	11.37	20.14	12.97	9.86	17.05
5	Memory-related disease	13.69	8.85	21.16	34.17	12.63	92.44	9.28	5.66	15.21
6										
7	Kidney disease	11.57	9.24	14.49	15.01	10.17	22.43	10.24	7.78	13.48
8										
9	Liver disease	11.10	8.37	14.71	16.07	9.70	26.63	9.15	6.49	12.89
10	Chronic lung diseases	9.87	8.43	11.55	10.71	8.26	13.88	9.74	8.00	11.86
11										
12	Low relative risk of multimorbidity									
13										
14	Emotional, nervous, or									
15	psychiatric problems	7.42	4.94	11.15	6.24	3.78	10.30	9.36	4.65	18.85
16										
17	Stomach or other digesti									
18	ve disease	5.73	5.25	6.25	6.20	5.48	7.02	5.23	4.62	5.91
19										
20	Hypertension	5.38	4.96	5.84	4.90	4.40	5.47	5.92	5.24	6.69
21										
22	Cancer or malignant									
23	tumor	4.88	3.20	7.45	5.33	3.06	9.29	3.99	2.07	7.72
24										
25	Arthritis or rheumatism	3.83	3.61	4.05	3.70	3.43	3.99	3.91	3.59	4.26
26										
27										
28										
29										
30										
31										
32										
33										
34										
35										
36										
37										
38										
39										
40										
41										
42										
43										
44										
45										
46										
47										
48										
49										
50										
51										
52										
53										
54										
55										
56										
57										
58										
59										
60										

Common multimorbidity combinations

There were 804 possible comorbidity combinations that were identified in the MCC group after statistical analysis, including 72 dyads and 169 triads. The 10 most frequently occurring morbidity dyads and triads are presented respectively in [Table 3](#) and [Table 4](#).

Table 3 Prevalence of the 10 most common morbidity dyads

Rank	Morbidity dyads	Prevalence			Mean Age
		All respondents	female	male	
1	Arthritis or rheumatism and Stomach or other digestive disease	4.73%	3.56%	5.96%	69.20
2	Arthritis or rheumatism and Hypertension	2.85%	2.20%	3.53%	71.25
3	Arthritis or rheumatism and Chronic lung diseases	1.13%	1.22%	1.04%	71.55
4	Hypertension and heart problems	1.03%	1.00%	1.06%	71.80
5	Hypertension and Stomach or other digestive disease	0.89%	0.83%	0.95%	69.07
6	Hypertension	0.86%	0.81%	0.91%	68.58

	and Dyslipidemia				
	Arthritis				
7	or rheumatism	0.76%	0.53%	1.00%	70.72
	and heart problems				
	Arthritis				
8	or rheumatism	0.64%	0.73%	0.54%	68.24
	and Kidney disease				
	Hypertension				
9	and Diabetes or high blood sugar	0.58%	0.50%	0.67%	70.97
	Chronic lung diseases and Asthma				
10		0.53%	0.65%	0.40%	71.15

Table 4 Prevalence of the 10 most common morbidity triads

Rank	Morbidity triads	Prevalence			Mean Age
		All respondents	female	male	
1	Arthritis or rheumatism, Stomach or other digestive disease and Hypertension	1.19%	0.80%	1.60%	70.96
2	Arthritis or rheumatism, Stomach or other digestive disease and Chronic lung diseases	0.82%	0.97%	0.67%	70.82
3	Arthritis or rheumatism, Heart disease and Hypertension	0.63%	0.37%	0.91%	69.93
4	Arthritis or rheumatism, Heart disease and Stomach or other digestive disease	0.59%	0.25%	0.95%	71.51
5	Hypertension, Dyslipidemia and Arthritis or rheumatism	0.44%	0.31%	0.57%	70.13
6	Hypertension, Dyslipidemia and Heart problems	0.42%	0.35%	0.49%	71.17
7	Arthritis or rheumatism, Kidney disease and Stomach or other digestive disease	0.42%	0.40%	0.44%	70.14
8	Arthritis or rheumatism, Asthma and Chronic lung diseases	0.40%	0.46%	0.33%	69.18
9	Hypertension, Dyslipidemia and Diabetes or high blood sugar	0.35%	0.35%	0.35%	71.51
10	Arthritis or rheumatism, Stomach or other digestive disease	0.53%	0.57%	0.49%	70.29

and Liver disease

Theoretically, there are 91 dyad combinations and 364 triad combinations possible given the 14 different chronic conditions considered in this study. However, only 72 types (79.12%) of dyads and 169 types (46.43%) of triads emerged in the sample. The 10 most frequently occurring morbidity dyads accounted for 69.01% of the 72 dyad combinations, and the proportion of the 10 most common triad combinations in the 169 triad combinations was 47.05%. Arthritis or rheumatism, which appeared in five of the top 10 dyad combinations and eight of the top 10 triad combinations of chronic conditions, was the main component of the leading morbidity dyads and triads.

There were significant gender differences observed in the occurrences of these multimorbidity combinations. The numbers of women with triad combinations of chronic diseases were generally higher than for men with the same morbidity triads. For example, women had significantly higher prevalence of arthritis and hypertension and hyperlipidemia than men (78.26% vs 21.74%). Among morbidity dyads, the prevalence of heart disease and arthritis or rheumatism in women was nearly two times higher than that in men, while the cluster of arthritis or rheumatism and kidney disease occurred more frequently in men than in women. No age difference was detected in the probability of these particular multimorbidity combinations occurring.

The O/E ratio was also used to analyze the multimorbidity pattern. [15] The higher the O/E value, the higher the probability of coexistence of chronic conditions. [16] Table 5 shows O/E ratios determined for the 10 most prevalent morbidity dyads and triads. The prevalence of each conditions and the dyad and triad prevalence are presented in Annex 2. In the midst of those triad combinations of chronic conditions, the two clusters with significantly higher O/E ratios were emotional, nervous, or psychiatric problems and stroke and memory-related disease (O/E ratio = 10287.72), emotional, nervous, or psychiatric problems and memory-related disorders and asthma (O/E ratio = 8498.56). These four conditions also dominated the three leading dyads

with the highest O/E ratios: 97.73 for the combination of emotional and mental disorders and memory- related diseases, 23.66 for the combination of stroke and memory related disease and 19.55 for the combination of memory-related disease and asthma.

Table 5 O/E ratios for the 10 most prevalent morbidity dyads and triads

Number of chronic conditions	Rank	Chronic conditions	O/E ratio
2	1	Chronic lung diseases and Asthma	162.15
	2	Emotional, nervous, or psychiatric problems and Memory-related disease	97.73
	3	Dyslipidemia and Diabetes or high blood sugar	38.39
	4	Heart disease and Memory-related disease	25.69
	5	Stroke and Memory-related disease	23.66
	6	Hypertension and Stroke	22.85
	7	Hypertension and Diabetes or high blood sugar	20.64
	8	Cancer or malignant tumor and Stroke	19.55
	9	Memory-related disease and Asthma	19.55
	10	Stroke and Asthma	19.55
3	1	Stroke, Emotional, nervous, or psychiatric problems and Memory-related disease	10287.72
	2	Emotional, nervous, or psychiatric problems, Memory-related disease and Asthma	8498.56
	3	Emotional, nervous, or psychiatric problems, Chronic lung diseases and Asthma	2274.26
	4	Heart disease, Stroke and Memory-related disease	2253.50
	5	Chronic lung diseases, Heart disease and Asthma	1992.69
	6	Dyslipidemia, Heart disease and Memory-related disease	1443.25
	7	Hypertension, Dyslipidemia and Diabetes or high blood sugar	1398.31

8	Hypertension, Stroke and Memory-related disease	1387.35
9	Chronic lung diseases, Memory-related disease and Asthma	1376.53
10	Chronic lung diseases, Arthritis or rheumatism and Asthma	1265.95

DISCUSSION

This is the first study to estimate the prevalence and patterns of multimorbidity among the elderly in China based on the nationally representative data from CHARLS, which covered 11,707 Chinese senior citizens of age 60 and over. The results of the study indicated that 69.1% of the elderly population in China had at least one of the 14 diseases and 43.6% of them suffered from multimorbidity. The average age of the MCC group was 0.66 years higher than that of the non-MCC group and in the MCC group, the mean age of women was 0.12 years higher than that of men, which was comparable to the results of previous studies. [17-21]

The prevalence of multimorbidity estimated in this study was much lower than that from previous studies in other developed countries. For example, a study of 543 patients over age 65 in Ghent, Belgium showed that the multimorbidity rate was as high as 82.6%, [22]. Another study in Australia showed that 83.2% of the respondents suffered from multimorbidity. [23] However, it is difficult to compare the prevalence generated from different studies due to differences in the selected definitions of multimorbidity, demographic characteristics of the samples, and different study methodologies. [24-28]

In agreement with previous reports, arthritis or rheumatism, hypertension, stomach or other digestive disease were the most common diseases in the MCC group. [11] The prevalence of these three conditions was each above 20% in the entire sample, and above 45% in the MCC group. The most prevalent chronic combinations in the sample could also be found in other studies. [22] The results of this study showed that the prevalence of arthritis or rheumatism was high and easy to coexist with other conditions.

1
2
3
4 In addition to the chronic conditions mentioned above, previous studies demonstrated
5 that women with rheumatoid arthritis might have a predisposition to gallstones which
6 could manifest in middle or older age compared with women in the general population.
7
8 This phenomenon could be related to chronic inflammation and HDL metabolism. [29]
9
10

11 Although arthritis or rheumatism, a component of all the leading three morbidity
12 dyads and triads, was also the most commonly occurring disease in multimorbidity, the
13 relative risk of this disease was only 4.65, the lowest in the 14 chronic diseases.
14 Moreover, arthritis or rheumatism is less common in morbidity clusters with large O/E
15 ratios. Therefore, the frequent occurrence of arthritis or rheumatism in multimorbidity
16 might be simply due to the high prevalence of the disease. Doctor-diagnosed arthritis
17 is a common and disabling chronic condition in the world. During 2013 to 2015, an
18 average of more than one in five (54.4 million) adults in the United States were
19 diagnosed with arthritis [30]. The unadjusted prevalences of arthritis among adults with
20 obesity, heart disease, or diabetes were 30.6%, 49.3%, and 47.1%, respectively. In
21 adults with obesity, heart disease, or diabetes, the age-adjusted prevalences of arthritis
22 were respectively 1.5, 1.7 and 1.9 times higher than those without these diseases.
23 Improving the health of adults with arthritis and related comorbid conditions calls for
24 wider dissemination and implementation of evidence-based interventions, such as self-
25 management education and physical activity promotion [31].
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41

42 The relative risks for asthma, stroke, heart disease, and six other conditions were all
43 above 10, which means that patients with these diseases were 10 times more likely to
44 be afflicted by multimorbidity. These diseases also occurred at a high frequency in
45 multimorbidity with high O/E ratios, such as the clusters of pulmonary disease and
46 asthma, emotional and mental illness and memory-related disease, dyslipidemia and
47 diabetes, and stroke and emotional or mental illness and memory-related disease.
48 Patients with these diseases were more likely to express comorbidity compared to those
49 without these diseases, and thus should be the focus of future research studies.
50
51
52
53
54
55
56
57

58 This study featured a nationally representative sample of the Chinese elderly
59
60

1
2
3
4 population, which was crucial to get an overall understanding of multimorbidity among
5 the elderly in China. However, there were also limitations with the data sample and
6 study. For example, this study used data from the third wave report of CHARLS, a
7 survey which was conducted in 2015, and there is accordingly a time lag to now that
8 exists. Additionally, the chronic diseases included in the study were not comprehensive,
9 since only 14 chronic conditions were included in the survey. Finally, the data obtained
10 from the survey was based on self-reporting, which may have introduced some
11 misclassification bias or other confounds. Later research on the prevalence and patterns
12 of multimorbidity should be carried out in-depth with a more extensive survey of
13 chronic disease.
14
15
16
17
18
19
20
21
22
23
24
25

26 CONCLUSIONS

27
28 Multimorbidity remains an underexplored area of research in China. [32]. Despite
29 the increasing prevalence of multimorbidity, there are no specific proposals for its
30 diagnosis and treatment. [33] This study contributes to the understanding of the
31 prevalence and patterns of comorbidity among the elderly in China. Considering
32 China's aging population and the high prevalence of comorbidity in senior citizens, the
33 elderly should be prioritized in the fields of disease prevention and health promotion.
34
35
36
37
38
39
40
41
42
43
44

45 **Acknowledgements** The authors would like to thank the Chinese Center for Disease
46 Control and Prevention and Peking University for access to China Health and
47 Retirement Longitudinal Survey data.
48
49

50 **Contributors** RZ analyzed and interpreted data, drafted the manuscript, approved the
51 final manuscript as submitted. YL revised the manuscript for important intellectual
52 content. YLS analyzed and interpreted data and revised the manuscript for important
53 intellectual content. SLZ analyzed and checked the data of the full text. FC helped on
54 the study design and revised the manuscript.
55
56
57
58
59
60

Funding This work was funded by the National Natural Science Foundation of China (7167030838).

Competing interests None declared.

Patient consent Obtained.

Ethics approval The original CHARLS was approved by the ethics review committee of Peking University, and all participants gave written informed consent at the time of participation

Data sharing statement No additional data are available

REFERENCES

1. Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. *Lancet* 2012; 380:37–43.doi:10.1016/S0140-6736(12)60240-2
2. World Health Organization. Global status report on noncommunicable diseases, 2014.<http://apps.who.int/nmh/publications/ncd-status-report-2014/en/index.html> (accessed 27 Oct 2017)
3. Lee J T, Hamid F, Pati S, et al. Impact of Noncommunicable Disease Multimorbidity on Healthcare Utilisation and Out-Of-Pocket Expenditures in Middle-Income Countries: Cross Sectional Analysis. *PLoS One* 2015;10:103-110. doi: 10.1371/journal.pone.0127199
4. Moffat K, Mercer SW. Challenges of managing people with multimorbidity in today's healthcare systems. *BMC Fam Prac* 2015;16:129.doi: 10.1186/s12875-015-0344-4
5. Schäfer Ingmar, von Leitner Eike-Christin, Schön Gerhard et al. Multimorbidity patterns in the elderly: a new approach of disease clustering identifies complex interrelations between chronic conditions. *PLoS One* 2010;12:e15941.doi: 10.1371/journal.pone.0015941
6. Atun R. Transitioning health systems for multimorbidity. *Lancet* 2015;386:721–

- 1
2
3
4 2.doi: 10.1016/S0140-6736(14)62254-6
5
6 7. Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of
7 multiple chronic conditions in the elderly. *Arch Intern Med* 2002;20: 2269-2276.doi:
8 10.1001/archinte.162.20.2269
9
10
11 8. Yang L, Wu M, Cui B, et al. Economic burden of cardiovascular diseases in China.
12 *Expert Rev Pharmacoecon Outcomes Res*2008;8:349–56.doi:
13 10.1586/14737167.8.4.349
14
15
16 9. Zhao Y, Hu Y, Smith JP, et al. Cohort profile: the China Health and Retirement
17 Longitudinal Study (CHARLS). *Int J Epidemiol* 2014;1:61-69.doi:
18 10.1093/ije/dys203
19
20
21 10. Van den Bussche H, Koller D, Kolonko T, et al. Which chronic diseases and disease
22 combinations are specific to multimorbidity in the elderly? Results of a claims data
23 based cross-sectional study in Germany. *BMC Public Health* 2011;11:101-110.doi:
24 10.1186/1471-2458-11-101
25
26
27 11. Viera AJ. Odds ratios and risk ratios: what's the difference and why does it matter?
28 *South Med J* 2008; 7: 30-34.doi:10.1097/SMJ.0b013e31817a7ee4
29
30
31 12. Vettore MV, Meira GF, Rebelo MA et al. Multimorbidity patterns of oral clinical
32 conditions, social position, and oral health-related quality of life in a population-
33 based survey of 12-yr-old children. *Eur J Oral Sci.*2016 ; 6:580-590. doi:
34 10.1111/eos.12304. Epub 2016 Oct 8.
35
36
37 13. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in
38 cohort studies of common outcomes. *JAMA*1998;19:1690-1691.doi:
39 10.1001/jama.280.19.1690
40
41
42 14. McNutt LA, Wu C, Xue X, et al. Estimating the Relative Risk in Cohort Studies
43 and Clinical Trials of Common Outcomes. *Am J Epidemiol* 2003;10:940–943.doi:
44 10.1002/cncr.30192
45
46
47 15. Marengoni A, Rizzuto D, Wang HX, et al. Patterns of chronic multimorbidity in the
48 elderly population. *J Am Geriatr Soc*2009;57:225–30.doi:10.1111/j.1532-
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4 5415.2008.02109.x
5
6 16. Best WR, Cowper DC. The Ratio of Observed-to-Expected Mortality as a Quality
7 of Care Indicator in Non-Surgical VA Patients. *Med Care* 1994;4:390-400.doi:
8 10.1097/00005650-199404000-00007
9
10
11 17. Kastenholz KE, Weis M, Hagelstein C, et al. Correlation of Observed-to-Expected
12 MRI Fetal Lung Volume and Ultrasound Lung-to-Head Ratio at Different
13 Gestational Times in Fetuses With Congenital Diaphragmatic Hernia. *AJR Am J*
14 *Roentgenol*2016;4:856-866.doi:10.2214/AJR.15.15018
15
16
17
18
19 18. Melis R, Marengoni A, Angleman S, et al. Incidence and predictors of
20 multimorbidity in the elderly: a population-based longitudinal study. *PLoS One*
21 2014; 9: e103120.doi:10.1371/journal.pone.0103120
22
23
24
25 19. Laan W, Bleijenberg N, Drubbel I, et al. Factors associated with increasing
26 functional decline in multimorbid independently living older people. *Maturitas*
27 2013; 75: 276–81.doi:10.1016/j.maturitas.2013.04.005
28
29
30
31 20. Eckerblad J, Theander K, Ekdahl A, et al. To adjust and endure: a qualitative study
32 of symptom burden in older people with multimorbidity. *Appl Nurs Res*
33 2015;28:322–7.doi:10.1016/j.apnr.2015.03.008
34
35
36
37 21. Wister A, Kendig H, Mitchell B, et al. Multimorbidity, health and aging in Canada
38 and Australia: a tale of two countries. *BMC Geriatr*2016;1:163-176.doi:
39 10.1186/s12877-016-0341-z
40
41
42
43 22. Afshar S, Roderick PJ, Kowal P, et al. Multimorbidity and the inequalities of global
44 ageing: a cross-sectional study of 28 countries using the World Health Surveys.
45 *BMC Public Health*2015;15:776-786.doi:10.1186/s12889-015-2008-7
46
47
48
49 23. Boeckxstaens P, Peersman W, Goubin G, et al. A practice-based analysis of
50 combinations of diseases in patients aged 65 or older in primary care. *BMC Family*
51 *Practice* 2014;1:1-6.doi: 10.1186/1471-2296-15-159.
52
53
54 24. Britt HC , Harrison CM , Miller GC , et al . Prevalence and patterns of
55 multimorbidity in Australia. *Med J Aust* 2008;2: 72-77
56
57
58 25. Glynn LG , Valderas JM , Healy P , et al . The prevalence of multimorbidity in
59
60

- 1
2
3 primary care and its effect on health care utilization and cost. *Fam Pract*
4 2011;28:516–23.doi:10.1093/fampra/cmr013
5
6
7 26. Marengoni A , Angleman S , Melis R , et al . Aging with multimorbidity: a
8 systematic review of the literature. *Ageing Res Rev* 2011;10:430–
9 9.doi:10.1016/j.arr.2011.03.003
10
11
12 27. Barnett K , Mercer SW , Norbury M , et al . Epidemiology of multimorbidity and
13 implications for health care, research, and medical education: a cross-sectional
14 study. *Lancet* 2012;380:37–43.doi:10.1016/S0140-6736(12)60240-2
15
16
17 28. Fortin M , Stewart M , Poitras ME , et al . A systematic review of prevalence studies
18 on multimorbidity: toward a more uniform methodology. *Ann Fam Med*
19 2012;10:142–51.doi:10.1370/afm.1337.
20
21
22 29. García-Gómez M C, De L E, Ordoñez-Palau S, et al. High Prevalence of Gallstone
23 Disease in Rheumatoid Arthritis: A New Comorbidity Related to Dyslipidemia? [J].
24 *Reumatol Clin*, 2017;14:294-300. doi: 10.1016/j.reuma.2018.03.012.
25
26
27 30. Barbour KE, Helmick CG, Boring M, et al. Vital Signs: Prevalence of Doctor-
28 Diagnosed Arthritis and Arthritis-Attributable Activity Limitation — United States,
29 2013–2015. *MMWR Morb Mortal Wkly Rep*, 2017;66:246–253. doi:
30 http://dx.doi.org/10.15585/mmwr.mm6609e1.
31
32
33 31. Ward BW, Schiller JS. Prevalence of multiple chronic conditions among US adults:
34 estimates from the National Health Interview Survey, 2010. *Prev Chronic Dis*
35 2013;10:120203. doi: 10.5888/pcd10.120203
36
37
38 32. Bao W, Hu D, Shi X, et al. Comorbidity increased the risk of falls in Chinese older
39 adults: A cross-sectional study. *Int J Clin Exp Med*,2017;7:10753-10763.
40
41
42 33. Gao N, Yuan Z, Tang X, et al. Prevalence of CHD-related metabolic comorbidity
43 of diabetes mellitus in Northern Chinese adults: the REACTION study. *J Diabetes*
44 *Complications*2016;2:199-205.doi:10.1016/j.jdiacomp.2015.11.018
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure legends

Figure 1 Flowchart for selecting the study sample from the original sample population. CHARLS, China Health and Retirement Longitudinal Survey

Figure 2 Frequency and percentage of people aged over 60 suffering from different diseases based on CHARLS data

Figure 3 Prevalence Rates of chronic condition in elderly people over 60 years old based on CHARLS data




Figure 1 Flowchart for selecting the study sample from the original sample population. CHARLS, China Health and Retirement Longitudinal Survey

171x93mm (300 x 300 DPI)




Figure 2 Frequency and percentage of people aged over 60 suffering from different diseases based on CHARLS data

222x119mm (300 x 300 DPI)




Figure 3 Prevalence Rates of chronic condition in elderly people over 60 years old based on CHARLS data

151x140mm (300 x 300 DPI)

Annex 1 Sensitivity analysis, Comparison of the characteristics of complete cases and incomplete cases

	Complete cases	Incomplete cases	P*
Number of people	11707	876	
Proportion (%)	93.04%	6.96%	
Mean age All respondents (SD)	70.20(7.907)	69.60 (7.824)	<0.001
Male (SD)	69.97(7.575)	69.58 (7.721)	<0.001
Female (SD)	70.39(8.189)	69.62 (7.973)	<0.001
Gender (% females)	51.28%	49.27%	0.193

p* = statistical significance of the difference between the complete cases and the incomplete cases (t-tests were performed for comparison of means, and chi-square-tests for differences between percentages)

Annex 2 O/E ratio of all binary and triads comorbidities pattern present in participants

Rank	binary comorbidities pattern	O/E ratio
1	Chronic lung diseases and Asthma	161.00
2	Emotional, nervous, or psychiatric problems and Memory-related disease	98.57
3	Dyslipidemia and Diabetes or high blood sugar	38.69
4	Heart disease and Memory-related disease	25.96
5	Stroke and Memory-related disease	24.19
6	Hypertension and Stroke	23.10
7	Hypertension and Diabetes or high blood sugar	20.77
8	Cancer or malignant tumor and Stroke	19.71
9	Memory-related disease and Asthma	19.71
10	Stroke and Asthma	19.71
11	Hypertension and Heart disease	19.07
12	Hypertension and Dyslipidemia	18.98
13	Dyslipidemia and Heart disease	17.39
14	Diabetes or high blood sugar and Heart disease	14.87
15	Diabetes or high blood sugar and Liver disease	14.40
16	Cancer or malignant tumor and Liver disease	13.65
17	Diabetes or high blood sugar and Kidney disease	13.38
18	Hypertension and Memory-related disease	13.33
19	Dyslipidemia and Cancer or malignant tumor	12.51
20	Stomach or other digestive disease and Arthritis or rheumatism	10.80
21	Liver disease and Heart disease	10.49
22	Dyslipidemia and Stroke	10.23
23	Dyslipidemia and Stomach or other digestive disease	9.81
24	Dyslipidemia and Kidney disease	9.61
25	Chronic lung diseases and Memory-related disease	9.56
26	Chronic lung diseases and Stroke	9.56
27	Kidney disease and Arthritis or rheumatism	9.42
28	Heart disease and Kidney disease	9.29
29	Chronic lung diseases and Heart disease	9.12
30	Stomach or other digestive disease and Asthma	9.03
31	Liver disease and Kidney disease	8.99
32	Kidney disease and Stomach or other digestive disease	8.92
33	Memory-related disease and Arthritis or rheumatism	8.89
34	Stroke and Arthritis or rheumatism	8.89
35	Arthritis or rheumatism and Asthma	8.77
36	Liver disease and Memory-related disease	8.38
37	Diabetes or high blood sugar and Memory-related disease	8.32
38	Diabetes or high blood sugar and Stroke	8.32
39	Chronic lung diseases and Arthritis or rheumatism	8.14
40	Heart disease and Stomach or other digestive disease	8.11

1			
2			
3	41	Heart disease and Arthritis or rheumatism	7.45
4			
5	42	Stomach or other digestive disease and Emotional, nervous, or	7.39
6		psychiatric problems	
7	43	Liver disease and Stomach or other digestive disease	7.33
8	44	Diabetes or high blood sugar and Cancer or malignant tumor	6.78
9	45	Diabetes or high blood sugar and Asthma	6.78
10	46	Diabetes or high blood sugar and Arthritis or rheumatism	6.44
11	47	Liver disease and Arthritis or rheumatism	6.16
12	48	Chronic lung diseases and Kidney disease	5.98
13	49	Chronic lung diseases and Stomach or other digestive disease	5.97
14	50	Hypertension and Arthritis or rheumatism	5.74
15	51	Chronic lung diseases and Liver disease	5.52
16	52	Kidney disease and Emotional, nervous, or psychiatric problems	5.29
17	53	Kidney disease and Asthma	5.29
18	54	Chronic lung diseases and Emotional, nervous, or psychiatric problems	5.19
19	55	Dyslipidemia and Memory-related disease	5.12
20	56	Hypertension and Emotional, nervous, or psychiatric problems	5.07
21	57	Hypertension and Chronic lung diseases	5.03
22	58	Hypertension and Kidney disease	5.01
23	59	Cancer or malignant tumor and Arthritis or rheumatism	4.96
24	60	Cancer or malignant tumor and Stomach or other digestive disease	4.93
25	61	Dyslipidemia and Arthritis or rheumatism	4.75
26	62	Hypertension and Liver disease	4.61
27	63	Diabetes or high blood sugar and Chronic lung diseases	4.38
28	64	Heart disease and Stroke	4.33
29	65	Dyslipidemia and Asthma	4.17
30	66	Hypertension and Stomach or other digestive disease	3.85
31	67	Cancer or malignant tumor and Heart disease	3.53
32	68	Heart disease and Asthma	3.53
33	69	Emotional, nervous, or psychiatric problems and Arthritis or rheumatism	3.43
34	70	Diabetes or high blood sugar and Stomach or other digestive disease	3.12
35	71	Hypertension and Cancer or malignant tumor	2.17
36	72	Hypertension and Asthma	2.17
37	73	Stomach or other digestive disease and Memory-related disease	2.02
38	74	Stroke and Stomach or other digestive disease	2.02
39	75	Dyslipidemia and Liver disease	1.77
40	76	Dyslipidemia and Chronic lung diseases	1.35
41			
42			
43			
44			
45			
46			
47			
48			
49			
50			
51			
52			
53			
54			
55			
56			
57			
58			
59			
60			

Rank	triads comorbidities pattern	O/E ratio
1	Stroke, Emotional, nervous, or psychiatric problems and Memory-related disease	10491.60
2	Emotional, nervous, or psychiatric problems, Memory-related disease, Asthma,	8548.88
3	Heart disease, Stroke and Memory-related disease	2302.62
4	Chronic lung diseases, Emotional, nervous, or psychiatric problems and Asthma	2252.13
5	Chronic lung diseases, Heart disease, Asthma,	1977.13
6	Dyslipidemia, Heart disease and Memory-related disease	1461.04
7	Hypertension, Stroke and Memory-related disease	1418.54
8	Hypertension, Dyslipidemia and Diabetes or high blood sugar	1409.29
9	Chronic lung diseases, Memory-related disease and Asthma	1381.96
10	Chronic lung diseases, Arthritis or rheumatism and Asthma	1256.63
11	Dyslipidemia, Diabetes or high blood sugar and Kidney disease	1255.51
12	Cancer or malignant tumor, Chronic lung diseases and Asthma	1126.07
13	Chronic lung diseases, Kidney disease and Asthma	1112.24
14	Liver disease, Kidney disease and Asthma	974.52
15	Dyslipidemia, Diabetes or high blood sugar and Liver disease	972.21
16	Chronic lung diseases, Liver disease and Asthma	956.96
17	Dyslipidemia, Diabetes or high blood sugar and Stroke	935.99
18	Chronic lung diseases, Stomach or other digestive disease and Asthma	921.21
19	Hypertension, Dyslipidemia and Heart disease	876.36
20	Diabetes or high blood sugar, Liver disease and Kidney disease	822.11
21	Hypertension, Diabetes or high blood sugar and Stroke	812.58
22	Hypertension, Chronic lung diseases and Asthma	812.01
23	Hypertension, Dyslipidemia and Stroke	800.07
24	Dyslipidemia, Heart disease and Asthma	793.67
25	Diabetes or high blood sugar, Heart disease and Stroke	791.41
26	Hypertension, Emotional, nervous, or psychiatric problems and Memory-related disease	770.58
27	Dyslipidemia, Diabetes or high blood sugar and Cancer or malignant tumor	762.67
28	Dyslipidemia, Diabetes or high blood sugar and Emotional, nervous, or psychiatric problems	762.67
29	Dyslipidemia, Diabetes or high blood sugar and Heart disease	669.54
30	Liver disease, Heart disease and Emotional, nervous, or psychiatric problems	649.62
31	Heart disease, Kidney disease and Memory-related disease	617.74
32	Heart disease, Stroke and Kidney disease	617.74
33	Dyslipidemia, Chronic lung diseases and Asthma	584.58
34	Diabetes or high blood sugar, Liver disease and Heart disease	548.02

35	Hypertension, Diabetes or high blood sugar and Heart disease	523.14
36	Hypertension, Heart disease and Stroke	507.36
37	Diabetes or high blood sugar, Chronic lung diseases and Asthma	474.98
38	Liver disease, Stomach or other digestive disease and Asthma	454.02
39	Stomach or other digestive disease, Emotional, nervous, or psychiatric problems and Memory-related disease	437.10
40	Hypertension, Memory-related disease, Asthma,	385.29
41	Diabetes or high blood sugar, Stomach or other digestive disease and Asthma	300.46
42	Hypertension, Dyslipidemia and Memory-related disease	300.03
43	Liver disease, Kidney disease and Arthritis or rheumatism	277.66
44	Hypertension, Heart disease and Memory-related disease	253.68
45	Dyslipidemia, Liver disease and Kidney disease	252.95
46	Hypertension, Chronic lung diseases and Stroke	249.13
47	Stroke, Memory-related disease and Arthritis or rheumatism	249.11
48	Dyslipidemia, Chronic lung diseases and Liver disease	248.40
49	Cancer or malignant tumor, Chronic lung diseases and Heart disease	247.14
50	Chronic lung diseases, Heart disease and Emotional, nervous, or psychiatric problems	247.14
51	Hypertension, Dyslipidemia and Asthma	244.47
52	Cancer or malignant tumor, Heart disease and Stomach or other digestive disease	234.50
53	Chronic lung diseases, Memory-related disease and Arthritis or rheumatism	229.69
54	Chronic lung diseases, Stroke and Stomach or other digestive disease	211.98
55	Hypertension, Stroke and Arthritis or rheumatism	210.41
56	Chronic lung diseases, Liver disease and Heart disease	210.03
57	Hypertension, Cancer or malignant tumor and Heart disease	206.71
58	Hypertension, Heart disease and Emotional, nervous, or psychiatric problems	206.71
59	Memory-related disease, Arthritis or rheumatism and Asthma	202.98
60	Emotional, nervous, or psychiatric problems, Memory-related disease and Arthritis or rheumatism	202.98
61	Stroke, Emotional, nervous, or psychiatric problems and Arthritis or rheumatism	202.98
62	Stroke, Kidney disease and Arthritis or rheumatism	200.49
63	Dyslipidemia, Diabetes or high blood sugar and Stomach or other digestive disease	194.98
64	Liver disease, Stomach or other digestive disease and Memory-related disease	185.73
65	Dyslipidemia, Stomach or other digestive disease and Asthma	184.90
66	Diabetes or high blood sugar, Stomach or other digestive disease and Memory-related disease	184.37
67	Diabetes or high blood sugar, Heart disease and Arthritis or rheumatism	183.74

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

68	Chronic lung diseases, Stroke and Arthritis or rheumatism	164.06
69	Kidney disease, Arthritis or rheumatism and Asthma	163.36
70	Dyslipidemia, Diabetes or high blood sugar and Arthritis or rheumatism	162.98
71	Hypertension, Diabetes or high blood sugar and Memory-related disease	162.52
72	Hypertension, Dyslipidemia and Kidney disease	160.98
73	Hypertension, Heart disease and Kidney disease	158.80
74	Chronic lung diseases, Liver disease and Kidney disease	157.53
75	Dyslipidemia, Liver disease and Stomach or other digestive disease	157.13
76	Heart disease, Kidney disease and Stomach or other digestive disease	154.42
77	Cancer or malignant tumor, Liver disease and Stomach or other digestive disease	151.34
78	Liver disease, Stomach or other digestive disease and Emotional, nervous, or psychiatric problems	151.34
79	Heart disease, Arthritis or rheumatism and Asthma	145.20
80	Stroke, Kidney disease and Stomach or other digestive disease	143.91
81	Liver disease, Emotional, nervous, or psychiatric problems and Arthritis or rheumatism	140.56
82	Diabetes or high blood sugar, Arthritis or rheumatism and Asthma	139.53
83	Hypertension, Dyslipidemia and Liver disease	138.50
84	Hypertension, Heart disease and Asthma	137.80
85	Kidney disease, Stomach or other digestive disease and Arthritis or rheumatism	136.43
86	Chronic lung diseases, Emotional, nervous, or psychiatric problems and Arthritis or rheumatism	133.68
87	Hypertension, Liver disease and Asthma	133.40
88	Hypertension, Diabetes or high blood sugar and Cancer or malignant tumor	132.42
89	Chronic lung diseases, Stomach or other digestive disease and Arthritis or rheumatism	131.24
90	Hypertension, Diabetes or high blood sugar and Kidney disease	130.80
91	Heart disease, Stomach or other digestive disease and Arthritis or rheumatism	128.06
92	Dyslipidemia, Heart disease and Stomach or other digestive disease	121.74
93	Hypertension, Heart disease and Arthritis or rheumatism	121.06
94	Stomach or other digestive disease, Arthritis or rheumatism and Asthma	118.39
95	Chronic lung diseases, Heart disease and Arthritis or rheumatism	117.36
96	Hypertension, Liver disease and Heart disease	117.11
97	Diabetes or high blood sugar, Kidney disease and Arthritis or rheumatism	114.85
98	Chronic lung diseases, Heart disease and Stomach or other digestive disease	113.73
99	Hypertension, Diabetes or high blood sugar and Liver disease	112.54
100	Diabetes or high blood sugar, Chronic lung diseases and Heart disease	104.24
101	Liver disease, Stomach or other digestive disease and Arthritis or rheumatism	104.21
102	Stroke, Stomach or other digestive disease and Arthritis or rheumatism	103.78

103	Hypertension, Kidney disease and Emotional, nervous, or psychiatric problems	103.36
104	Chronic lung diseases, Liver disease and Arthritis or rheumatism	102.25
105	Hypertension, Dyslipidemia and Arthritis or rheumatism	100.61
106	Liver disease, Kidney disease and Stomach or other digestive disease	99.65
107	Dyslipidemia, Cancer or malignant tumor and Stomach or other digestive disease	92.45
108	Dyslipidemia, Stomach or other digestive disease and Emotional, nervous, or psychiatric problems	92.45
109	Hypertension, Dyslipidemia and Chronic lung diseases	92.21
110	Hypertension, Chronic lung diseases and Heart disease	89.11
111	Heart disease, Stroke and Arthritis or rheumatism	89.10
112	Hypertension, Heart disease and Stomach or other digestive disease	88.07
113	Chronic lung diseases, Heart disease and Kidney disease	81.37
114	Chronic lung diseases, Kidney disease and Arthritis or rheumatism	79.23
115	Diabetes or high blood sugar, Chronic lung diseases and Arthritis or rheumatism	78.94
116	Chronic lung diseases, Kidney disease and Stomach or other digestive disease	75.82
117	Hypertension, Diabetes or high blood sugar and Arthritis or rheumatism	75.46
118	Hypertension, Dyslipidemia and Stomach or other digestive disease	75.00
119	Chronic lung diseases, Liver disease and Stomach or other digestive disease	73.39
120	Hypertension, Memory-related disease and Arthritis or rheumatism	73.19
121	Stomach or other digestive disease, Memory-related disease and Arthritis or rheumatism	72.65
122	Heart disease, Kidney disease and Arthritis or rheumatism	71.71
123	Liver disease, Arthritis or rheumatism and Asthma	70.28
124	Diabetes or high blood sugar, Cancer or malignant tumor and Arthritis or rheumatism	69.76
125	Kidney disease, Memory-related disease and Arthritis or rheumatism	66.83
126	Dyslipidemia, Heart disease and Arthritis or rheumatism	65.96
127	Diabetes or high blood sugar, Heart disease and Stomach or other digestive disease	65.94
128	Dyslipidemia, Chronic lung diseases and Heart disease	64.15
129	Hypertension, Kidney disease and Arthritis or rheumatism	63.81
130	Dyslipidemia, Stomach or other digestive disease and Arthritis or rheumatism	63.66
131	Hypertension, Chronic lung diseases and Memory-related disease	62.28
132	Dyslipidemia, Kidney disease and Stomach or other digestive disease	60.88
133	Hypertension, Stroke and Stomach or other digestive disease	59.10
134	Cancer or malignant tumor, Chronic lung diseases and Stomach or other digestive disease	57.58

1		
2		
3		
4	135	Cancer or malignant tumor, Chronic lung diseases and Arthritis or
5		rheumatism
6		53.47
7	136	Hypertension, Stomach or other digestive disease and Arthritis or
8		rheumatism
9		52.98
10	137	Dyslipidemia, Memory-related disease and Arthritis or rheumatism
11		52.69
12	138	Dyslipidemia, Stroke and Arthritis or rheumatism
13		52.69
14	139	Hypertension, Cancer or malignant tumor and Chronic lung diseases
15		50.75
16	140	Hypertension, Chronic lung diseases and Kidney disease
17		50.13
18	141	Liver disease, Heart disease and Arthritis or rheumatism
19		46.27
20	142	Hypertension, Cancer or malignant tumor and Arthritis or rheumatism
21		44.73
22	143	Hypertension, Liver disease and Kidney disease
23		43.92
24	144	Hypertension, Chronic lung diseases and Liver disease
25		43.13
26	145	Dyslipidemia, Cancer or malignant tumor and Arthritis or rheumatism
27		42.93
28	146	Dyslipidemia, Arthritis or rheumatism and Asthma
29		42.93
30	147	Hypertension, Diabetes or high blood sugar and Chronic lung diseases
31		42.81
32	148	Dyslipidemia, Kidney disease and Arthritis or rheumatism
33		42.40
34	149	Stomach or other digestive disease, Emotional, nervous, or psychiatric
35		problems and Arthritis or rheumatism
36		42.28
37	150	Hypertension, Liver disease and Arthritis or rheumatism
38		41.18
39	151	Hypertension, Stomach or other digestive disease and Memory-related
40		disease
41		39.40
42	152	Diabetes or high blood sugar, Stomach or other digestive disease and
43		Arthritis or rheumatism
44		39.24
45	153	Hypertension, Arthritis or rheumatism and Asthma
46		37.27
47	154	Dyslipidemia, Liver disease and Arthritis or rheumatism
48		36.48
49	155	Heart disease, Emotional, nervous, or psychiatric problems and Arthritis or
50		rheumatism
51		36.30
52	156	Hypertension, Chronic lung diseases and Arthritis or rheumatism
53		34.95
54	157	Dyslipidemia, Chronic lung diseases and Arthritis or rheumatism
55		34.70
56	158	Hypertension, Diabetes or high blood sugar and Stomach or other digestive
57		disease
58		33.85
59	159	Cancer or malignant tumor, Stomach or other digestive disease and
60		Arthritis or rheumatism
		33.83
	160	Liver disease, Heart disease and Stomach or other digestive disease
		33.21
	161	Dyslipidemia, Chronic lung diseases and Stomach or other digestive
		disease
		29.89
	162	Diabetes or high blood sugar, Liver disease and Arthritis or rheumatism
		29.64
	163	Hypertension, Kidney disease and Stomach or other digestive disease
		26.42
	164	Diabetes or high blood sugar, Chronic lung diseases and Stomach or other
		digestive disease
		24.29
	165	Hypertension, Emotional, nervous, or psychiatric problems and Arthritis or
		rheumatism
		22.36
	166	Hypertension, Liver disease and Stomach or other digestive disease
		20.46

167	Hypertension, Cancer or malignant tumor and Stomach or other digestive disease	16.05
168	Hypertension, Stomach or other digestive disease and Emotional, nervous, or psychiatric problems	16.05
169	Hypertension, Chronic lung diseases and Stomach or other digestive disease	15.57

For peer review only

BMJ Open

Prevalence and patterns of multimorbidity among the elderly in China: a cross-sectional study using national survey data

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2018-024268.R4
Article Type:	Research
Date Submitted by the Author:	30-May-2019
Complete List of Authors:	zhang, ran; China Pharmaceutical University, School of International Pharmaceutical Business Lu, Yun; China Pharmaceutical University, School of International Pharmaceutical Business Shi, Liuyan; China Pharmaceutical University, School of International Pharmaceutical Business Zhang, SongLin; China Pharmaceutical University, School of International Pharmaceutical Business Chang, Feng; China Pharmaceutical University, School of International Pharmaceutical Business
Primary Subject Heading:	Health informatics
Secondary Subject Heading:	Public health, Qualitative research
Keywords:	multimorbidity, cross-sectional study, Prevalence, Observed-to-expected ratio, China

SCHOLARONE™
Manuscripts

1
2
3
4 **Prevalence and patterns of multimorbidity among the elderly**
5
6 **in China: a cross-sectional study using national survey data**
7
8

9 **Author**

10 **NAME: Ran Zhang**

11 **Postal address: 639 Longmian Road, Nanjing, Jiangsu Province, CHINA**

12 **E-mail: ranzai7@126.com**

13 **Institutions: China Pharmaceutical University**

14 **City & Country: Jiangsu Province, CHINA**

15 **Telephone: +86-18115161231**

16 **Co-Authors**

17 **NAME: Yun Lu, Liuyan Shi, Songlin Zhang**

18 **Institutions: China Pharmaceutical University**

19 **City & Country: Jiangsu Province, CHINA**

20 **Corresponding Author**

21 **NAME: Feng Chang**

22 **Postal address: 639 Longmian Road, Nanjing, Jiangsu Province, CHINA**

23 **E-mail: cpucf@163.com**

24 **Institutions: China Pharmaceutical University**

25 **City & Country: Jiangsu Province, CHINA**

26 **Telephone: +86-13805153128**

27 **Keywords:**

28 **multimorbidity, Cross-sectional study, Prevalence, Observed-to-expected ratio,**

29 **China**

30 **Word count: 4911**

ABSTRACT

Objectives: Examination of the prevalence and patterns of multimorbidity among the elderly in China.

Design: Cross-sectional study.

Setting: More than 10,000 households in 28 of the 34 provinces of mainland China.

Participants: 11,707 Chinese adults aged 60 and over.

Primary outcome measures: Prevalence and patterns of multimorbidity among the participants. Relative risks were calculated to estimate the probability of up to 14 chronic conditions coexisting with each other. Observed-to-expected (O/E) ratios were used to analyze the patterns of multimorbidity.

Results: Multimorbidity was present in 43.6% of respondents from the sample population, with women having the greater prevalence compared to men. There were 804 different comorbidity combinations identified, including 76 dyad combinations and 169 triad combinations. The top 10 morbidity dyads and triads accounted for 69.01% and 47.05% of the total dyad and triad combinations observed, respectively. Among the 14 chronic conditions included in the study, asthma, stroke, heart attack and six other chronic conditions were the main components of multimorbidity due to their high relative risk ratios. The most frequently occurring clusters with higher O/E ratios were stroke along with emotional, nervous, or psychiatric problems; memory-related diseases together emotional, nervous, or psychiatric problems; and memory-related diseases and asthma accompanied by chronic lung diseases and asthma.

Conclusions: The results of this study highlight the high prevalence of multimorbidity in the elderly population in China. Further studies are required to understand the etiology of multimorbidity, and future primary healthcare policies should be made while taking multimorbidity into consideration.

Strengths and limitations of this study

Strengths

- This is the first study to estimate the prevalence and patterns of multimorbidity among the elderly population in China.
- Data for this study were collected from a nationally representative longitudinal survey of 17,708 Chinese residents.

Limitations

- Only 14 predefined chronic diseases were included in the study, and these may not be comprehensive of the conditions of the population.
- The data analyzed from the CHARLS were originally collected by population self-reporting, not clinician evaluation, and could partially reflect some associated biases or confounds.
- This study only included older patients aged 60 years and above with complete data. Although exclusion of incomplete data may cause a selection bias, significant differences between included and excluded cases were not observed.

INTRODUCTION

Multimorbidity, or the simultaneous occurrence of two or more chronic conditions in an individual, is becoming increasingly common, and this has been reported to increase progressively with age. [1, 2] At present, with China's aging population having an increasing prevalence of chronic conditions, multimorbidity among the elderly poses an enormous societal cost due to increased mortality rates and healthcare utilization. [3] However, to date, research on chronic conditions in China has focused on single disease states, and the coexistence of multiple chronic conditions has not been investigated systematically and thoroughly.

There is a significant difference in the etiological analysis between patients with single chronic conditions and those with multimorbidity. [4] The coexistence of chronic conditions in a patient is more than a random event, it is more typically due to the causal relationship between some diseases and shared pathogenic factors. [5, 6] Moreover, the interactions between diseases or between a disease and host result in differences in the severity of multimorbidity and functional status and prognosis of patients with multimorbidity. [7] Consequently, it is imperative to begin research on multimorbidity in China for the cost-effective treatments that the results may help to suggest. [8] The purpose of this study was therefore to determine the prevalence of multimorbidity among the elderly in China and to reveal morbidity combinations, which may benefit the design and implementation of a modified healthcare system with consideration for patients with multimorbidity.

METHODS

Data source

Data for this study were collected from the third response of the China Health and Retirement Longitudinal Survey (CHARLS), which is the most current data available. The CHARLS is a nationally representative longitudinal survey of Chinese residents aged 45 and older that was conducted by the Chinese Center for Disease Control and Prevention, along with Peking University, to help China to adjust to the rapid aging of its population through the evaluation of social, economic, and health circumstances on

1
2
3 the community level using data collected by interviews, physical measurements and
4 blood sample collection. [9] The national baseline survey began in 2011 and involved
5 17,708 respondents from 150 county-level units, 450 village-level units, and
6 approximately 10,000 households. Afterwards, CHARLS respondents were followed
7 every second year, with their informed consent, and the study was approved by the
8 Peking University Biomedical Ethics Committee (IRB00001052-14013-exemption).
9
10
11
12
13

14 15 **Variables**

16
17 The core CHARLS questionnaires included sections requesting information on
18 demographic factors, family structure and changes, health status and functioning,
19 healthcare and insurance, work, retirement and pension, income and consumption, and
20 assets (individual and household). Information was collected by interview by trained
21 staff. For the current study, the eligible and included participants were determined by
22 being aged 60 and over, and data on gender, age and health status was used from the
23 general health status and disease history section of senior citizens in the 2015 CHARLS
24 data. This information included the following 14 common chronic health problems:
25 hypertension, dyslipidemia (high blood lipids or low cholesterol), diabetes or elevated
26 blood glucose (including impaired glucose tolerance and fasting blood glucose), cancer
27 (excluding mild skin cancers), chronic lung disease such as chronic bronchitis or
28 emphysema, pulmonary heart disease (excluding tumors or cancer), liver disease (other
29 than fatty liver, tumors, or cancer), heart disease (such as myocardial infarction,
30 coronary heart disease, angina pectoris, congestive heart failure and other heart
31 diseases), stroke, kidney disease (excluding tumors or cancer), stomach or other
32 digestive diseases (excluding tumors or cancer), emotional and mental problems,
33 memory-related diseases (such as Alzheimer's disease, brain atrophy, Parkinson's
34 disease), arthritis or rheumatism, and asthma. All these data were based on self-reports.
35 Accordingly, multimorbidity was defined as the coexistence of more than one of the 14
36 chronic conditions, with acute or subacute forms of certain conditions being excluded
37 in this study due to the CHARLS data collection protocol.
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54

55 **Statistical analysis**

56 To detect the demographic characteristics of patients with multimorbidity,
57 respondents were divided into two groups: those with multiple chronic conditions
58 (MCC group) and those without multiple chronic conditions (Non-MCC group).
59
60

1
2
3 Descriptive statistics were calculated and expressed as means (SD) and frequencies
4 (percentage). We applied the T² and χ^2 tests to test the differences in age, gender and
5 the mean number of chronic conditions across different subgroups. Respective
6 prevalence in the MCC group and the non-MCC group were calculated separately.
7
8 Given the exclusion of participants with incomplete data, a sensitivity analysis was
9 conducted to compare the characteristics of the complete cases aged 60 years and above
10 and the counterpart in the incomplete cases, which is presented in [Annex 1](#).
11
12
13
14

15 To determine the most common combination of chronic diseases, the prevalence of
16 morbidity and multimorbidity dyads and triads were estimated, respectively. Next, the
17 expected number of patients with a chronic disease were calculated, and the observed-
18 to-expected (O/E) ratios were determined by dividing the number of patients in those
19 groups by the expected number of patients. Observed-to-expected ratios were used to
20 estimate the conditional probability of coexistence of two or three chronic conditions.
21 [10] As an important indicator for assessing the correlation between diseases, the O/E
22 ratio has been used in many areas of comorbidity. [10, 11] The relative risk of
23 comorbidity for individual chronic conditions was also calculated. Relative risk of
24 comorbidity (RR) is the ratio of the number of people with a certain chronic condition
25 who suffer from multimorbidity to the number of patients with the same disease who
26 do not suffer from multimorbidity. [11, 12] In other words, a higher RR value means a
27 higher probability that the disease coexists with other diseases. However, it should be
28 noted that there is no direct relationship between the relative risk of comorbidity and
29 the overall prevalence of the diseases. [13, 14]
30
31
32
33
34
35
36
37
38
39
40

41 All analyses in this study were completed using Stata software V.14.0 for Windows
42 (Stata Corp). P Values <0.05 were considered to be statistically significant.
43
44
45

46 **Patient and public involvement**

47 Patients and the public were not involved in the development of the research
48 question or outcome measures of the study, nor were they involved in study design and
49 execution. There are no plans to disseminate the research results to study participants.
50
51
52
53

54 **RESULTS**

55 **Characteristics of participants**

56 The data were gathered from the third response set of CHARLS. After exclusion
57
58
59
60

of participants with incomplete data (1,002) or aged under 60 (9,259), there were 11,707 respondents with available information on related chronic diseases that were included in this study. The selection process of study sample is shown in Figure 1. The demographic characteristics of sample respondents and statistical significance test results are presented in Table 1.

Overall, the mean age for the sample population was 70.5 (ranging from 60 to 107). The sample population consisted of 5,705 (48.7%) males and 6002 (51.2%) females, and 43.6% of them suffered from multimorbidity. The median of chronic conditions in the MCC group was 3.01, compared to 0.45 in the Non-MCC group. Samples in the MCC group were 0.66 year older than those belonged to the non-MCC group. Gender differences with regard to the age of samples between the MCC group and the non-MCC group (70.57 for MCC group and 69.51 for non-MCC group) were small but statistically significant ($p < 0.001$). The prevalence of multimorbidity in the female population was higher than that for the males (54.41% vs 45.59%). Figure 2 shows the number and proportion of respondents over 60 according to morbidity numbers. It can be seen that among all the participants aged over 60, only 30.9% of them did not have the 14 chronic diseases and 43.6% suffer from multimorbidity.

Table 1. Demographic characteristics of all respondents, the MCC group and non-MCC group

	All respondent	MCC group	Non-MCC group	P*
Number of people	11707	5107	6600	
Proportion (%)	100%	43.62%	56.38%	
Mean age				
All respondents (SD)	70.20(7.907)	70.57(7.701)	69.91(8.051)	<0.001
Male (SD)	69.97(7.575)	70.50(7.348)	69.60(7.707)	<0.001
Female (SD)	70.39(8.189)	70.62(7.892)	70.19(8.359)	<0.001
Gender (% females)	51.28%	54.41%	48.83%	<0.001
Mean number of chronic conditions				
All respondents (SD)	1.57(1.560)	3.01(1.259)	0.45(0.498)	<0.001
Male (SD)	1.47(1.534)	2.98(1.265)	0.44(0.496)	<0.001
Female (SD)	1.65(1.581)	3.03(7.982)	0.47(0.499)	<0.001

SD = standard deviation;

p* = statistical significance of the difference between the MCC and the non-MCC sample (t-tests were performed for comparison of means, and chi-square-tests for differences between percentages)

Prevalence of chronic conditions

The prevalence of chronic conditions in the entire sample, the MCC group and the non-MCC group are shown in Figure 3. The prevalence of all fourteen chronic conditions in the MCC group was significantly higher than that in the entire sample. For instance, the prevalence of arthritis or rheumatism, hypertension, stomach or other digestive disease, heart disease and chronic lung disease were 65.97%, 48.82%, 45.86%, 29.00% and 24.97% in the MCC group, compared to 38.49%, 26.41%, 24.52%, 12.32% and 12.32% in the entire sample, respectively.

Table 2 shows the relative risks of comorbidity determined for the 14 chronic diseases reported in this study. It can be seen that the overall relative risks for asthma, stroke, heart disease and six other conditions were all above 10, which meant these diseases were >10 times easier to coexist with other chronic conditions and result in multimorbidity. In addition, the relative risks for certain diseases were positively associated with gender. For example, men had significantly higher relative risks for asthma, but lower relative risks for diabetes or high blood sugar, compared to women.

Table 2 Relative risks of multimorbidity for different chronic conditions according to gender

Chronic conditions	All respondents	95% Confidence Interval		Female	95% Confidence Interval		Male	95% Confidence Interval		
		Lower Bound	Upper Bound		Lower Bound	Upper Bound		Lower Bound	Upper Bound	
High relative risk of multimorbidity										
Asthma	26.18	17.82	38.46	20.67	11.85	36.06	32.68	19.18	55.67	
Stroke	18.62	12.11	28.64	21.57	10.61	43.86	17.43	10.13	29.99	
Heart disease	15.56	12.99	18.63	16.48	12.80	21.21	14.26	11.02	18.46	
Diabetes or high blood sugar	14.40	11.18	18.55	15.68	10.86	22.63	13.11	9.24	18.62	

1										
2										
3										
4	Dyslipidemia	14.05	11.54	17.12	15.13	11.37	20.14	12.97	9.86	17.05
5	Memory-related disease	13.69	8.85	21.16	34.17	12.63	92.44	9.28	5.66	15.21
6										
7	Kidney disease	11.57	9.24	14.49	15.01	10.17	22.43	10.24	7.78	13.48
8										
9	Liver disease	11.10	8.37	14.71	16.07	9.70	26.63	9.15	6.49	12.89
10	Chronic lung diseases	9.87	8.43	11.55	10.71	8.26	13.88	9.74	8.00	11.86
11										
12	Low relative risk of multimorbidity									
13										
14	Emotional, nervous, or									
15	psychiatric problems	7.42	4.94	11.15	6.24	3.78	10.30	9.36	4.65	18.85
16										
17	Stomach or other digesti									
18	ve disease	5.73	5.25	6.25	6.20	5.48	7.02	5.23	4.62	5.91
19										
20	Hypertension	5.38	4.96	5.84	4.90	4.40	5.47	5.92	5.24	6.69
21										
22	Cancer or malignant									
23	tumor	4.88	3.20	7.45	5.33	3.06	9.29	3.99	2.07	7.72
24										
25	Arthritis or rheumatism	3.83	3.61	4.05	3.70	3.43	3.99	3.91	3.59	4.26
26										
27										
28										
29										
30										
31										
32										
33										
34										
35										
36										
37										
38										
39										
40										
41										
42										
43										
44										
45										
46										
47										
48										
49										
50										
51										
52										
53										
54										
55										
56										
57										
58										
59										
60										

Common multimorbidity combinations

There were 804 possible comorbidity combinations that were identified in the MCC group after statistical analysis, including 72 dyads and 169 triads. The 10 most frequently occurring morbidity dyads and triads are presented respectively in [Table 3](#) and [Table 4](#).

Table 3 Prevalence of the 10 most common morbidity dyads

Rank	Morbidity dyads	Prevalence			Mean Age
		All respondents	female	male	
1	Arthritis or rheumatism and Stomach or other digestive disease	4.73%	3.56%	5.96%	69.20
2	Arthritis or rheumatism and Hypertension	2.85%	2.20%	3.53%	71.25
3	Arthritis or rheumatism and Chronic lung diseases	1.13%	1.22%	1.04%	71.55
4	Hypertension and heart problems	1.03%	1.00%	1.06%	71.80
5	Hypertension and Stomach or other digestive disease	0.89%	0.83%	0.95%	69.07
6	Hypertension	0.86%	0.81%	0.91%	68.58

	and Dyslipidemia				
	Arthritis				
7	or rheumatism	0.76%	0.53%	1.00%	70.72
	and heart problems				
	Arthritis				
8	or rheumatism	0.64%	0.73%	0.54%	68.24
	and Kidney disease				
	Hypertension				
9	and Diabetes or high blood sugar	0.58%	0.50%	0.67%	70.97
	Chronic lung diseases and Asthma				
10		0.53%	0.65%	0.40%	71.15

Table 4 Prevalence of the 10 most common morbidity triads

Rank	Morbidity triads	Prevalence			Mean Age
		All respondents	female	male	
1	Arthritis or rheumatism, Stomach or other digestive disease and Hypertension	1.19%	0.80%	1.60%	70.96
2	Arthritis or rheumatism, Stomach or other digestive disease and Chronic lung diseases	0.82%	0.97%	0.67%	70.82
3	Arthritis or rheumatism, Heart disease and Hypertension	0.63%	0.37%	0.91%	69.93
4	Arthritis or rheumatism, Heart disease and Stomach or other digestive disease	0.59%	0.25%	0.95%	71.51
5	Hypertension, Dyslipidemia and Arthritis or rheumatism	0.44%	0.31%	0.57%	70.13
6	Hypertension, Dyslipidemia and Heart problems	0.42%	0.35%	0.49%	71.17
7	Arthritis or rheumatism, Kidney disease and Stomach or other digestive disease	0.42%	0.40%	0.44%	70.14
8	Arthritis or rheumatism, Asthma and Chronic lung diseases	0.40%	0.46%	0.33%	69.18
9	Hypertension, Dyslipidemia and Diabetes or high blood sugar	0.35%	0.35%	0.35%	71.51
10	Arthritis or rheumatism, Stomach or other digestive disease	0.53%	0.57%	0.49%	70.29

and Liver disease

Theoretically, there are 91 dyad combinations and 364 triad combinations possible given the 14 different chronic conditions considered in this study. However, only 72 types (79.12%) of dyads and 169 types (46.43%) of triads emerged in the sample. The 10 most frequently occurring morbidity dyads accounted for 69.01% of the 72 dyad combinations, and the proportion of the 10 most common triad combinations in the 169 triad combinations was 47.05%. Arthritis or rheumatism, which appeared in five of the top 10 dyad combinations and eight of the top 10 triad combinations of chronic conditions, was the main component of the leading morbidity dyads and triads.

There were significant gender differences observed in the occurrences of these multimorbidity combinations. The numbers of women with triad combinations of chronic diseases were generally higher than for men with the same morbidity triads. For example, women had significantly higher prevalence of arthritis and hypertension and hyperlipidemia than men (78.26% vs 21.74%). Among morbidity dyads, the prevalence of heart disease and arthritis or rheumatism in women was nearly two times higher than that in men, while the cluster of arthritis or rheumatism and kidney disease occurred more frequently in men than in women. No age difference was detected in the probability of these particular multimorbidity combinations occurring.

The O/E ratio was also used to analyze the multimorbidity pattern. [15] The higher the O/E value, the higher the probability of coexistence of chronic conditions. [16] Table 5 shows O/E ratios determined for the 10 most prevalent morbidity dyads and triads. The prevalence of each conditions and the dyad and triad prevalence are presented in Annex 2. In the midst of those triad combinations of chronic conditions, the two clusters with significantly higher O/E ratios were emotional, nervous, or psychiatric problems and stroke and memory-related disease (O/E ratio = 10287.72), emotional, nervous, or psychiatric problems and memory-related disorders and asthma (O/E ratio = 8498.56). These four conditions also dominated the three leading dyads

with the highest O/E ratios: 97.73 for the combination of emotional and mental disorders and memory-related diseases, 23.66 for the combination of stroke and memory-related disease and 19.55 for the combination of memory-related disease and asthma.

Table 5 O/E ratios for the 10 most prevalent morbidity dyads and triads

Number of chronic conditions	Rank	Chronic conditions	O/E ratio
2	1	Chronic lung diseases and Asthma	162.15
	2	Emotional, nervous, or psychiatric problems and Memory-related disease	97.73
	3	Dyslipidemia and Diabetes or high blood sugar	38.39
	4	Heart disease and Memory-related disease	25.69
	5	Stroke and Memory-related disease	23.66
	6	Hypertension and Stroke	22.85
	7	Hypertension and Diabetes or high blood sugar	20.64
	8	Cancer or malignant tumor and Stroke	19.55
	9	Memory-related disease and Asthma	19.55
	10	Stroke and Asthma	19.55
3	1	Stroke, Emotional, nervous, or psychiatric problems and Memory-related disease	10287.72
	2	Emotional, nervous, or psychiatric problems, Memory-related disease and Asthma	8498.56
	3	Emotional, nervous, or psychiatric problems, Chronic lung diseases and Asthma	2274.26
	4	Heart disease, Stroke and Memory-related disease	2253.50
	5	Chronic lung diseases, Heart disease and Asthma	1992.69
	6	Dyslipidemia, Heart disease and Memory-related disease	1443.25
	7	Hypertension, Dyslipidemia and Diabetes or high blood sugar	1398.31

8	Hypertension, Stroke and Memory-related disease	1387.35
9	Chronic lung diseases, Memory-related disease and Asthma	1376.53
10	Chronic lung diseases, Arthritis or rheumatism and Asthma	1265.95

DISCUSSION

This is the first study to estimate the prevalence and patterns of multimorbidity among the elderly in China based on the nationally representative data from CHARLS, which included 11,707 older patients aged 60 years and above with complete data. Although exclusion of incomplete data may cause a selection bias, significant differences between included and excluded cases were not observed. The results of the study indicated that 69.1% of the elderly population in China had at least one of the 14 diseases and 43.6% of them suffered from multimorbidity. The average age of the MCC group was 0.66 years higher than that of the non-MCC group and in the MCC group, the mean age of women was 0.12 years higher than that of men, which was comparable to the results of previous studies. [17-21]

The prevalence of multimorbidity estimated in this study was much lower than that from previous studies in other developed countries. For example, a study of 543 patients over age 65 in Ghent, Belgium showed that the multimorbidity rate was as high as 82.6%, [22]. Another study in Australia showed that 83.2% of the respondents suffered from multimorbidity. [23] However, it is difficult to compare the prevalence generated from different studies due to differences in the selected definitions of multimorbidity, demographic characteristics of the samples, and different study methodologies. [24-28]

In agreement with previous reports, arthritis or rheumatism, hypertension, stomach or other digestive disease were the most common diseases in the MCC group. [11] The prevalence of these three conditions was each above 20% in the entire sample, and above 45% in the MCC group. The most prevalent chronic combinations in the sample

1
2
3
4 could also be found in other studies. [22] The results of this study showed that the
5 prevalence of arthritis or rheumatism was high and easy to coexist with other conditions.
6
7 In addition to the chronic conditions mentioned above, previous studies demonstrated
8 that women with rheumatoid arthritis might have a predisposition to gallstones which
9 could manifest in middle or older age compared with women in the general population.
10
11 This phenomenon could be related to chronic inflammation and HDL metabolism. [29]
12
13

14
15
16 Although arthritis or rheumatism, a component of all the leading three morbidity
17 dyads and triads, was also the most commonly occurring disease in multimorbidity, the
18 relative risk of this disease was only 4.65, the lowest in the 14 chronic diseases.
19
20 Moreover, arthritis or rheumatism is less common in morbidity clusters with large O/E
21 ratios. Therefore, the frequent occurrence of arthritis or rheumatism in multimorbidity
22 might be simply due to the high prevalence of the disease. Doctor-diagnosed arthritis
23 is a common and disabling chronic condition in the world. During 2013 to 2015, an
24 average of more than one in five (54.4 million) adults in the United States were
25 diagnosed with arthritis [30]. The unadjusted prevalences of arthritis among adults with
26 obesity, heart disease, or diabetes were 30.6%, 49.3%, and 47.1%, respectively. In
27 adults with obesity, heart disease, or diabetes, the age-adjusted prevalences of arthritis
28 were respectively 1.5, 1.7 and 1.9 times higher than those without these diseases.
29
30 Improving the health of adults with arthritis and related comorbid conditions calls for
31 wider dissemination and implementation of evidence-based interventions, such as self-
32 management education and physical activity promotion [31].
33
34
35
36
37
38
39
40
41
42
43
44
45

46
47 The relative risks for asthma, stroke, heart disease, and six other conditions were all
48 above 10, which means that patients with these diseases were 10 times more likely to
49 be afflicted by multimorbidity. These diseases also occurred at a high frequency in
50 multimorbidity with high O/E ratios, such as the clusters of pulmonary disease and
51 asthma, emotional and mental illness and memory-related disease, dyslipidemia and
52 diabetes, and stroke and emotional or mental illness and memory-related disease.
53
54
55
56
57
58
59 Patients with these diseases were more likely to express comorbidity compared to those
60

without these diseases, and thus should be the focus of future research studies.

This study featured a nationally representative sample of the Chinese elderly population, which was crucial to get an overall understanding of multimorbidity among the elderly in China. However, there were also limitations with the data sample and study. For example, this study used data from the third wave report of CHARLS, a survey which was conducted in 2015, and there is accordingly a time lag to now that exists. Additionally, the chronic diseases included in the study were not comprehensive, since only 14 chronic conditions were included in the survey. Finally, the data obtained from the survey was based on self-reporting, which may have introduced some misclassification bias or other confounds. Later research on the prevalence and patterns of multimorbidity should be carried out in-depth with a more extensive survey of chronic disease.

CONCLUSIONS

Multimorbidity remains an underexplored area of research in China. [32]. Despite the increasing prevalence of multimorbidity, there are no specific proposals for its diagnosis and treatment. [33] This study contributes to the understanding of the prevalence and patterns of comorbidity among the elderly in China. Considering China's aging population and the high prevalence of comorbidity in senior citizens, the elderly should be prioritized in the fields of disease prevention and health promotion.

Acknowledgements The authors would like to thank the Chinese Center for Disease Control and Prevention and Peking University for access to China Health and Retirement Longitudinal Survey data.

Contributors RZ analyzed and interpreted data, drafted the manuscript, approved the final manuscript as submitted. YL revised the manuscript for important intellectual content. YLS analyzed and interpreted data and revised the manuscript for important

1
2
3
4 intellectual content. SLZ analyzed and checked the data of the full text. FC helped on
5
6 the study design and revised the manuscript.

7
8 **Funding** This work was funded by the National Natural Science Foundation of China
9
10 (7167030838).

11
12 **Competing interests** None declared.

13
14 **Patient consent** Obtained.

15
16 **Ethics approval** The original CHARLS was approved by the ethics review committee
17
18 of Peking University, and all participants gave written informed consent at the time of
19
20 participation

21
22 **Data sharing statement** No additional data are available
23
24
25

26 REFERENCES

- 27
28 1. Barnett K, Mercer SW, Norbury M, et al. Epidemiology of multimorbidity and
29
30 implications for health care, research, and medical education: a cross-sectional
31
32 study. *Lancet* 2012; 380:37–43.doi:10.1016/S0140-6736(12)60240-2
33
- 34
35 2. World Health Organization. Global status report on noncommunicable diseases,
36
37 2014.http://apps.who.int/nmh/publications/ncd-status-report-2014/en/index.html
38
39 (accessed 27 Oct 2017)
- 40
41 3. Lee J T, Hamid F, Pati S, et al. Impact of Noncommunicable Disease
42
43 Multimorbidity on Healthcare Utilisation and Out-Of-Pocket Expenditures in
44
45 Middle-Income Countries: Cross Sectional Analysis. *PLoS One* 2015;10:103-110.
46
47 doi: 10.1371/journal.pone.0127199
- 48
49 4. Moffat K, Mercer SW. Challenges of managing people with multimorbidity in
50
51 today's healthcare systems. *BMC Fam Prac*2015;16:129.doi: 10.1186/s12875-015-
52
53 0344-4
- 54
55 5. Schäfer Ingmar, von Leitner Eike-Christin, Schön Gerhard et al. Multimorbidity
56
57 patterns in the elderly: a new approach of disease clustering identifies complex
58
59 interrelations between chronic conditions. *PLoS One*2010;12:e15941.doi:
60

- 1
2
3
4 10.1371/journal.pone.0015941
5
6 6. Atun R. Transitioning health systems for multimorbidity. *Lancet* 2015;386:721–
7
8 2.doi: 10.1016/S0140-6736(14)62254-6
9
10 7. Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of
11
12 multiple chronic conditions in the elderly. *Arch Intern Med* 2002;20: 2269-2276.doi:
13
14 10.1001/archinte.162.20.2269
15
16 8. Yang L, Wu M, Cui B, et al. Economic burden of cardiovascular diseases in China.
17
18 *Expert Rev Pharmacoecon Outcomes Res*2008;8:349–56.doi:
19
20 10.1586/14737167.8.4.349
21
22 9. Zhao Y, Hu Y, Smith JP, et al. Cohort profile: the China Health and Retirement
23
24 Longitudinal Study (CHARLS). *Int J Epidemiol* 2014;1:61-69.doi:
25
26 10.1093/ije/dys203
27
28 10. Van den Bussche H, Koller D, Kolonko T, et al. Which chronic diseases and disease
29
30 combinations are specific to multimorbidity in the elderly? Results of a claims data
31
32 based cross-sectional study in Germany. *BMC Public Health* 2011;11:101-110.doi:
33
34 10.1186/1471-2458-11-101
35
36 11. Viera AJ. Odds ratios and risk ratios: what's the difference and why does it matter?
37
38 *South Med J* 2008; 7: 30-34.doi:10.1097/SMJ.0b013e31817a7ee4
39
40 12. Vettore MV, Meira GF, Rebelo MA et al. Multimorbidity patterns of oral clinical
41
42 conditions, social position, and oral health-related quality of life in a population-
43
44 based survey of 12-yr-old children. *Eur J Oral Sci.*2016 ; 6:580-590. doi:
45
46 10.1111/eos.12304. Epub 2016 Oct 8.
47
48 13. Zhang J, Yu KF. What's the relative risk? A method of correcting the odds ratio in
49
50 cohort studies of common outcomes. *JAMA*1998;19:1690-1691.doi:
51
52 10.1001/jama.280.19.1690
53
54 14. McNutt LA, Wu C, Xue X, et al. Estimating the Relative Risk in Cohort Studies
55
56 and Clinical Trials of Common Outcomes. *Am J Epidemiol* 2003;10:940–943.doi:
57
58 10.1002/cncr.30192
59
60

15. Marengoni A, Rizzuto D, Wang HX, et al. Patterns of chronic multimorbidity in the elderly population. *J Am Geriatr Soc* 2009;57:225–30.doi:10.1111/j.1532-5415.2008.02109.x
16. Best WR, Cowper DC. The Ratio of Observed-to-Expected Mortality as a Quality of Care Indicator in Non-Surgical VA Patients. *Med Care* 1994;4:390-400.doi:10.1097/00005650-199404000-00007
17. Kastenholz KE, Weis M, Hagelstein C, et al. Correlation of Observed-to-Expected MRI Fetal Lung Volume and Ultrasound Lung-to-Head Ratio at Different Gestational Times in Fetuses With Congenital Diaphragmatic Hernia. *AJR Am J Roentgenol* 2016;4:856-866.doi:10.2214/AJR.15.15018
18. Melis R, Marengoni A, Angleman S, et al. Incidence and predictors of multimorbidity in the elderly: a population-based longitudinal study. *PLoS One* 2014; 9: e103120.doi:10.1371/journal.pone.0103120
19. Laan W, Bleijenberg N, Drubbel I, et al. Factors associated with increasing functional decline in multimorbid independently living older people. *Maturitas* 2013; 75: 276–81.doi:10.1016/j.maturitas.2013.04.005
20. Eckerblad J, Theander K, Ekdahl A, et al. To adjust and endure: a qualitative study of symptom burden in older people with multimorbidity. *Appl Nurs Res* 2015;28:322–7.doi:10.1016/j.apnr.2015.03.008
21. Wister A, Kendig H, Mitchell B, et al. Multimorbidity, health and aging in Canada and Australia: a tale of two countries. *BMC Geriatr* 2016;1:163-176.doi:10.1186/s12877-016-0341-z
22. Afshar S, Roderick PJ, Kowal P, et al. Multimorbidity and the inequalities of global ageing: a cross-sectional study of 28 countries using the World Health Surveys. *BMC Public Health* 2015;15:776-786.doi:10.1186/s12889-015-2008-7
23. Boeckxstaens P, Peersman W, Goubin G, et al. A practice-based analysis of combinations of diseases in patients aged 65 or older in primary care. *BMC Family Practice* 2014;1:1-6.doi: 10.1186/1471-2296-15-159.
24. Britt HC , Harrison CM , Miller GC , et al . Prevalence and patterns of

- 1
2
3 multimorbidity in Australia. *Med J Aust* 2008;2: 72-77
4
5 25. Glynn LG , Valderas JM , Healy P , et al . The prevalence of multimorbidity in
6 primary care and its effect on health care utilization and cost. *Fam Pract*
7 2011;28:516–23.doi:10.1093/fampra/cmr013
8
9 26. Marengoni A , Angleman S , Melis R , et al . Aging with multimorbidity: a
10 systematic review of the literature. *Ageing Res Rev* 2011;10:430–
11 9.doi:10.1016/j.arr.2011.03.003
12
13 27. Barnett K , Mercer SW , Norbury M , et al . Epidemiology of multimorbidity and
14 implications for health care, research, and medical education: a cross-sectional
15 study. *Lancet* 2012;380:37–43.doi:10.1016/S0140-6736(12)60240-2
16
17 28. Fortin M , Stewart M , Poitras ME , et al . A systematic review of prevalence studies
18 on multimorbidity: toward a more uniform methodology. *Ann Fam Med*
19 2012;10:142–51.doi:10.1370/afm.1337.
20
21 29. García-Gómez M C, De L E, Ordoñez-Palau S, et al. High Prevalence of Gallstone
22 Disease in Rheumatoid Arthritis: A New Comorbidity Related to Dyslipidemia? [J].
23 *Reumatol Clin*, 2017;14:294-300. doi: 10.1016/j.reuma.2018.03.012.
24
25 30. Barbour KE, Helmick CG, Boring M, et al. Vital Signs: Prevalence of Doctor-
26 Diagnosed Arthritis and Arthritis-Attributable Activity Limitation — United States,
27 2013–2015. *MMWR Morb Mortal Wkly Rep*, 2017;66:246–253. doi:
28 http://dx.doi.org/10.15585/mmwr.mm6609e1.
29
30 31. Ward BW, Schiller JS. Prevalence of multiple chronic conditions among US adults:
31 estimates from the National Health Interview Survey, 2010. *Prev Chronic Dis*
32 2013;10:120203. doi: 10.5888/pcd10.120203
33
34 32. Bao W, Hu D, Shi X, et al. Comorbidity increased the risk of falls in Chinese older
35 adults: A cross-sectional study. *Int J Clin Exp Med*,2017;7:10753-10763.
36
37 33. Gao N, Yuan Z, Tang X, et al. Prevalence of CHD-related metabolic comorbidity
38 of diabetes mellitus in Northern Chinese adults: the REACTION study. *J Diabetes*
39 *Complications*2016;2:199-205.doi:10.1016/j.jdiacomp.2015.11.018
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure legends

Figure 1 Flowchart for selecting the study sample from the original sample population. CHARLS, China Health and Retirement Longitudinal Survey

Figure 2 Frequency and percentage of people aged over 60 suffering from different diseases based on CHARLS data

Figure 3 Prevalence Rates of chronic condition in elderly people over 60 years old based on CHARLS data




Figure 1 Flowchart for selecting the study sample from the original sample population. CHARLS, China Health and Retirement Longitudinal Survey

171x93mm (300 x 300 DPI)




Figure 2 Frequency and percentage of people aged over 60 suffering from different diseases based on CHARLS data

222x119mm (300 x 300 DPI)




Figure 3 Prevalence Rates of chronic condition in elderly people over 60 years old based on CHARLS data

151x140mm (300 x 300 DPI)

Annex 1 Sensitivity analysis, Comparison of the characteristics of complete cases and incomplete cases

	Complete cases	Incomplete cases	P*
Number of people	11707	876	
Proportion (%)	93.04%	6.96%	
Mean age All respondents (SD)	70.20(7.907)	69.60 (7.824)	<0.001
Male (SD)	69.97(7.575)	69.58 (7.721)	<0.001
Female (SD)	70.39(8.189)	69.62 (7.973)	<0.001
Gender (% females)	51.28%	49.27%	0.193

p* = statistical significance of the difference between the complete cases and the incomplete cases (t-tests were performed for comparison of means, and chi-square-tests for differences between percentages)

Annex 2 O/E ratio of all binary and triads comorbidities pattern present in participants

Rank	binary comorbidities pattern	O/E ratio
1	Chronic lung diseases and Asthma	161.00
2	Emotional, nervous, or psychiatric problems and Memory-related disease	98.57
3	Dyslipidemia and Diabetes or high blood sugar	38.69
4	Heart disease and Memory-related disease	25.96
5	Stroke and Memory-related disease	24.19
6	Hypertension and Stroke	23.10
7	Hypertension and Diabetes or high blood sugar	20.77
8	Cancer or malignant tumor and Stroke	19.71
9	Memory-related disease and Asthma	19.71
10	Stroke and Asthma	19.71
11	Hypertension and Heart disease	19.07
12	Hypertension and Dyslipidemia	18.98
13	Dyslipidemia and Heart disease	17.39
14	Diabetes or high blood sugar and Heart disease	14.87
15	Diabetes or high blood sugar and Liver disease	14.40
16	Cancer or malignant tumor and Liver disease	13.65
17	Diabetes or high blood sugar and Kidney disease	13.38
18	Hypertension and Memory-related disease	13.33
19	Dyslipidemia and Cancer or malignant tumor	12.51
20	Stomach or other digestive disease and Arthritis or rheumatism	10.80
21	Liver disease and Heart disease	10.49
22	Dyslipidemia and Stroke	10.23
23	Dyslipidemia and Stomach or other digestive disease	9.81
24	Dyslipidemia and Kidney disease	9.61
25	Chronic lung diseases and Memory-related disease	9.56
26	Chronic lung diseases and Stroke	9.56
27	Kidney disease and Arthritis or rheumatism	9.42
28	Heart disease and Kidney disease	9.29
29	Chronic lung diseases and Heart disease	9.12
30	Stomach or other digestive disease and Asthma	9.03
31	Liver disease and Kidney disease	8.99
32	Kidney disease and Stomach or other digestive disease	8.92
33	Memory-related disease and Arthritis or rheumatism	8.89
34	Stroke and Arthritis or rheumatism	8.89
35	Arthritis or rheumatism and Asthma	8.77
36	Liver disease and Memory-related disease	8.38
37	Diabetes or high blood sugar and Memory-related disease	8.32
38	Diabetes or high blood sugar and Stroke	8.32
39	Chronic lung diseases and Arthritis or rheumatism	8.14
40	Heart disease and Stomach or other digestive disease	8.11

1			
2			
3	41	Heart disease and Arthritis or rheumatism	7.45
4			
5	42	Stomach or other digestive disease and Emotional, nervous, or	7.39
6		psychiatric problems	
7	43	Liver disease and Stomach or other digestive disease	7.33
8	44	Diabetes or high blood sugar and Cancer or malignant tumor	6.78
9	45	Diabetes or high blood sugar and Asthma	6.78
10	46	Diabetes or high blood sugar and Arthritis or rheumatism	6.44
11	47	Liver disease and Arthritis or rheumatism	6.16
12	48	Chronic lung diseases and Kidney disease	5.98
13	49	Chronic lung diseases and Stomach or other digestive disease	5.97
14	50	Hypertension and Arthritis or rheumatism	5.74
15	51	Chronic lung diseases and Liver disease	5.52
16	52	Kidney disease and Emotional, nervous, or psychiatric problems	5.29
17	53	Kidney disease and Asthma	5.29
18	54	Chronic lung diseases and Emotional, nervous, or psychiatric problems	5.19
19	55	Dyslipidemia and Memory-related disease	5.12
20	56	Hypertension and Emotional, nervous, or psychiatric problems	5.07
21	57	Hypertension and Chronic lung diseases	5.03
22	58	Hypertension and Kidney disease	5.01
23	59	Cancer or malignant tumor and Arthritis or rheumatism	4.96
24	60	Cancer or malignant tumor and Stomach or other digestive disease	4.93
25	61	Dyslipidemia and Arthritis or rheumatism	4.75
26	62	Hypertension and Liver disease	4.61
27	63	Diabetes or high blood sugar and Chronic lung diseases	4.38
28	64	Heart disease and Stroke	4.33
29	65	Dyslipidemia and Asthma	4.17
30	66	Hypertension and Stomach or other digestive disease	3.85
31	67	Cancer or malignant tumor and Heart disease	3.53
32	68	Heart disease and Asthma	3.53
33	69	Emotional, nervous, or psychiatric problems and Arthritis or rheumatism	3.43
34	70	Diabetes or high blood sugar and Stomach or other digestive disease	3.12
35	71	Hypertension and Cancer or malignant tumor	2.17
36	72	Hypertension and Asthma	2.17
37	73	Stomach or other digestive disease and Memory-related disease	2.02
38	74	Stroke and Stomach or other digestive disease	2.02
39	75	Dyslipidemia and Liver disease	1.77
40	76	Dyslipidemia and Chronic lung diseases	1.35
41			
42			
43			
44			
45			
46			
47			
48			
49			
50			
51			
52			
53			
54			
55			
56			
57			
58			
59			
60			

Rank	triads comorbidities pattern	O/E ratio
1	Stroke, Emotional, nervous, or psychiatric problems and Memory-related disease	10491.60
2	Emotional, nervous, or psychiatric problems, Memory-related disease, Asthma,	8548.88
3	Heart disease, Stroke and Memory-related disease	2302.62
4	Chronic lung diseases, Emotional, nervous, or psychiatric problems and Asthma	2252.13
5	Chronic lung diseases, Heart disease, Asthma,	1977.13
6	Dyslipidemia, Heart disease and Memory-related disease	1461.04
7	Hypertension, Stroke and Memory-related disease	1418.54
8	Hypertension, Dyslipidemia and Diabetes or high blood sugar	1409.29
9	Chronic lung diseases, Memory-related disease and Asthma	1381.96
10	Chronic lung diseases, Arthritis or rheumatism and Asthma	1256.63
11	Dyslipidemia, Diabetes or high blood sugar and Kidney disease	1255.51
12	Cancer or malignant tumor, Chronic lung diseases and Asthma	1126.07
13	Chronic lung diseases, Kidney disease and Asthma	1112.24
14	Liver disease, Kidney disease and Asthma	974.52
15	Dyslipidemia, Diabetes or high blood sugar and Liver disease	972.21
16	Chronic lung diseases, Liver disease and Asthma	956.96
17	Dyslipidemia, Diabetes or high blood sugar and Stroke	935.99
18	Chronic lung diseases, Stomach or other digestive disease and Asthma	921.21
19	Hypertension, Dyslipidemia and Heart disease	876.36
20	Diabetes or high blood sugar, Liver disease and Kidney disease	822.11
21	Hypertension, Diabetes or high blood sugar and Stroke	812.58
22	Hypertension, Chronic lung diseases and Asthma	812.01
23	Hypertension, Dyslipidemia and Stroke	800.07
24	Dyslipidemia, Heart disease and Asthma	793.67
25	Diabetes or high blood sugar, Heart disease and Stroke	791.41
26	Hypertension, Emotional, nervous, or psychiatric problems and Memory-related disease	770.58
27	Dyslipidemia, Diabetes or high blood sugar and Cancer or malignant tumor	762.67
28	Dyslipidemia, Diabetes or high blood sugar and Emotional, nervous, or psychiatric problems	762.67
29	Dyslipidemia, Diabetes or high blood sugar and Heart disease	669.54
30	Liver disease, Heart disease and Emotional, nervous, or psychiatric problems	649.62
31	Heart disease, Kidney disease and Memory-related disease	617.74
32	Heart disease, Stroke and Kidney disease	617.74
33	Dyslipidemia, Chronic lung diseases and Asthma	584.58
34	Diabetes or high blood sugar, Liver disease and Heart disease	548.02

35	Hypertension, Diabetes or high blood sugar and Heart disease	523.14
36	Hypertension, Heart disease and Stroke	507.36
37	Diabetes or high blood sugar, Chronic lung diseases and Asthma	474.98
38	Liver disease, Stomach or other digestive disease and Asthma	454.02
39	Stomach or other digestive disease, Emotional, nervous, or psychiatric problems and Memory-related disease	437.10
40	Hypertension, Memory-related disease, Asthma,	385.29
41	Diabetes or high blood sugar, Stomach or other digestive disease and Asthma	300.46
42	Hypertension, Dyslipidemia and Memory-related disease	300.03
43	Liver disease, Kidney disease and Arthritis or rheumatism	277.66
44	Hypertension, Heart disease and Memory-related disease	253.68
45	Dyslipidemia, Liver disease and Kidney disease	252.95
46	Hypertension, Chronic lung diseases and Stroke	249.13
47	Stroke, Memory-related disease and Arthritis or rheumatism	249.11
48	Dyslipidemia, Chronic lung diseases and Liver disease	248.40
49	Cancer or malignant tumor, Chronic lung diseases and Heart disease	247.14
50	Chronic lung diseases, Heart disease and Emotional, nervous, or psychiatric problems	247.14
51	Hypertension, Dyslipidemia and Asthma	244.47
52	Cancer or malignant tumor, Heart disease and Stomach or other digestive disease	234.50
53	Chronic lung diseases, Memory-related disease and Arthritis or rheumatism	229.69
54	Chronic lung diseases, Stroke and Stomach or other digestive disease	211.98
55	Hypertension, Stroke and Arthritis or rheumatism	210.41
56	Chronic lung diseases, Liver disease and Heart disease	210.03
57	Hypertension, Cancer or malignant tumor and Heart disease	206.71
58	Hypertension, Heart disease and Emotional, nervous, or psychiatric problems	206.71
59	Memory-related disease, Arthritis or rheumatism and Asthma	202.98
60	Emotional, nervous, or psychiatric problems, Memory-related disease and Arthritis or rheumatism	202.98
61	Stroke, Emotional, nervous, or psychiatric problems and Arthritis or rheumatism	202.98
62	Stroke, Kidney disease and Arthritis or rheumatism	200.49
63	Dyslipidemia, Diabetes or high blood sugar and Stomach or other digestive disease	194.98
64	Liver disease, Stomach or other digestive disease and Memory-related disease	185.73
65	Dyslipidemia, Stomach or other digestive disease and Asthma	184.90
66	Diabetes or high blood sugar, Stomach or other digestive disease and Memory-related disease	184.37
67	Diabetes or high blood sugar, Heart disease and Arthritis or rheumatism	183.74

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

68	Chronic lung diseases, Stroke and Arthritis or rheumatism	164.06
69	Kidney disease, Arthritis or rheumatism and Asthma	163.36
70	Dyslipidemia, Diabetes or high blood sugar and Arthritis or rheumatism	162.98
71	Hypertension, Diabetes or high blood sugar and Memory-related disease	162.52
72	Hypertension, Dyslipidemia and Kidney disease	160.98
73	Hypertension, Heart disease and Kidney disease	158.80
74	Chronic lung diseases, Liver disease and Kidney disease	157.53
75	Dyslipidemia, Liver disease and Stomach or other digestive disease	157.13
76	Heart disease, Kidney disease and Stomach or other digestive disease	154.42
77	Cancer or malignant tumor, Liver disease and Stomach or other digestive disease	151.34
78	Liver disease, Stomach or other digestive disease and Emotional, nervous, or psychiatric problems	151.34
79	Heart disease, Arthritis or rheumatism and Asthma	145.20
80	Stroke, Kidney disease and Stomach or other digestive disease	143.91
81	Liver disease, Emotional, nervous, or psychiatric problems and Arthritis or rheumatism	140.56
82	Diabetes or high blood sugar, Arthritis or rheumatism and Asthma	139.53
83	Hypertension, Dyslipidemia and Liver disease	138.50
84	Hypertension, Heart disease and Asthma	137.80
85	Kidney disease, Stomach or other digestive disease and Arthritis or rheumatism	136.43
86	Chronic lung diseases, Emotional, nervous, or psychiatric problems and Arthritis or rheumatism	133.68
87	Hypertension, Liver disease and Asthma	133.40
88	Hypertension, Diabetes or high blood sugar and Cancer or malignant tumor	132.42
89	Chronic lung diseases, Stomach or other digestive disease and Arthritis or rheumatism	131.24
90	Hypertension, Diabetes or high blood sugar and Kidney disease	130.80
91	Heart disease, Stomach or other digestive disease and Arthritis or rheumatism	128.06
92	Dyslipidemia, Heart disease and Stomach or other digestive disease	121.74
93	Hypertension, Heart disease and Arthritis or rheumatism	121.06
94	Stomach or other digestive disease, Arthritis or rheumatism and Asthma	118.39
95	Chronic lung diseases, Heart disease and Arthritis or rheumatism	117.36
96	Hypertension, Liver disease and Heart disease	117.11
97	Diabetes or high blood sugar, Kidney disease and Arthritis or rheumatism	114.85
98	Chronic lung diseases, Heart disease and Stomach or other digestive disease	113.73
99	Hypertension, Diabetes or high blood sugar and Liver disease	112.54
100	Diabetes or high blood sugar, Chronic lung diseases and Heart disease	104.24
101	Liver disease, Stomach or other digestive disease and Arthritis or rheumatism	104.21
102	Stroke, Stomach or other digestive disease and Arthritis or rheumatism	103.78

103	Hypertension, Kidney disease and Emotional, nervous, or psychiatric problems	103.36
104	Chronic lung diseases, Liver disease and Arthritis or rheumatism	102.25
105	Hypertension, Dyslipidemia and Arthritis or rheumatism	100.61
106	Liver disease, Kidney disease and Stomach or other digestive disease	99.65
107	Dyslipidemia, Cancer or malignant tumor and Stomach or other digestive disease	92.45
108	Dyslipidemia, Stomach or other digestive disease and Emotional, nervous, or psychiatric problems	92.45
109	Hypertension, Dyslipidemia and Chronic lung diseases	92.21
110	Hypertension, Chronic lung diseases and Heart disease	89.11
111	Heart disease, Stroke and Arthritis or rheumatism	89.10
112	Hypertension, Heart disease and Stomach or other digestive disease	88.07
113	Chronic lung diseases, Heart disease and Kidney disease	81.37
114	Chronic lung diseases, Kidney disease and Arthritis or rheumatism	79.23
115	Diabetes or high blood sugar, Chronic lung diseases and Arthritis or rheumatism	78.94
116	Chronic lung diseases, Kidney disease and Stomach or other digestive disease	75.82
117	Hypertension, Diabetes or high blood sugar and Arthritis or rheumatism	75.46
118	Hypertension, Dyslipidemia and Stomach or other digestive disease	75.00
119	Chronic lung diseases, Liver disease and Stomach or other digestive disease	73.39
120	Hypertension, Memory-related disease and Arthritis or rheumatism	73.19
121	Stomach or other digestive disease, Memory-related disease and Arthritis or rheumatism	72.65
122	Heart disease, Kidney disease and Arthritis or rheumatism	71.71
123	Liver disease, Arthritis or rheumatism and Asthma	70.28
124	Diabetes or high blood sugar, Cancer or malignant tumor and Arthritis or rheumatism	69.76
125	Kidney disease, Memory-related disease and Arthritis or rheumatism	66.83
126	Dyslipidemia, Heart disease and Arthritis or rheumatism	65.96
127	Diabetes or high blood sugar, Heart disease and Stomach or other digestive disease	65.94
128	Dyslipidemia, Chronic lung diseases and Heart disease	64.15
129	Hypertension, Kidney disease and Arthritis or rheumatism	63.81
130	Dyslipidemia, Stomach or other digestive disease and Arthritis or rheumatism	63.66
131	Hypertension, Chronic lung diseases and Memory-related disease	62.28
132	Dyslipidemia, Kidney disease and Stomach or other digestive disease	60.88
133	Hypertension, Stroke and Stomach or other digestive disease	59.10
134	Cancer or malignant tumor, Chronic lung diseases and Stomach or other digestive disease	57.58

1		
2		
3		
4	135	Cancer or malignant tumor, Chronic lung diseases and Arthritis or
5		rheumatism
6		53.47
7	136	Hypertension, Stomach or other digestive disease and Arthritis or
8		rheumatism
9		52.98
10	137	Dyslipidemia, Memory-related disease and Arthritis or rheumatism
11		52.69
12	138	Dyslipidemia, Stroke and Arthritis or rheumatism
13		52.69
14	139	Hypertension, Cancer or malignant tumor and Chronic lung diseases
15		50.75
16	140	Hypertension, Chronic lung diseases and Kidney disease
17		50.13
18	141	Liver disease, Heart disease and Arthritis or rheumatism
19		46.27
20	142	Hypertension, Cancer or malignant tumor and Arthritis or rheumatism
21		44.73
22	143	Hypertension, Liver disease and Kidney disease
23		43.92
24	144	Hypertension, Chronic lung diseases and Liver disease
25		43.13
26	145	Dyslipidemia, Cancer or malignant tumor and Arthritis or rheumatism
27		42.93
28	146	Dyslipidemia, Arthritis or rheumatism and Asthma
29		42.93
30	147	Hypertension, Diabetes or high blood sugar and Chronic lung diseases
31		42.81
32	148	Dyslipidemia, Kidney disease and Arthritis or rheumatism
33		42.40
34	149	Stomach or other digestive disease, Emotional, nervous, or psychiatric
35		problems and Arthritis or rheumatism
36		42.28
37	150	Hypertension, Liver disease and Arthritis or rheumatism
38		41.18
39	151	Hypertension, Stomach or other digestive disease and Memory-related
40		disease
41		39.40
42	152	Diabetes or high blood sugar, Stomach or other digestive disease and
43		Arthritis or rheumatism
44		39.24
45	153	Hypertension, Arthritis or rheumatism and Asthma
46		37.27
47	154	Dyslipidemia, Liver disease and Arthritis or rheumatism
48		36.48
49	155	Heart disease, Emotional, nervous, or psychiatric problems and Arthritis or
50		rheumatism
51		36.30
52	156	Hypertension, Chronic lung diseases and Arthritis or rheumatism
53		34.95
54	157	Dyslipidemia, Chronic lung diseases and Arthritis or rheumatism
55		34.70
56	158	Hypertension, Diabetes or high blood sugar and Stomach or other digestive
57		disease
58		33.85
59	159	Cancer or malignant tumor, Stomach or other digestive disease and
60		Arthritis or rheumatism
		33.83
	160	Liver disease, Heart disease and Stomach or other digestive disease
		33.21
	161	Dyslipidemia, Chronic lung diseases and Stomach or other digestive
		disease
		29.89
	162	Diabetes or high blood sugar, Liver disease and Arthritis or rheumatism
		29.64
	163	Hypertension, Kidney disease and Stomach or other digestive disease
		26.42
	164	Diabetes or high blood sugar, Chronic lung diseases and Stomach or other
		digestive disease
		24.29
	165	Hypertension, Emotional, nervous, or psychiatric problems and Arthritis or
		rheumatism
		22.36
	166	Hypertension, Liver disease and Stomach or other digestive disease
		20.46

167	Hypertension, Cancer or malignant tumor and Stomach or other digestive disease	16.05
168	Hypertension, Stomach or other digestive disease and Emotional, nervous, or psychiatric problems	16.05
169	Hypertension, Chronic lung diseases and Stomach or other digestive disease	15.57

For peer review only

STROBE 2007 (v4) checklist of items to be included in reports of observational studies in epidemiology*
Checklist for cohort, case-control, and cross-sectional studies (combined)

Section/Topic	Item #	Recommendation	Reported on page #
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract	1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found	2
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	4
Objectives	3	State specific objectives, including any pre-specified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	4
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	4
Participants	6	(a) <i>Cohort study</i> —Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up <i>Case-control study</i> —Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls <i>Cross-sectional study</i> —Give the eligibility criteria, and the sources and methods of selection of participants	4
		(b) <i>Cohort study</i> —For matched studies, give matching criteria and number of exposed and unexposed <i>Case-control study</i> —For matched studies, give matching criteria and the number of controls per case	Not applicable
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	5
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	4
Bias	9	Describe any efforts to address potential sources of bias	Not applicable
Study size	10	Explain how the study size was arrived at	4
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	5
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding	5
		(b) Describe any methods used to examine subgroups and interactions	5
		(c) Explain how missing data were addressed	Not applicable
		(d) <i>Cohort study</i> —If applicable, explain how loss to follow-up was addressed <i>Case-control study</i> —If applicable, explain how matching of cases and controls was addressed	5

		<i>Cross-sectional study</i> —If applicable, describe analytical methods taking account of sampling strategy	
		(e) Describe any sensitivity analyses	Not applicable
Results			
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	4
		(b) Give reasons for non-participation at each stage	Not applicable
		(c) Consider use of a flow diagram	Not applicable
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	6
		(b) Indicate number of participants with missing data for each variable of interest	5
		(c) <i>Cohort study</i> —Summarise follow-up time (eg, average and total amount)	Not applicable
Outcome data	15*	<i>Cohort study</i> —Report numbers of outcome events or summary measures over time	Not applicable
		<i>Case-control study</i> —Report numbers in each exposure category, or summary measures of exposure	Not applicable
		<i>Cross-sectional study</i> —Report numbers of outcome events or summary measures	5
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	6
		(b) Report category boundaries when continuous variables were categorized	8
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	10
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	6-12
Discussion			
Key results	18	Summarise key results with reference to study objectives	12
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	14
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	14
Generalisability	21	Discuss the generalisability (external validity) of the study results	14
Other information			
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	14

*Give information separately for cases and controls in case-control studies and, if applicable, for exposed and unexposed groups in cohort and cross-sectional studies.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at www.strobe-statement.org.